INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(15017, 687, 'sections_1_block_footer', ''),
(15018, 687, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15019, 688, '_wp_attached_file', '2020/09/gangagen-bacteria.jpg'),
(15020, 688, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1920;s:6:\"height\";i:1280;s:4:\"file\";s:29:\"2020/09/gangagen-bacteria.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:29:\"gangagen-bacteria-300x200.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:200;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:30:\"gangagen-bacteria-1024x683.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:683;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:29:\"gangagen-bacteria-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:29:\"gangagen-bacteria-768x512.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:512;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:31:\"gangagen-bacteria-1536x1024.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15021, 257, '_thumbnail_id', '688'),
(15022, 689, '_wp_attached_file', '2020/09/gangagen-disinfect.jpg'),
(15023, 689, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1920;s:6:\"height\";i:1281;s:4:\"file\";s:30:\"2020/09/gangagen-disinfect.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:30:\"gangagen-disinfect-300x200.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:200;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:31:\"gangagen-disinfect-1024x683.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:683;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:30:\"gangagen-disinfect-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:30:\"gangagen-disinfect-768x512.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:512;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:32:\"gangagen-disinfect-1536x1025.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1025;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15024, 690, '_wp_attached_file', '2020/09/gg-dean-cash.jpg'),
(15025, 690, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:917;s:6:\"height\";i:917;s:4:\"file\";s:24:\"2020/09/gg-dean-cash.jpg\";s:5:\"sizes\";a:3:{s:6:\"medium\";a:4:{s:4:\"file\";s:24:\"gg-dean-cash-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:24:\"gg-dean-cash-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:24:\"gg-dean-cash-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15026, 691, 'custom_page_logo', ''),
(15027, 691, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15028, 691, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(15029, 691, '_sections', 'field_5e1273c3f12ad'),
(15030, 691, 'sections_0_admin_title', 'Header Banner'),
(15031, 691, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15032, 691, 'sections_0_disable_mode', '0'),
(15033, 691, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15034, 691, 'sections_0_template_block_part', '/templates/header-banner'),
(15035, 691, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15036, 691, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(15037, 691, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(15038, 691, 'sections_1_disable_mode', '0'),
(15039, 691, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(15040, 691, 'sections_1_template_block_part', '/templates/directors'),
(15041, 691, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(15042, 691, 'management_0_name', 'Suchad Chiaranussati'),
(15043, 691, '_management_0_name', 'field_5efe20a3d7829'),
(15044, 691, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(15045, 691, '_management_0_title', 'field_5efe20add782a'),
(15046, 691, 'management_0_image', ''),
(15047, 691, '_management_0_image', 'field_5f5516e46507c'),
(15048, 691, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014.</p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities.</p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004.</p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand.</p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London.</p>'),
(15049, 691, '_management_0_bio', 'field_5efe20b4d782b'),
(15050, 691, 'management_1_name', 'Dean Cash'),
(15051, 691, '_management_1_name', 'field_5efe20a3d7829'),
(15052, 691, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(15053, 691, '_management_1_title', 'field_5efe20add782a'),
(15054, 691, 'management_1_image', '690'),
(15055, 691, '_management_1_image', 'field_5f5516e46507c'),
(15056, 691, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computer and patient records systems around North America. A transfer to GEISCO, General Electric’s information systems division selling computer time sharing followed. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO.</p>\r\n\r\n<p>Mr. Cash served on the board of directors of the Gangagen Incorporation, a biotech company researching new anti-bacterial treatments for “super bugs”. He also owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 600 employees.</p>\r\n\r\n<p>Mr. Cash is active within the non-profit community in San Francisco and serves on the Board of Governors of the San Francisco Symphony. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities.</p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons – Max, 25 years old who is a graduate of USC; and Sam, 22 years old and is currently a senior at USC.</p>'),
(15057, 691, '_management_1_bio', 'field_5efe20b4d782b'),
(15058, 691, 'management_2_name', 'Vinod Jadhav'),
(15059, 691, '_management_2_name', 'field_5efe20a3d7829'),
(15060, 691, 'management_2_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(15061, 691, '_management_2_title', 'field_5efe20add782a'),
(15062, 691, 'management_2_image', ''),
(15063, 691, '_management_2_image', 'field_5f5516e46507c'),
(15064, 691, 'management_2_bio', '<p>Mr. Vinod Jadhav is Managing Director of SAVA Medica Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to a full-fledged pharmaceutical organisation with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing and has presence in 30 countries through various SAVA Group companies.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 21 years of experience includes Marketing, Sales, Supply Chain Management, Regulatory and Corporate Affairs in various capacities.</p>'),
(15065, 691, '_management_2_bio', 'field_5efe20b4d782b'),
(15066, 691, 'management', '6'),
(15067, 691, '_management', 'field_5efe2097d7828'),
(15068, 691, 'management_0_board_type', 'bactoclear'),
(15069, 691, '_management_0_board_type', 'field_5f554dca6181e'),
(15070, 691, 'management_1_board_type', 'bactoclear'),
(15071, 691, '_management_1_board_type', 'field_5f554dca6181e'),
(15072, 691, 'management_2_board_type', 'bactoclear'),
(15073, 691, '_management_2_board_type', 'field_5f554dca6181e'),
(15074, 691, 'management_3_name', 'Dr. T. S. Balganesh'),
(15075, 691, '_management_3_name', 'field_5efe20a3d7829'),
(15076, 691, 'management_3_board_type', 'gbpl'),
(15077, 691, '_management_3_board_type', 'field_5f554dca6181e'),
(15078, 691, 'management_3_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(15079, 691, '_management_3_title', 'field_5efe20add782a'),
(15080, 691, 'management_3_image', '501'),
(15081, 691, '_management_3_image', 'field_5f5516e46507c'),
(15082, 691, 'management_3_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(15083, 691, '_management_3_bio', 'field_5efe20b4d782b'),
(15084, 691, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(15085, 691, '_management_4_name', 'field_5efe20a3d7829'),
(15086, 691, 'management_4_board_type', 'gbpl'),
(15087, 691, '_management_4_board_type', 'field_5f554dca6181e'),
(15088, 691, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(15089, 691, '_management_4_title', 'field_5efe20add782a'),
(15090, 691, 'management_4_image', ''),
(15091, 691, '_management_4_image', 'field_5f5516e46507c'),
(15092, 691, 'management_4_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(15093, 691, '_management_4_bio', 'field_5efe20b4d782b'),
(15094, 691, 'management_5_name', 'Dr. Manur Jayasheela'),
(15095, 691, '_management_5_name', 'field_5efe20a3d7829'),
(15096, 691, 'management_5_board_type', 'gbpl'),
(15097, 691, '_management_5_board_type', 'field_5f554dca6181e'),
(15098, 691, 'management_5_title', 'Member, Board of Directors GBPL'),
(15099, 691, '_management_5_title', 'field_5efe20add782a'),
(15100, 691, 'management_5_image', ''),
(15101, 691, '_management_5_image', 'field_5f5516e46507c'),
(15102, 691, 'management_5_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(15103, 691, '_management_5_bio', 'field_5efe20b4d782b'),
(15104, 692, '_wp_attached_file', '2020/09/gg-cute-dogs.jpg'),
(15105, 692, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1120;s:6:\"height\";i:520;s:4:\"file\";s:24:\"2020/09/gg-cute-dogs.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:24:\"gg-cute-dogs-300x139.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:139;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:25:\"gg-cute-dogs-1024x475.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:475;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:24:\"gg-cute-dogs-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:24:\"gg-cute-dogs-768x357.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:357;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15106, 693, '_wp_attached_file', '2020/09/gangagen-beginninigs-e1600361407146.jpg'),
(15107, 693, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:817;s:6:\"height\";i:630;s:4:\"file\";s:47:\"2020/09/gangagen-beginninigs-e1600361407146.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:47:\"gangagen-beginninigs-e1600361407146-300x231.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:231;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:33:\"gangagen-beginninigs-1024x769.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:769;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:47:\"gangagen-beginninigs-e1600361407146-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:47:\"gangagen-beginninigs-e1600361407146-768x592.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:592;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15108, 694, 'custom_page_logo', ''),
(15109, 694, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15110, 694, 'sections_0_admin_title', 'Header Banner'),
(15111, 694, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15112, 694, 'sections_0_disable_mode', '0'),
(15113, 694, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15114, 694, 'sections_0_template_block_part', '/templates/header-banner'),
(15115, 694, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15116, 694, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15117, 694, '_sections', 'field_5e1273c3f12ad'),
(15118, 694, 'sections_1_admin_title', 'Body Text'),
(15119, 694, '_sections_1_admin_title', 'field_5e865038f6507'),
(15120, 694, 'sections_1_disable_mode', '0'),
(15121, 694, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15122, 694, 'sections_1_content', '<div id=\"gangagen-mission\" class=\"gg-japanese-laurel\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n    <h2 class=\"fw-700 abx-white-text anim-hidden fade-in\">Our mission is to discover, design and develop highly specific and safe Protein Antiobiotics for treating bacterial infections.</h2>\r\n  </div>\r\n</div>\r\n\r\n<div id=\"gangagen-overview\">\r\n\r\n  	<div class=\"abx-white\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n              <div class=\"col-12 col-md-6 py-2\">\r\n                  <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                    <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GangaGen Overview</h2>\r\n                    <p style=\"font-size:1.4rem; line-height:2;\">GangaGen Biotechnologies Private Limited (GBPL) is a biologics company specialized in discovering, designing and developing novel therapies for treating serious bacterial infections. GangaGen advanced it’s candidate compound into human clinical trials for the clearance of Methicillin Resistant Staphylococcus aureus from human nares in 2015.</p>\r\n                  </div>\r\n              </div>\r\n              <div class=\"col-12 col-md-6 py-3 text-center\">\r\n                  <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                    <img src=\"http://gangagen.com/wp-content/uploads/2020/09/gangagen-facility-06.jpg\" alt=\"gangagen-image\" />\r\n                  </div>\r\n              </div>\r\n           </div>\r\n        </div>\r\n    </div>\r\n  \r\n    <div class=\"gg-light\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n                <div class=\"col-12 col-md-6 py-3 text-center\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                      <img src=\"/wp-content/uploads/2020/09/gangagen-beginninigs.jpg\" alt=\"gangagen-image\" />\r\n                    </div>\r\n                </div>\r\n             	<div class=\"col-12 col-md-6 py-2\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                      <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GangaGen\'s Beginnings</h2>\r\n                      <p style=\"font-size:1.4rem; line-height:2;\">GBPL was founded and registered in India in 2000 by Prof J. Ramachandran and became a subsidiary of GangaGen Incorporation, a Delaware company in the US in 2001. The assets of GangaGen Inc. were transferred to Bactoclear Holdings in 2019.</p>\r\n                    </div>\r\n                </div>\r\n            </div>\r\n        </div>\r\n  	</div>\r\n  \r\n    <div class=\"abx-white\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n                <div class=\"col-12 col-md-6 py-2\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                      <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GangaGen Ownership</h2>\r\n                      <p style=\"font-size:1.4rem; line-height:2;\">Presently, GBPL is a wholly owned subsidiary of <a class=\"gg-japanese-laurel-text\" href=\"https://bactoclear.com\" target=\"_blank\">Bactoclear Holdings Pte. Limited, Singapore</a>. The board of Bactoclear Holdings is made up of investors from different parts of the world, committed to make a difference in tackling antimicrobial resistance.</p>\r\n                    </div>\r\n                </div>\r\n             	<div class=\"col-12 col-md-6 py-3 text-center\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                      <img src=\"/wp-content/uploads/2020/09/gangagen-facility-02.jpg\" alt=\"gangagen-image\" />\r\n                    </div>\r\n                </div>\r\n            </div>\r\n        </div>\r\n  	</div>\r\n  \r\n  	<div class=\"gg-japanese-laurel abx-white-text text-center\" style=\"border-bottom:solid 3px var(--gg-light);\">\r\n      <div class=\"centerize ctz-lg px-3 py-5\">\r\n      	<h2 class=\"anim-hidden fade-in-up\">GangaGen\'s Research Focus</h2>\r\n      	<p class=\"anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">GangaGen’s expertise towards designing novel Protein Antibiotics is based on the proprietary technology platforms</p>\r\n      </div>\r\n    </div>\r\n  \r\n</div>'),
(15123, 694, '_sections_1_content', 'field_5e127410f12ae'),
(15124, 694, 'sections_1_disable_section', '0'),
(15125, 694, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15126, 694, 'sections_1_section_id', ''),
(15127, 694, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15128, 694, 'sections_1_klasses', ''),
(15129, 694, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15130, 694, 'sections_1_styles', ''),
(15131, 694, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15132, 694, 'sections_1_attributes', ''),
(15133, 694, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15134, 694, 'sections_1_background_image', ''),
(15135, 694, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15136, 694, 'sections_1_background_color', ''),
(15137, 694, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15138, 694, 'sections_1_text_color', ''),
(15139, 694, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15140, 694, 'sections_1_block_header', ''),
(15141, 694, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15142, 694, 'sections_1_block_footer', ''),
(15143, 694, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15144, 695, 'custom_page_logo', ''),
(15145, 695, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15146, 695, 'sections_0_admin_title', 'Header Banner'),
(15147, 695, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15148, 695, 'sections_0_disable_mode', '0'),
(15149, 695, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15150, 695, 'sections_0_template_block_part', '/templates/header-banner'),
(15151, 695, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15152, 695, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15153, 695, '_sections', 'field_5e1273c3f12ad'),
(15154, 695, 'sections_1_admin_title', 'Body Text'),
(15155, 695, '_sections_1_admin_title', 'field_5e865038f6507'),
(15156, 695, 'sections_1_disable_mode', '0'),
(15157, 695, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15158, 695, 'sections_1_content', '<div id=\"gangagen-mission\" class=\"gg-japanese-laurel\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n    <h2 class=\"fw-700 abx-white-text anim-hidden fade-in\">Our mission is to discover, design and develop highly specific and safe Protein Antiobiotics for treating bacterial infections.</h2>\r\n  </div>\r\n</div>\r\n\r\n<div id=\"gangagen-overview\">\r\n\r\n  	<div class=\"abx-white\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n              <div class=\"col-12 col-md-6 py-2\">\r\n                  <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                    <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GangaGen Overview</h2>\r\n                    <p style=\"font-size:1.4rem; line-height:2;\">GangaGen Biotechnologies Private Limited (GBPL) is a biologics company specialized in discovering, designing and developing novel therapies for treating serious bacterial infections. GangaGen advanced it’s candidate compound into human clinical trials for the clearance of Methicillin Resistant Staphylococcus aureus from human nares in 2015.</p>\r\n                  </div>\r\n              </div>\r\n              <div class=\"col-12 col-md-6 py-3 text-center\">\r\n                  <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                    <img src=\"http://gangagen.com/wp-content/uploads/2020/09/gangagen-facility-06.jpg\" alt=\"gangagen-image\" />\r\n                  </div>\r\n              </div>\r\n           </div>\r\n        </div>\r\n    </div>\r\n  \r\n    <div class=\"gg-light\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n                <div class=\"col-12 col-md-6 py-3 text-center\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                      <img src=\"/wp-content/uploads/2020/09/gangagen-beginninigs.jpg\" alt=\"gangagen-image\" />\r\n                    </div>\r\n                </div>\r\n             	<div class=\"col-12 col-md-6 py-2\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                      <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GBPL\'s Beginnings</h2>\r\n                      <p style=\"font-size:1.4rem; line-height:2;\">GBPL was founded and registered in India in 2000 by Prof J. Ramachandran and became a subsidiary of GangaGen Incorporation, a Delaware company in the US in 2001. The assets of GangaGen Inc. were transferred to Bactoclear Holdings in 2019.</p>\r\n                    </div>\r\n                </div>\r\n            </div>\r\n        </div>\r\n  	</div>\r\n  \r\n    <div class=\"abx-white\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n                <div class=\"col-12 col-md-6 py-2\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                      <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GangaGen Ownership</h2>\r\n                      <p style=\"font-size:1.4rem; line-height:2;\">Presently, GBPL is a wholly owned subsidiary of <a class=\"gg-japanese-laurel-text\" href=\"https://bactoclear.com\" target=\"_blank\">Bactoclear Holdings Pte. Limited, Singapore</a>. The board of Bactoclear Holdings is made up of investors from different parts of the world, committed to make a difference in tackling antimicrobial resistance.</p>\r\n                    </div>\r\n                </div>\r\n             	<div class=\"col-12 col-md-6 py-3 text-center\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                      <img src=\"/wp-content/uploads/2020/09/gangagen-facility-02.jpg\" alt=\"gangagen-image\" />\r\n                    </div>\r\n                </div>\r\n            </div>\r\n        </div>\r\n  	</div>\r\n  \r\n  	<div class=\"gg-japanese-laurel abx-white-text text-center\" style=\"border-bottom:solid 3px var(--gg-light);\">\r\n      <div class=\"centerize ctz-lg px-3 py-5\">\r\n      	<h2 class=\"anim-hidden fade-in-up\">GangaGen\'s Research Focus</h2>\r\n      	<p class=\"anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">GangaGen’s expertise towards designing novel Protein Antibiotics is based on the proprietary technology platforms</p>\r\n      </div>\r\n    </div>\r\n  \r\n</div>'),
(15159, 695, '_sections_1_content', 'field_5e127410f12ae'),
(15160, 695, 'sections_1_disable_section', '0'),
(15161, 695, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15162, 695, 'sections_1_section_id', ''),
(15163, 695, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15164, 695, 'sections_1_klasses', ''),
(15165, 695, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15166, 695, 'sections_1_styles', ''),
(15167, 695, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15168, 695, 'sections_1_attributes', ''),
(15169, 695, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15170, 695, 'sections_1_background_image', ''),
(15171, 695, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15172, 695, 'sections_1_background_color', ''),
(15173, 695, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15174, 695, 'sections_1_text_color', ''),
(15175, 695, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15176, 695, 'sections_1_block_header', ''),
(15177, 695, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15178, 695, 'sections_1_block_footer', ''),
(15179, 695, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15180, 278, 'sections_1_admin_title', ''),
(15181, 278, '_sections_1_admin_title', 'field_5e865038f6507'),
(15182, 278, 'sections_1_disable_mode', '0'),
(15183, 278, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15184, 278, 'sections_1_content', ''),
(15185, 278, '_sections_1_content', 'field_5e127410f12ae'),
(15186, 278, 'sections_1_disable_section', '0'),
(15187, 278, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15188, 278, 'sections_1_section_id', ''),
(15189, 278, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15190, 278, 'sections_1_klasses', ''),
(15191, 278, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15192, 278, 'sections_1_styles', ''),
(15193, 278, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15194, 278, 'sections_1_attributes', ''),
(15195, 278, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15196, 278, 'sections_1_background_image', ''),
(15197, 278, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15198, 278, 'sections_1_background_color', ''),
(15199, 278, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15200, 278, 'sections_1_text_color', ''),
(15201, 278, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15202, 278, 'sections_1_block_header', ''),
(15203, 278, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15204, 278, 'sections_1_block_footer', ''),
(15205, 278, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15206, 696, 'custom_page_logo', ''),
(15207, 696, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15208, 696, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15209, 696, '_sections', 'field_5e1273c3f12ad'),
(15210, 696, 'sections_0_admin_title', 'Header Banner'),
(15211, 696, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15212, 696, 'sections_0_disable_mode', '0'),
(15213, 696, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15214, 696, 'sections_0_template_block_part', '/templates/header-banner'),
(15215, 696, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15216, 696, 'sections_1_admin_title', ''),
(15217, 696, '_sections_1_admin_title', 'field_5e865038f6507'),
(15218, 696, 'sections_1_disable_mode', '0'),
(15219, 696, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15220, 696, 'sections_1_content', '<div id=\"bacteriophage-pipeline\">\r\n  <div class=\"gg-japanese-laurel abx-white-text\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <h2>Detection of adventitious phage contamination in Bacterial cell banks:</h2>\r\n    </div>\r\n  </div>\r\n  <div class=\"gg-light\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div>\r\n        <p class=\"gg-japanese-laurel-text\" style=\"line-height:2; font-size:1.4rem;\">GangaGen, with expertise in phage biology offers customized bacteriophage testing services to determine the presence or absence of phage contaminants in bacterial cell banks or production cells. Our team has more than fifteen years of experience and provides high quality phage testing services in tune with regulatory requirements in a timely manner. We offer both lytic and lysogenic phage detection for E. coli cell banks. Currently this service is offered as a Non-GLP activity.</p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n</div>'),
(15221, 696, '_sections_1_content', 'field_5e127410f12ae'),
(15222, 696, 'sections_1_disable_section', '0'),
(15223, 696, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15224, 696, 'sections_1_section_id', ''),
(15225, 696, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15226, 696, 'sections_1_klasses', ''),
(15227, 696, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15228, 696, 'sections_1_styles', ''),
(15229, 696, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15230, 696, 'sections_1_attributes', ''),
(15231, 696, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15232, 696, 'sections_1_background_image', ''),
(15233, 696, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15234, 696, 'sections_1_background_color', ''),
(15235, 696, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15236, 696, 'sections_1_text_color', ''),
(15237, 696, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15238, 696, 'sections_1_block_header', ''),
(15239, 696, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15240, 696, 'sections_1_block_footer', ''),
(15241, 696, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15242, 697, 'custom_page_logo', ''),
(15243, 697, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15244, 697, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15245, 697, '_sections', 'field_5e1273c3f12ad'),
(15246, 697, 'sections_0_admin_title', 'Header Banner'),
(15247, 697, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15248, 697, 'sections_0_disable_mode', '0'),
(15249, 697, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15250, 697, 'sections_0_template_block_part', '/templates/header-banner'),
(15251, 697, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15252, 697, 'sections_1_admin_title', ''),
(15253, 697, '_sections_1_admin_title', 'field_5e865038f6507'),
(15254, 697, 'sections_1_disable_mode', '0'),
(15255, 697, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15256, 697, 'sections_1_content', '<div id=\"bacteriophage-pipeline\">\r\n  <div class=\"gg-japanese-laurel abx-white-text\">\r\n    <div class=\"centerize ctz-md px-3 py-5 text-center\">\r\n      <h2 class=\"anim-hidden fade-in-up\">Detection of adventitious phage contamination in Bacterial cell banks:</h2>\r\n    </div>\r\n  </div>\r\n  <div class=\"gg-light\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div>\r\n        <p class=\"gg-japanese-laurel-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">GangaGen, with expertise in phage biology offers customized bacteriophage testing services to determine the presence or absence of phage contaminants in bacterial cell banks or production cells. Our team has more than fifteen years of experience and provides high quality phage testing services in tune with regulatory requirements in a timely manner. We offer both lytic and lysogenic phage detection for E. coli cell banks. Currently this service is offered as a Non-GLP activity.</p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n</div>'),
(15257, 697, '_sections_1_content', 'field_5e127410f12ae'),
(15258, 697, 'sections_1_disable_section', '0'),
(15259, 697, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15260, 697, 'sections_1_section_id', ''),
(15261, 697, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15262, 697, 'sections_1_klasses', ''),
(15263, 697, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15264, 697, 'sections_1_styles', ''),
(15265, 697, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15266, 697, 'sections_1_attributes', ''),
(15267, 697, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15268, 697, 'sections_1_background_image', ''),
(15269, 697, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15270, 697, 'sections_1_background_color', ''),
(15271, 697, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15272, 697, 'sections_1_text_color', ''),
(15273, 697, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15274, 697, 'sections_1_block_header', ''),
(15275, 697, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15276, 697, 'sections_1_block_footer', ''),
(15277, 697, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15278, 698, 'custom_page_logo', ''),
(15279, 698, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15280, 698, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15281, 698, '_sections', 'field_5e1273c3f12ad'),
(15282, 698, 'sections_0_admin_title', 'Header Banner'),
(15283, 698, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15284, 698, 'sections_0_disable_mode', '0'),
(15285, 698, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15286, 698, 'sections_0_template_block_part', '/templates/header-banner'),
(15287, 698, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15288, 698, 'sections_1_admin_title', ''),
(15289, 698, '_sections_1_admin_title', 'field_5e865038f6507'),
(15290, 698, 'sections_1_disable_mode', '0'),
(15291, 698, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15292, 698, 'sections_1_content', ''),
(15293, 698, '_sections_1_content', 'field_5e127410f12ae'),
(15294, 698, 'sections_1_disable_section', '0'),
(15295, 698, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15296, 698, 'sections_1_section_id', ''),
(15297, 698, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15298, 698, 'sections_1_klasses', ''),
(15299, 698, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15300, 698, 'sections_1_styles', ''),
(15301, 698, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15302, 698, 'sections_1_attributes', ''),
(15303, 698, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15304, 698, 'sections_1_background_image', ''),
(15305, 698, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15306, 698, 'sections_1_background_color', ''),
(15307, 698, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15308, 698, 'sections_1_text_color', ''),
(15309, 698, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15310, 698, 'sections_1_block_header', ''),
(15311, 698, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15312, 698, 'sections_1_block_footer', ''),
(15313, 698, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15323, 700, 'custom_page_logo', ''),
(15324, 700, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15325, 700, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15326, 700, '_sections', 'field_5e1273c3f12ad'),
(15327, 700, 'sections_0_admin_title', 'Header Banner'),
(15328, 700, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15329, 700, 'sections_0_disable_mode', '0'),
(15330, 700, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15331, 700, 'sections_0_template_block_part', '/templates/header-banner'),
(15332, 700, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15333, 700, 'sections_1_admin_title', 'Office Locations'),
(15334, 700, '_sections_1_admin_title', 'field_5e865038f6507'),
(15335, 700, 'sections_1_disable_mode', '0'),
(15336, 700, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15337, 700, 'sections_1_content', '<style>\r\n  #office-locations th, #office-locations td {border:none !important; padding:0;}\r\n  iframe {max-width:100% !important;}\r\n</style>\r\n<div id=\"office-locations\">\r\n  \r\n  <div class=\"gg-japanese-laurel\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n      <h2 class=\"fw-900 abx-white-text\">Research and Development Center: GangaGen Biotechnologies Pvt. Ltd.</h2>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div class=\"row\">\r\n        <div class=\"col-12 col-md-6 order-2 order-md-1\">\r\n          <table class=\"table table-borderless gg-japanese-laurel-text\" style=\"font-size:1.4rem; line-height:2;\"><tbody>\r\n            <tr><td colspan=\"2\">No 12, 5th Cross, Raghavendra Layout,</td></tr>\r\n          	<tr><td colspan=\"2\">Opposite to MEI Ltd, Tumkur Road,</td></tr>\r\n      		<tr><td colspan=\"2\">Yeshwanthpur, Bangalore -560022, India</td></tr>\r\n  			<tr><th>Phone:</th><td>+91-80-40621300 To 40621328<br/>(29 lines)</td></tr>\r\n            <tr class=\"mb-4\"><th>Fax:</th><td>+91-80-40621329</td></tr>\r\n            <tr><th>Email:</th><td><a class=\"gangagen-button-calypso\" href=\"mailto:info@gangagen.com\" style=\"padding:0.4rem;\">info@gangagen.com</a></td></tr>\r\n          </tbody></table>\r\n        </div>\r\n        <div class=\"col-12 col-md-6 order-1 order-md-2\">\r\n          <!-- Embedded Google Map <iframe> -->\r\n          <iframe src=\"https://www.google.com/maps/embed?pb=!1m18!1m12!1m3!1d62196.688524009136!2d77.55521500337848!3d13.017002148046354!2m3!1f0!2f0!3f0!3m2!1i1024!2i768!4f13.1!3m3!1m2!1s0x3bae3d69506541f7%3A0xfe0757fd08c9f59a!2sGangagen%20Biotechnologies%20Pvt%20Ltd!5e0!3m2!1sen!2sus!4v1600048283304!5m2!1sen!2sus\" width=\"600\" height=\"450\" frameborder=\"0\" style=\"border:0;\" allowfullscreen=\"\" aria-hidden=\"false\" tabindex=\"0\"></iframe>\r\n        </div>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  <!-- Hidden \r\n  <div class=\"gg-calypso\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n      <h2 class=\"fw-900 abx-white-text\">Corporate Office:</h2>\r\n    </div>\r\n  </div>\r\n\r\n  <div class=\"gg-light\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div class=\"row\">\r\n        <div class=\"col-12 col-md-6 order-2 order-md-1\">\r\n          	<table class=\"table table-borderless gg-calypso-text\" style=\"font-size:1.4rem; line-height:2;\"><tbody>\r\n              <tr><td colspan=\"2\">Bactoclear Holdings Pte. Ltd</td></tr>\r\n              <tr><td colspan=\"2\">1 Robinson Road, #17-00, Aia Tower,</td></tr>\r\n              <tr><td colspan=\"2\">Singapore 04854</td></tr>\r\n            </tbody></table>\r\n        </div>\r\n        <div class=\"col-12 col-md-6 order-1 order-md-2\">\r\n          <\r\n          <iframe src=\"https://www.google.com/maps/embed?pb=!1m18!1m12!1m3!1d3988.8197875173364!2d103.84893321528233!3d1.2818915990650341!2m3!1f0!2f0!3f0!3m2!1i1024!2i768!4f13.1!3m3!1m2!1s0x31da197d9f6c9b21%3A0xa9404ebb62830a8c!2sAIA%20Tower!5e0!3m2!1sen!2sus!4v1600048353502!5m2!1sen!2sus\" width=\"600\" height=\"450\" frameborder=\"0\" style=\"border:0;\" allowfullscreen=\"\" aria-hidden=\"false\" tabindex=\"0\"></iframe>\r\n        </div>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  -->\r\n</div>'),
(15338, 700, '_sections_1_content', 'field_5e127410f12ae'),
(15339, 700, 'sections_1_disable_section', '0'),
(15340, 700, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15341, 700, 'sections_1_section_id', ''),
(15342, 700, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15343, 700, 'sections_1_klasses', ''),
(15344, 700, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15345, 700, 'sections_1_styles', ''),
(15346, 700, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15347, 700, 'sections_1_attributes', ''),
(15348, 700, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15349, 700, 'sections_1_background_image', ''),
(15350, 700, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15351, 700, 'sections_1_background_color', ''),
(15352, 700, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15353, 700, 'sections_1_text_color', ''),
(15354, 700, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15355, 700, 'sections_1_block_header', ''),
(15356, 700, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15357, 700, 'sections_1_block_footer', ''),
(15358, 700, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15359, 701, '_wp_attached_file', '2020/09/1a.-Bacteriocins.jpg.jpg'),
(15360, 701, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:2508;s:6:\"height\";i:1152;s:4:\"file\";s:32:\"2020/09/1a.-Bacteriocins.jpg.jpg\";s:5:\"sizes\";a:6:{s:6:\"medium\";a:4:{s:4:\"file\";s:32:\"1a.-Bacteriocins.jpg-300x138.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:138;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:33:\"1a.-Bacteriocins.jpg-1024x470.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:470;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:32:\"1a.-Bacteriocins.jpg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:32:\"1a.-Bacteriocins.jpg-768x353.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:353;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:33:\"1a.-Bacteriocins.jpg-1536x706.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:706;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"2048x2048\";a:4:{s:4:\"file\";s:33:\"1a.-Bacteriocins.jpg-2048x941.jpg\";s:5:\"width\";i:2048;s:6:\"height\";i:941;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15361, 702, '_wp_attached_file', '2020/09/1b.Lysins.jpg-e1600360004397.jpg');
INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(15362, 702, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:2331;s:6:\"height\";i:1305;s:4:\"file\";s:40:\"2020/09/1b.Lysins.jpg-e1600360004397.jpg\";s:5:\"sizes\";a:6:{s:6:\"medium\";a:4:{s:4:\"file\";s:40:\"1b.Lysins.jpg-e1600360004397-300x168.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:168;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:41:\"1b.Lysins.jpg-e1600360004397-1024x573.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:573;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:40:\"1b.Lysins.jpg-e1600360004397-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:40:\"1b.Lysins.jpg-e1600360004397-768x430.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:430;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:41:\"1b.Lysins.jpg-e1600360004397-1536x860.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:860;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"2048x2048\";a:4:{s:4:\"file\";s:42:\"1b.Lysins.jpg-e1600360004397-2048x1147.jpg\";s:5:\"width\";i:2048;s:6:\"height\";i:1147;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15363, 703, '_wp_attached_file', '2020/09/2a.-Peptide-Bacteriocins.jpg.jpg'),
(15364, 703, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:917;s:6:\"height\";i:604;s:4:\"file\";s:40:\"2020/09/2a.-Peptide-Bacteriocins.jpg.jpg\";s:5:\"sizes\";a:3:{s:6:\"medium\";a:4:{s:4:\"file\";s:40:\"2a.-Peptide-Bacteriocins.jpg-300x198.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:198;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:40:\"2a.-Peptide-Bacteriocins.jpg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:40:\"2a.-Peptide-Bacteriocins.jpg-768x506.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:506;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15365, 704, '_wp_attached_file', '2020/09/2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990.jpg'),
(15366, 704, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1828;s:6:\"height\";i:1391;s:4:\"file\";s:61:\"2020/09/2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:61:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990-300x228.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:228;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:62:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990-1024x779.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:779;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:61:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:61:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990-768x584.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:584;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:63:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990-1536x1169.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1169;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15367, 705, '_wp_attached_file', '2020/09/3a.-Bacteriocin-Models-for-website.jpg'),
(15368, 705, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1900;s:6:\"height\";i:1774;s:4:\"file\";s:46:\"2020/09/3a.-Bacteriocin-Models-for-website.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:46:\"3a.-Bacteriocin-Models-for-website-300x280.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:280;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:47:\"3a.-Bacteriocin-Models-for-website-1024x956.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:956;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:46:\"3a.-Bacteriocin-Models-for-website-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:46:\"3a.-Bacteriocin-Models-for-website-768x717.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:717;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:48:\"3a.-Bacteriocin-Models-for-website-1536x1434.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1434;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15369, 706, '_wp_attached_file', '2020/09/3b.-Double-models_1.jpg'),
(15370, 706, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1900;s:6:\"height\";i:1593;s:4:\"file\";s:31:\"2020/09/3b.-Double-models_1.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:31:\"3b.-Double-models_1-300x252.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:252;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:32:\"3b.-Double-models_1-1024x859.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:859;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:31:\"3b.-Double-models_1-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:31:\"3b.-Double-models_1-768x644.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:644;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:33:\"3b.-Double-models_1-1536x1288.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1288;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15371, 707, '_wp_attached_file', '2020/09/4.-P128-Mechanism-of-Action.jpg'),
(15372, 707, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1900;s:6:\"height\";i:1056;s:4:\"file\";s:39:\"2020/09/4.-P128-Mechanism-of-Action.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:39:\"4.-P128-Mechanism-of-Action-300x167.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:167;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:40:\"4.-P128-Mechanism-of-Action-1024x569.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:569;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:39:\"4.-P128-Mechanism-of-Action-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:39:\"4.-P128-Mechanism-of-Action-768x427.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:427;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:40:\"4.-P128-Mechanism-of-Action-1536x854.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:854;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15373, 708, '_wp_attached_file', '2020/09/5a.-ORF56-localization-on-tail.jpg'),
(15374, 708, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1834;s:6:\"height\";i:1932;s:4:\"file\";s:42:\"2020/09/5a.-ORF56-localization-on-tail.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:42:\"5a.-ORF56-localization-on-tail-285x300.jpg\";s:5:\"width\";i:285;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:43:\"5a.-ORF56-localization-on-tail-972x1024.jpg\";s:5:\"width\";i:972;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:42:\"5a.-ORF56-localization-on-tail-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:42:\"5a.-ORF56-localization-on-tail-768x809.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:809;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:44:\"5a.-ORF56-localization-on-tail-1458x1536.jpg\";s:5:\"width\";i:1458;s:6:\"height\";i:1536;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15375, 709, '_wp_attached_file', '2020/09/5b.-p128.jpg'),
(15376, 709, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1900;s:6:\"height\";i:2481;s:4:\"file\";s:20:\"2020/09/5b.-p128.jpg\";s:5:\"sizes\";a:6:{s:6:\"medium\";a:4:{s:4:\"file\";s:20:\"5b.-p128-230x300.jpg\";s:5:\"width\";i:230;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:21:\"5b.-p128-784x1024.jpg\";s:5:\"width\";i:784;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:20:\"5b.-p128-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:21:\"5b.-p128-768x1003.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:1003;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:22:\"5b.-p128-1176x1536.jpg\";s:5:\"width\";i:1176;s:6:\"height\";i:1536;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"2048x2048\";a:4:{s:4:\"file\";s:22:\"5b.-p128-1568x2048.jpg\";s:5:\"width\";i:1568;s:6:\"height\";i:2048;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15377, 710, '_wp_attached_file', '2020/09/6.-P128-banner_final-scaled.jpg'),
(15378, 710, '_wp_attachment_metadata', 'a:6:{s:5:\"width\";i:2560;s:6:\"height\";i:573;s:4:\"file\";s:39:\"2020/09/6.-P128-banner_final-scaled.jpg\";s:5:\"sizes\";a:6:{s:6:\"medium\";a:4:{s:4:\"file\";s:31:\"6.-P128-banner_final-300x67.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:67;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:33:\"6.-P128-banner_final-1024x229.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:229;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:32:\"6.-P128-banner_final-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:32:\"6.-P128-banner_final-768x172.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:172;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:33:\"6.-P128-banner_final-1536x344.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:344;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"2048x2048\";a:4:{s:4:\"file\";s:33:\"6.-P128-banner_final-2048x458.jpg\";s:5:\"width\";i:2048;s:6:\"height\";i:458;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}s:14:\"original_image\";s:24:\"6.-P128-banner_final.jpg\";}'),
(15379, 711, '_wp_attached_file', '2020/09/7.-Protein-Antibiotics-scaled.jpg'),
(15380, 711, '_wp_attachment_metadata', 'a:6:{s:5:\"width\";i:2560;s:6:\"height\";i:666;s:4:\"file\";s:41:\"2020/09/7.-Protein-Antibiotics-scaled.jpg\";s:5:\"sizes\";a:6:{s:6:\"medium\";a:4:{s:4:\"file\";s:33:\"7.-Protein-Antibiotics-300x78.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:78;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:35:\"7.-Protein-Antibiotics-1024x266.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:266;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:34:\"7.-Protein-Antibiotics-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:34:\"7.-Protein-Antibiotics-768x200.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:200;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:35:\"7.-Protein-Antibiotics-1536x400.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:400;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"2048x2048\";a:4:{s:4:\"file\";s:35:\"7.-Protein-Antibiotics-2048x533.jpg\";s:5:\"width\";i:2048;s:6:\"height\";i:533;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}s:14:\"original_image\";s:26:\"7.-Protein-Antibiotics.jpg\";}'),
(15381, 702, '_wp_attachment_backup_sizes', 'a:14:{s:9:\"full-orig\";a:3:{s:5:\"width\";i:1900;s:6:\"height\";i:2331;s:4:\"file\";s:17:\"1b.Lysins.jpg.jpg\";}s:14:\"thumbnail-orig\";a:4:{s:4:\"file\";s:25:\"1b.Lysins.jpg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:11:\"medium-orig\";a:4:{s:4:\"file\";s:25:\"1b.Lysins.jpg-245x300.jpg\";s:5:\"width\";i:245;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:17:\"medium_large-orig\";a:4:{s:4:\"file\";s:25:\"1b.Lysins.jpg-768x942.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:942;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:10:\"large-orig\";a:4:{s:4:\"file\";s:26:\"1b.Lysins.jpg-835x1024.jpg\";s:5:\"width\";i:835;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:14:\"1536x1536-orig\";a:4:{s:4:\"file\";s:27:\"1b.Lysins.jpg-1252x1536.jpg\";s:5:\"width\";i:1252;s:6:\"height\";i:1536;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:14:\"2048x2048-orig\";a:4:{s:4:\"file\";s:27:\"1b.Lysins.jpg-1669x2048.jpg\";s:5:\"width\";i:1669;s:6:\"height\";i:2048;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:18:\"full-1600360004397\";a:3:{s:5:\"width\";i:2331;s:6:\"height\";i:1900;s:4:\"file\";s:32:\"1b.Lysins.jpg-e1600359912294.jpg\";}s:23:\"thumbnail-1600360004397\";a:4:{s:4:\"file\";s:40:\"1b.Lysins.jpg-e1600359912294-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:20:\"medium-1600360004397\";a:4:{s:4:\"file\";s:40:\"1b.Lysins.jpg-e1600359912294-300x245.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:245;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:26:\"medium_large-1600360004397\";a:4:{s:4:\"file\";s:40:\"1b.Lysins.jpg-e1600359912294-768x626.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:626;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:19:\"large-1600360004397\";a:4:{s:4:\"file\";s:41:\"1b.Lysins.jpg-e1600359912294-1024x835.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:835;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:23:\"1536x1536-1600360004397\";a:4:{s:4:\"file\";s:42:\"1b.Lysins.jpg-e1600359912294-1536x1252.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1252;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:23:\"2048x2048-1600360004397\";a:4:{s:4:\"file\";s:42:\"1b.Lysins.jpg-e1600359912294-2048x1669.jpg\";s:5:\"width\";i:2048;s:6:\"height\";i:1669;s:9:\"mime-type\";s:10:\"image/jpeg\";}}'),
(15382, 712, 'custom_page_logo', ''),
(15383, 712, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15384, 712, 'sections', 'a:3:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";i:2;s:10:\"code_block\";}'),
(15385, 712, '_sections', 'field_5e1273c3f12ad'),
(15386, 712, 'sections_0_admin_title', 'Header Banner'),
(15387, 712, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15388, 712, 'sections_0_disable_mode', '0'),
(15389, 712, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15390, 712, 'sections_0_template_block_part', '/templates/header-banner'),
(15391, 712, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15392, 712, 'sections_1_admin_title', 'Protein Antibiotic Technology'),
(15393, 712, '_sections_1_admin_title', 'field_5e865038f6507'),
(15394, 712, 'sections_1_disable_mode', '0'),
(15395, 712, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15396, 712, 'sections_1_content', '<div id=\"protein-antibiotic-technology\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center anim-hidden fade-in-up\">\r\n    <p class=\"gg-japanese-laurel-text\" style=\"font-size:1.4rem; line-height:2;\">GangaGen’s ‘Protein Antibiotic Technology Platform (PATP) is based on GBPL’S extensive knowledge of phage biology, naturally occurring antibacterial proteins and the ability to identify and model functional domains of putative antibacterial proteins using detailed bioinformatics. The proprietary bioinformatic platform and the standardized cascade of experiments allow rapid confirmation of antibacterial activity targeting different bacterial pathogens.</p>\r\n  </div>\r\n</div>\r\n\r\n<div id=\"protein-antibiotics-image\" class=\"abx-white\">\r\n  <div class=\"px-3 py-5\">\r\n    <img class=\"anim-hidden fade-in\" src=\"http://gangagen.com/wp-content/uploads/2020/09/7.-Protein-Antibiotics-scaled.jpg\" alt=\"gangagen-protein-antibiotics\" />\r\n  </div>\r\n</div>'),
(15397, 712, '_sections_1_content', 'field_5e127410f12ae'),
(15398, 712, 'sections_1_disable_section', '0'),
(15399, 712, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15400, 712, 'sections_1_section_id', ''),
(15401, 712, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15402, 712, 'sections_1_klasses', ''),
(15403, 712, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15404, 712, 'sections_1_styles', ''),
(15405, 712, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15406, 712, 'sections_1_attributes', ''),
(15407, 712, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15408, 712, 'sections_1_background_image', ''),
(15409, 712, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15410, 712, 'sections_1_background_color', ''),
(15411, 712, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15412, 712, 'sections_1_text_color', ''),
(15413, 712, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15414, 712, 'sections_1_block_header', ''),
(15415, 712, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15416, 712, 'sections_1_block_footer', ''),
(15417, 712, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15418, 712, 'sections_2_admin_title', 'Protein Antibiotic Classes'),
(15419, 712, '_sections_2_admin_title', 'field_5e865038f6507'),
(15420, 712, 'sections_2_disable_mode', '0'),
(15421, 712, '_sections_2_disable_mode', 'field_5e865043f6508'),
(15422, 712, 'sections_2_content', '<div id=\"protein-antibiotic-classes\">\r\n  \r\n  <div class=\"gg-japanese-laurel abx-white-text\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 text-center anim-hidden fade-in\">\r\n      <h2>Protein Antibiotic Classes</h2>\r\n      <p>Protein Antibiotics being researched at GangaGen belong to 2 major classes:</p>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-md px-3 py-5\">\r\n      <div class=\"row\">\r\n\r\n        <div class=\"col-12 col-md-6 text-center anim-hidden fade-in-left\">\r\n			<img class=\"mb-4\" src=\"/wp-content/uploads/2020/09/1a.-Bacteriocins.jpg.jpg\" style=\"height:160px;\" alt=\"gangagen-bacteriocins\" />\r\n          	<h3 class=\"mb-4 gg-japanese-laurel-text\">Bacteriocins</h3>\r\n            <a href=\"/bacteriocins\"><button class=\"gangagen-button\">Learn More</button></a>\r\n        </div>\r\n\r\n        <div class=\"col-12 col-md-6 text-center anim-hidden fade-in-right\">\r\n			<img class=\"mb-4\" src=\"/wp-content/uploads/2020/09/1b.Lysins.jpg-e1600360004397.jpg\" style=\"height:160px;\" alt=\"gangagen-lysins\" />\r\n          	<h3 class=\"mb-4 gg-japanese-laurel-text\">Lysins</h3>\r\n            <a href=\"/lysins\"><button class=\"gangagen-button\">Learn More</button></a>\r\n        </div>\r\n\r\n      </div>\r\n    </div>\r\n  </div>\r\n</div>'),
(15423, 712, '_sections_2_content', 'field_5e127410f12ae'),
(15424, 712, 'sections_2_disable_section', '0'),
(15425, 712, '_sections_2_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15426, 712, 'sections_2_section_id', ''),
(15427, 712, '_sections_2_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15428, 712, 'sections_2_klasses', ''),
(15429, 712, '_sections_2_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15430, 712, 'sections_2_styles', ''),
(15431, 712, '_sections_2_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15432, 712, 'sections_2_attributes', ''),
(15433, 712, '_sections_2_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15434, 712, 'sections_2_background_image', ''),
(15435, 712, '_sections_2_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15436, 712, 'sections_2_background_color', ''),
(15437, 712, '_sections_2_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15438, 712, 'sections_2_text_color', ''),
(15439, 712, '_sections_2_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15440, 712, 'sections_2_block_header', ''),
(15441, 712, '_sections_2_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15442, 712, 'sections_2_block_footer', ''),
(15443, 712, '_sections_2_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15444, 280, 'sections_1_admin_title', 'Bacteriophage Detection Services'),
(15445, 280, '_sections_1_admin_title', 'field_5e865038f6507'),
(15446, 280, 'sections_1_disable_mode', '0'),
(15447, 280, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15448, 280, 'sections_1_content', '<div id=\"bacteriophage-pipeline\">\r\n  \r\n  <div class=\"gg-japanese-laurel abx-white-text\">\r\n    <div class=\"centerize ctz-md px-3 py-5 text-center\">\r\n      <h2 class=\"anim-hidden fade-in-up\">Detection of adventitious phage contamination in Bacterial cell banks:</h2>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"gg-light\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div>\r\n        <p class=\"gg-japanese-laurel-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">GangaGen, with expertise in phage biology offers customized bacteriophage testing services to determine the presence or absence of phage contaminants in <em>E. coli</em> cell banks or production cells. Our team has about twenty years of experience and provides high quality phage testing services in tune with regulatory requirements in a timely manner. We offer both lytic and lysogenic phage detection for <em>E. coli</em> cell banks.</p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <p class=\"gg-calypso-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">The commercial production of recombinant biologicals and therapeutics is an important outcome of modern biotechnology. Selecting an ideal host bacterium to produce specific protein of interest is an important step in developing a production process. Widespread use of <em>E. coli</em> and other bacterial systems in biotechnology has led to the development of many different strains/cell lines. The process developed in production of therapeutics has to be taken to industrial scale to get viable industrial production mainly through fermentation technology.</p>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"gg-light\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div>\r\n        <p class=\"gg-japanese-laurel-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">The starting material for manufacturing includes a well characterized bacterial culture, known to be free from bacteriophage and is capable of expressing the protein product of interest in good measure. Production host bacterial cell “seed lot” system is used by manufacturers to assure identity and purity of the starting raw material viz., production host culture. A cell seed lot/research cell bank consists of aliquots of a single culture from where the <strong><em>“Master Cell Bank” (MCB)</em></strong> and <strong><em>“Working Cell Bank” (WCB)</em></strong> are derived. A well-characterized cell bank assures lot-to-lot consistency of the product. Regulatory agencies such as USFDA, EMEA require MCBs to adhere to ICH guidelines which emphasizes on characterization and testing to establish identity, purity and genetic stability of the cell line. A phage contaminated cell bank cannot be termed as <em>\"stable\"</em> as it may not generate the required cell density in a sustainable fashion during the fermentation process because of contaminating phages. Thus, it becomes essential to establish absence of phages in cell banks by conducting the prescribed battery of tests. </p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div>\r\n        <h2 class=\"gg-calypso-text anim-hidden fade-in-up\">Bacteriophage Detection Services</h2>\r\n        <p class=\"gg-calypso-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">We offer both lytic and lysogenic phage detection for <em>E. coli</em> cell banks. This service offered by GangaGen is an ISO-9001:2015 certified activity.</p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"gg-calypso abx-white-text\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n      <h2 class=\"fw-900 anim-hidden fade-in-down animated visible fadeInDown full-visible\">For More Information:</h2>\r\n      <div class=\"text-center\">\r\n    	<a href=\"mailto:info@gangagen\"><button class=\"gangagen-button-clear anim-hidden fade-in-up animated visible fadeInUp full-visible\">Email</button></a>\r\n    	<a href=\"/contact\"><button class=\"gangagen-button-clear anim-hidden fade-in-up animated visible fadeInUp full-visible\">Contact Form</button></a>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  \r\n</div>'),
(23912, 940, '_edit_last', '3'),
(15449, 280, '_sections_1_content', 'field_5e127410f12ae'),
(15450, 280, 'sections_1_disable_section', '0'),
(15451, 280, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15452, 280, 'sections_1_section_id', ''),
(15453, 280, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15454, 280, 'sections_1_klasses', ''),
(15455, 280, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15456, 280, 'sections_1_styles', ''),
(15457, 280, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15458, 280, 'sections_1_attributes', ''),
(15459, 280, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15460, 280, 'sections_1_background_image', ''),
(15461, 280, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15462, 280, 'sections_1_background_color', ''),
(15463, 280, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15464, 280, 'sections_1_text_color', ''),
(15465, 280, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15466, 280, 'sections_1_block_header', ''),
(15467, 280, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15468, 280, 'sections_1_block_footer', ''),
(15469, 280, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15470, 713, 'custom_page_logo', ''),
(15471, 713, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15472, 713, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15473, 713, '_sections', 'field_5e1273c3f12ad'),
(15474, 713, 'sections_0_admin_title', 'Header Banner'),
(15475, 713, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15476, 713, 'sections_0_disable_mode', '0'),
(15477, 713, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15478, 713, 'sections_0_template_block_part', '/templates/header-banner'),
(15479, 713, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15480, 713, 'sections_1_admin_title', 'Phage Detection Services'),
(15481, 713, '_sections_1_admin_title', 'field_5e865038f6507'),
(15482, 713, 'sections_1_disable_mode', '0'),
(15483, 713, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15484, 713, 'sections_1_content', '<div id=\"bacteriophage-pipeline\">\r\n  \r\n  <div class=\"gg-japanese-laurel abx-white-text\">\r\n    <div class=\"centerize ctz-md px-3 py-5 text-center\">\r\n      <h2 class=\"anim-hidden fade-in-up\">Detection of adventitious phage contamination in Bacterial cell banks:</h2>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"gg-light\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div>\r\n        <p class=\"gg-japanese-laurel-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">GangaGen, with expertise in phage biology offers customized bacteriophage testing services to determine the presence or absence of phage contaminants in bacterial cell banks or production cells. Our team has more than fifteen years of experience and provides high quality phage testing services in tune with regulatory requirements in a timely manner. We offer both lytic and lysogenic phage detection for E. coli cell banks. Currently this service is offered as a Non-GLP activity.</p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <p class=\"gg-calypso-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">The commercial production of recombinant biologicals and therapeutics is an important outcome of modern biotechnology. Selecting an ideal host bacterium to produce specific protein of interest is an important step in developing a production process. Widespread use of E. coli and other bacterial systems in biotechnology has led to the development of many different strains/cell lines. The process developed in production of therapeutics has to be taken to industrial scale to get viable industrial production mainly through fermentation technology.</p>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"gg-light\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n      <div>\r\n        <p class=\"gg-japanese-laurel-text anim-hidden fade-in-up\" style=\"line-height:2; font-size:1.4rem;\">The starting material for manufacturing includes a well characterized bacterial culture, known to be free from bacteriophage and is capable of expressing the protein product of interest in good measure. Production host bacterial cell “seed lot” system is used by manufacturers to assure identity and purity of the starting raw material viz., production host culture. A cell seed lot/research cell bank consists of aliquots of a single culture from where the <strong><em>“Master Cell Bank” (MCB)</em></strong> and <strong><em>“Working Cell Bank” (WCB)</em></strong> are derived. A well-characterized cell bank assures lot-to-lot consistency of the product. Regulatory agencies such as USFDA, EMEA require MCBs to adhere to ICH guidelines which emphasizes on characterization and testing to establish identity, purity and genetic stability of the cell line. A phage contaminated cell bank cannot be termed as <em>\"stable\"</em> as it may not generate the required cell density in a sustainable fashion during the fermentation process because of contaminating phages. Thus, it becomes essential to establish absence of phages in cell banks by conducting the prescribed battery of tests. </p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n  \r\n</div>'),
(15485, 713, '_sections_1_content', 'field_5e127410f12ae'),
(15486, 713, 'sections_1_disable_section', '0'),
(15487, 713, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15488, 713, 'sections_1_section_id', ''),
(15489, 713, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15490, 713, 'sections_1_klasses', ''),
(15491, 713, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15492, 713, 'sections_1_styles', ''),
(15493, 713, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15494, 713, 'sections_1_attributes', ''),
(15495, 713, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15496, 713, 'sections_1_background_image', ''),
(15497, 713, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15498, 713, 'sections_1_background_color', ''),
(15499, 713, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15500, 713, 'sections_1_text_color', ''),
(15501, 713, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15502, 713, 'sections_1_block_header', ''),
(15503, 713, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15504, 713, 'sections_1_block_footer', ''),
(15505, 713, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15506, 714, '_menu_item_type', 'post_type'),
(15507, 714, '_menu_item_menu_item_parent', '662'),
(15508, 714, '_menu_item_object_id', '280'),
(15509, 714, '_menu_item_object', 'page'),
(15510, 714, '_menu_item_target', ''),
(15511, 714, '_menu_item_classes', 'a:1:{i:0;s:0:\"\";}'),
(15512, 714, '_menu_item_xfn', ''),
(15513, 714, '_menu_item_url', ''),
(15515, 715, '_menu_item_type', 'post_type'),
(15516, 715, '_menu_item_menu_item_parent', '345'),
(15517, 715, '_menu_item_object_id', '259'),
(15518, 715, '_menu_item_object', 'page'),
(15519, 715, '_menu_item_target', ''),
(15520, 715, '_menu_item_classes', 'a:1:{i:0;s:0:\"\";}'),
(15521, 715, '_menu_item_xfn', ''),
(15522, 715, '_menu_item_url', ''),
(15524, 716, '_wp_attached_file', '2020/09/gangagen-chart.jpg'),
(15525, 716, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1051;s:6:\"height\";i:760;s:4:\"file\";s:26:\"2020/09/gangagen-chart.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:26:\"gangagen-chart-300x217.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:217;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:27:\"gangagen-chart-1024x740.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:740;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:26:\"gangagen-chart-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:26:\"gangagen-chart-768x555.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:555;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15526, 259, 'sections_1_admin_title', ''),
(15527, 259, '_sections_1_admin_title', 'field_5e865038f6507'),
(15528, 259, 'sections_1_disable_mode', '0'),
(15529, 259, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15530, 259, 'sections_1_content', '<div id=\"protein-antibiotics-pipeline\">\r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n      <img src=\"/wp-content/uploads/2023/05/20230529_GangaGen-Pipeline.jpg\" alt=\"protein-antibiotics-pipeline\" class=\"anim-hidden fade-in-up\" style=\"border:solid 3px var(--gg-calypso);\" />\r\n    </div>\r\n  </div>\r\n</div>'),
(15531, 259, '_sections_1_content', 'field_5e127410f12ae'),
(15532, 259, 'sections_1_disable_section', '0'),
(15533, 259, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15534, 259, 'sections_1_section_id', ''),
(15535, 259, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15536, 259, 'sections_1_klasses', ''),
(15537, 259, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15538, 259, 'sections_1_styles', ''),
(15539, 259, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15540, 259, 'sections_1_attributes', ''),
(15541, 259, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15542, 259, 'sections_1_background_image', ''),
(15543, 259, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15544, 259, 'sections_1_background_color', ''),
(15545, 259, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15546, 259, 'sections_1_text_color', ''),
(15547, 259, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15548, 259, 'sections_1_block_header', ''),
(15549, 259, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15550, 259, 'sections_1_block_footer', ''),
(15551, 259, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15552, 717, 'custom_page_logo', ''),
(15553, 717, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15554, 717, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15555, 717, '_sections', 'field_5e1273c3f12ad'),
(15556, 717, 'sections_0_admin_title', 'Header Banner'),
(15557, 717, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15558, 717, 'sections_0_disable_mode', '0'),
(15559, 717, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15560, 717, 'sections_0_template_block_part', '/templates/header-banner'),
(15561, 717, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15562, 717, 'sections_1_admin_title', ''),
(15563, 717, '_sections_1_admin_title', 'field_5e865038f6507'),
(15564, 717, 'sections_1_disable_mode', '0'),
(15565, 717, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15566, 717, 'sections_1_content', '<div id=\"protein-antibiotics-pipeline\">\r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n      <img src=\"/wp-content/uploads/2020/09/pipeline-main.jpg\" alt=\"protein-antibiotics-pipeline\" class=\"anim-hidden fade-in-up\" style=\"border:solid 3px var(--gg-calypso);\" />\r\n    </div>\r\n  </div>\r\n</div>'),
(15567, 717, '_sections_1_content', 'field_5e127410f12ae'),
(15568, 717, 'sections_1_disable_section', '0'),
(15569, 717, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15570, 717, 'sections_1_section_id', ''),
(15571, 717, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15572, 717, 'sections_1_klasses', ''),
(15573, 717, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15574, 717, 'sections_1_styles', ''),
(15575, 717, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15576, 717, 'sections_1_attributes', ''),
(15577, 717, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15578, 717, 'sections_1_background_image', ''),
(15579, 717, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15580, 717, 'sections_1_background_color', ''),
(15581, 717, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15582, 717, 'sections_1_text_color', ''),
(15583, 717, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15584, 717, 'sections_1_block_header', ''),
(15585, 717, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15586, 717, 'sections_1_block_footer', ''),
(15587, 717, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15588, 718, '_wp_attached_file', '2020/09/protein-antibiotics-pipeline-banner.jpg'),
(15589, 718, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1920;s:6:\"height\";i:940;s:4:\"file\";s:47:\"2020/09/protein-antibiotics-pipeline-banner.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:47:\"protein-antibiotics-pipeline-banner-300x147.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:147;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:48:\"protein-antibiotics-pipeline-banner-1024x501.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:501;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:47:\"protein-antibiotics-pipeline-banner-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:47:\"protein-antibiotics-pipeline-banner-768x376.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:376;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:48:\"protein-antibiotics-pipeline-banner-1536x752.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:752;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15590, 259, '_thumbnail_id', '743'),
(15591, 719, 'custom_page_logo', ''),
(15592, 719, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15593, 719, 'sections_0_admin_title', 'Header Banner'),
(15594, 719, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15595, 719, 'sections_0_disable_mode', '0'),
(15596, 719, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15597, 719, 'sections_0_template_block_part', '/templates/header-banner'),
(15598, 719, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15599, 719, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(15600, 719, '_sections', 'field_5e1273c3f12ad'),
(15601, 719, 'sections_1_admin_title', 'Body Text'),
(15602, 719, '_sections_1_admin_title', 'field_5e865038f6507'),
(15603, 719, 'sections_1_disable_mode', '0'),
(15604, 719, '_sections_1_disable_mode', 'field_5e865043f6508'),
(15605, 719, 'sections_1_content', '<div id=\"gangagen-mission\" class=\"gg-japanese-laurel\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n    <h2 class=\"fw-700 abx-white-text anim-hidden fade-in\">Our mission is to discover, design and develop highly specific and safe Protein Antiobiotics for treating bacterial infections.</h2>\r\n  </div>\r\n</div>\r\n\r\n<div id=\"gangagen-overview\">\r\n\r\n  	<div class=\"abx-white\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n              <div class=\"col-12 col-md-6 py-2\">\r\n                  <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                    <h2 class=\"text-center gg-japanese-laurel-text fw-700\">Overview</h2>\r\n                    <p style=\"font-size:1.4rem; line-height:2;\">GangaGen Biotechnologies Private Limited, India (GBPL), is a biologics company specialized in discovering, designing and developing novel therapies for treating serious bacterial infections. GangaGen advanced it’s candidate compound into human clinical trials for the clearance of Methicillin Resistant Staphylococcus aureus from human nares in 2015.</p>\r\n                  </div>\r\n              </div>\r\n              <div class=\"col-12 col-md-6 py-3 text-center\">\r\n                  <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                    <img src=\"/wp-content/uploads/2020/09/gangagen-facility-02.jpg\" alt=\"gangagen-image\" />\r\n                  </div>\r\n              </div>\r\n           </div>\r\n        </div>\r\n    </div>\r\n  \r\n    <div class=\"gg-light\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n                <div class=\"col-12 col-md-6 py-3 text-center\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-left\">\r\n                      <img src=\"/wp-content/uploads/2020/09/gangagen-beginninigs-e1600361407146.jpg\" alt=\"gangagen-image\" />\r\n                    </div>\r\n                </div>\r\n             	<div class=\"col-12 col-md-6 py-2\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-right\">\r\n                      <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GBPL\'s Beginnings</h2>\r\n                      <p style=\"font-size:1.4rem; line-height:2;\">GBPL was founded and registered in India in 2000 by Prof J. Ramachandran and became a subsidiary of GangaGen Incorporation, a Delaware company in the US in 2001. The assets of GangaGen Inc. were transferred to Bactoclear Holdings in 2019.</p>\r\n                    </div>\r\n                </div>\r\n            </div>\r\n        </div>\r\n  	</div>\r\n  \r\n    <div class=\"abx-white\">\r\n        <div class=\"centerize ctz-lg px-3 py-5\">\r\n           <div class=\"row\">\r\n                <div class=\"col-12 py-2 text-center\">\r\n                    <div class=\"content-group mb-4 anim-hidden fade-in-up\">\r\n                      <h2 class=\"text-center gg-japanese-laurel-text fw-700\">GangaGen Ownership</h2>\r\n                      <p style=\"font-size:1.4rem; line-height:2;\">GBPL is a wholly owned subsidiary of <a class=\"gg-japanese-laurel-text\" href=\"https://bactoclear.com\" target=\"_blank\">Bactoclear Holdings Pte. Limited, Singapore</a>. The board of Bactoclear Holdings is made up of investors from different parts of the world, committed to make a difference in tackling antimicrobial resistance.</p>\r\n                    </div>\r\n                </div>\r\n            </div>\r\n        </div>\r\n  	</div>\r\n  \r\n  	<div class=\"gg-japanese-laurel abx-white-text text-center\" style=\"border-bottom:solid 3px var(--gg-light);\">\r\n      <div class=\"centerize ctz-lg px-3 py-5\">\r\n      	<h2 class=\"anim-hidden fade-in-up\">GangaGen\'s Research Focus</h2>\r\n      	<p class=\"anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">GangaGen’s expertise towards designing novel Protein Antibiotics is based on the proprietary technology platforms</p>\r\n      </div>\r\n    </div>\r\n  \r\n</div>'),
(15606, 719, '_sections_1_content', 'field_5e127410f12ae'),
(15607, 719, 'sections_1_disable_section', '0'),
(15608, 719, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(15609, 719, 'sections_1_section_id', ''),
(15610, 719, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(15611, 719, 'sections_1_klasses', ''),
(15612, 719, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(15613, 719, 'sections_1_styles', ''),
(15614, 719, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(15615, 719, 'sections_1_attributes', ''),
(15616, 719, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(15617, 719, 'sections_1_background_image', ''),
(15618, 719, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(15619, 719, 'sections_1_background_color', ''),
(15620, 719, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(15621, 719, 'sections_1_text_color', ''),
(15622, 719, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(15623, 719, 'sections_1_block_header', ''),
(15624, 719, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(15625, 719, 'sections_1_block_footer', ''),
(15626, 719, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(15627, 693, '_wp_attachment_backup_sizes', 'a:5:{s:9:\"full-orig\";a:3:{s:5:\"width\";i:1042;s:6:\"height\";i:783;s:4:\"file\";s:24:\"gangagen-beginninigs.jpg\";}s:14:\"thumbnail-orig\";a:4:{s:4:\"file\";s:32:\"gangagen-beginninigs-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:11:\"medium-orig\";a:4:{s:4:\"file\";s:32:\"gangagen-beginninigs-300x225.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:225;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:17:\"medium_large-orig\";a:4:{s:4:\"file\";s:32:\"gangagen-beginninigs-768x577.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:577;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:10:\"large-orig\";a:4:{s:4:\"file\";s:33:\"gangagen-beginninigs-1024x769.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:769;s:9:\"mime-type\";s:10:\"image/jpeg\";}}'),
(15628, 228, 'management_6_name', 'Dr. Manur Jayasheela'),
(15629, 228, '_management_6_name', 'field_5efe20a3d7829'),
(15630, 228, 'management_6_board_type', 'gbpl'),
(15631, 228, '_management_6_board_type', 'field_5f554dca6181e'),
(15632, 228, 'management_6_title', 'Member, Board of Directors GBPL'),
(15633, 228, '_management_6_title', 'field_5efe20add782a'),
(15634, 228, 'management_6_image', '768');
INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(15635, 228, '_management_6_image', 'field_5f5516e46507c'),
(15636, 228, 'management_6_bio', 'The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.\r\n\r\nDr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chengalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.\r\n\r\nDr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.'),
(15637, 228, '_management_6_bio', 'field_5efe20b4d782b'),
(15638, 720, 'custom_page_logo', ''),
(15639, 720, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15640, 720, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(15641, 720, '_sections', 'field_5e1273c3f12ad'),
(15642, 720, 'sections_0_admin_title', 'Header Banner'),
(15643, 720, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15644, 720, 'sections_0_disable_mode', '0'),
(15645, 720, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15646, 720, 'sections_0_template_block_part', '/templates/header-banner'),
(15647, 720, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15648, 720, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(15649, 720, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(15650, 720, 'sections_1_disable_mode', '0'),
(15651, 720, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(15652, 720, 'sections_1_template_block_part', '/templates/directors'),
(15653, 720, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(15654, 720, 'management_0_name', 'Suchad Chiaranussati'),
(15655, 720, '_management_0_name', 'field_5efe20a3d7829'),
(15656, 720, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(15657, 720, '_management_0_title', 'field_5efe20add782a'),
(15658, 720, 'management_0_image', ''),
(15659, 720, '_management_0_image', 'field_5f5516e46507c'),
(15660, 720, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014.</p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities.</p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004.</p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand.</p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London.</p>'),
(15661, 720, '_management_0_bio', 'field_5efe20b4d782b'),
(15662, 720, 'management_1_name', 'Dean Cash'),
(15663, 720, '_management_1_name', 'field_5efe20a3d7829'),
(15664, 720, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(15665, 720, '_management_1_title', 'field_5efe20add782a'),
(15666, 720, 'management_1_image', '690'),
(15667, 720, '_management_1_image', 'field_5f5516e46507c'),
(15668, 720, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computer and patient records systems around North America. A transfer to GEISCO, General Electric’s information systems division selling computer time sharing followed. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO.</p>\r\n\r\n<p>Mr. Cash served on the board of directors of the Gangagen Incorporation, a biotech company researching new anti-bacterial treatments for “super bugs”. He also owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 600 employees.</p>\r\n\r\n<p>Mr. Cash is active within the non-profit community in San Francisco and serves on the Board of Governors of the San Francisco Symphony. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities.</p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons – Max, 25 years old who is a graduate of USC; and Sam, 22 years old and is currently a senior at USC.</p>'),
(15669, 720, '_management_1_bio', 'field_5efe20b4d782b'),
(15670, 720, 'management_2_name', 'Vinod Jadhav'),
(15671, 720, '_management_2_name', 'field_5efe20a3d7829'),
(15672, 720, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(15673, 720, '_management_2_title', 'field_5efe20add782a'),
(15674, 720, 'management_2_image', ''),
(15675, 720, '_management_2_image', 'field_5f5516e46507c'),
(15676, 720, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(15677, 720, '_management_2_bio', 'field_5efe20b4d782b'),
(15678, 720, 'management', '7'),
(15679, 720, '_management', 'field_5efe2097d7828'),
(15680, 720, 'management_0_board_type', 'bactoclear'),
(15681, 720, '_management_0_board_type', 'field_5f554dca6181e'),
(15682, 720, 'management_1_board_type', 'bactoclear'),
(15683, 720, '_management_1_board_type', 'field_5f554dca6181e'),
(15684, 720, 'management_2_board_type', 'bactoclear'),
(15685, 720, '_management_2_board_type', 'field_5f554dca6181e'),
(15686, 720, 'management_3_name', 'Jeffrey Leow'),
(15687, 720, '_management_3_name', 'field_5efe20a3d7829'),
(15688, 720, 'management_3_board_type', 'bactoclear'),
(15689, 720, '_management_3_board_type', 'field_5f554dca6181e'),
(15690, 720, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(15691, 720, '_management_3_title', 'field_5efe20add782a'),
(15692, 720, 'management_3_image', ''),
(15693, 720, '_management_3_image', 'field_5f5516e46507c'),
(15694, 720, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(15695, 720, '_management_3_bio', 'field_5efe20b4d782b'),
(15696, 720, 'management_4_name', 'Dr. T. S. Balganesh'),
(15697, 720, '_management_4_name', 'field_5efe20a3d7829'),
(15698, 720, 'management_4_board_type', 'gbpl'),
(15699, 720, '_management_4_board_type', 'field_5f554dca6181e'),
(15700, 720, 'management_4_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(15701, 720, '_management_4_title', 'field_5efe20add782a'),
(15702, 720, 'management_4_image', '501'),
(15703, 720, '_management_4_image', 'field_5f5516e46507c'),
(15704, 720, 'management_4_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(15705, 720, '_management_4_bio', 'field_5efe20b4d782b'),
(15706, 720, 'management_5_name', 'Dr. Janakiraman Ramachandran'),
(15707, 720, '_management_5_name', 'field_5efe20a3d7829'),
(15708, 720, 'management_5_board_type', 'gbpl'),
(15709, 720, '_management_5_board_type', 'field_5f554dca6181e'),
(15710, 720, 'management_5_title', 'Founder and Chairman - Board of Directors, GBPL'),
(15711, 720, '_management_5_title', 'field_5efe20add782a'),
(15712, 720, 'management_5_image', ''),
(15713, 720, '_management_5_image', 'field_5f5516e46507c'),
(15714, 720, 'management_5_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(15715, 720, '_management_5_bio', 'field_5efe20b4d782b'),
(15716, 720, 'management_6_name', 'Dr. Manur Jayasheela'),
(15717, 720, '_management_6_name', 'field_5efe20a3d7829'),
(15718, 720, 'management_6_board_type', 'gbpl'),
(15719, 720, '_management_6_board_type', 'field_5f554dca6181e'),
(15720, 720, 'management_6_title', 'Member, Board of Directors GBPL'),
(15721, 720, '_management_6_title', 'field_5efe20add782a'),
(15722, 720, 'management_6_image', ''),
(15723, 720, '_management_6_image', 'field_5f5516e46507c'),
(15724, 720, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(15725, 720, '_management_6_bio', 'field_5efe20b4d782b'),
(15726, 721, 'custom_page_logo', ''),
(15727, 721, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15728, 721, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(15729, 721, '_sections', 'field_5e1273c3f12ad'),
(15730, 721, 'sections_0_admin_title', 'Header Banner'),
(15731, 721, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15732, 721, 'sections_0_disable_mode', '0'),
(15733, 721, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15734, 721, 'sections_0_template_block_part', '/templates/header-banner'),
(15735, 721, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15736, 721, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(15737, 721, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(15738, 721, 'sections_1_disable_mode', '0'),
(15739, 721, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(15740, 721, 'sections_1_template_block_part', '/templates/directors'),
(15741, 721, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(15742, 721, 'management_0_name', 'Suchad Chiaranussati'),
(15743, 721, '_management_0_name', 'field_5efe20a3d7829'),
(15744, 721, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(15745, 721, '_management_0_title', 'field_5efe20add782a'),
(15746, 721, 'management_0_image', ''),
(15747, 721, '_management_0_image', 'field_5f5516e46507c'),
(15748, 721, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014.</p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities.</p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004.</p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand.</p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London.</p>'),
(15749, 721, '_management_0_bio', 'field_5efe20b4d782b'),
(15750, 721, 'management_1_name', 'Dean Cash'),
(15751, 721, '_management_1_name', 'field_5efe20a3d7829'),
(15752, 721, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(15753, 721, '_management_1_title', 'field_5efe20add782a'),
(15754, 721, 'management_1_image', '690'),
(15755, 721, '_management_1_image', 'field_5f5516e46507c'),
(15756, 721, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\\\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(15757, 721, '_management_1_bio', 'field_5efe20b4d782b'),
(15758, 721, 'management_2_name', 'Vinod Jadhav'),
(15759, 721, '_management_2_name', 'field_5efe20a3d7829'),
(15760, 721, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(15761, 721, '_management_2_title', 'field_5efe20add782a'),
(15762, 721, 'management_2_image', ''),
(15763, 721, '_management_2_image', 'field_5f5516e46507c'),
(15764, 721, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(15765, 721, '_management_2_bio', 'field_5efe20b4d782b'),
(15766, 721, 'management', '7'),
(15767, 721, '_management', 'field_5efe2097d7828'),
(15768, 721, 'management_0_board_type', 'bactoclear'),
(15769, 721, '_management_0_board_type', 'field_5f554dca6181e'),
(15770, 721, 'management_1_board_type', 'bactoclear'),
(15771, 721, '_management_1_board_type', 'field_5f554dca6181e'),
(15772, 721, 'management_2_board_type', 'bactoclear'),
(15773, 721, '_management_2_board_type', 'field_5f554dca6181e'),
(15774, 721, 'management_3_name', 'Jeffrey Leow'),
(15775, 721, '_management_3_name', 'field_5efe20a3d7829'),
(15776, 721, 'management_3_board_type', 'bactoclear'),
(15777, 721, '_management_3_board_type', 'field_5f554dca6181e'),
(15778, 721, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(15779, 721, '_management_3_title', 'field_5efe20add782a'),
(15780, 721, 'management_3_image', ''),
(15781, 721, '_management_3_image', 'field_5f5516e46507c'),
(15782, 721, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(15783, 721, '_management_3_bio', 'field_5efe20b4d782b'),
(15784, 721, 'management_4_name', 'Dr. T. S. Balganesh'),
(15785, 721, '_management_4_name', 'field_5efe20a3d7829'),
(15786, 721, 'management_4_board_type', 'gbpl'),
(15787, 721, '_management_4_board_type', 'field_5f554dca6181e'),
(15788, 721, 'management_4_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(15789, 721, '_management_4_title', 'field_5efe20add782a'),
(15790, 721, 'management_4_image', '501'),
(15791, 721, '_management_4_image', 'field_5f5516e46507c'),
(15792, 721, 'management_4_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(15793, 721, '_management_4_bio', 'field_5efe20b4d782b'),
(15794, 721, 'management_5_name', 'Dr. Janakiraman Ramachandran'),
(15795, 721, '_management_5_name', 'field_5efe20a3d7829'),
(15796, 721, 'management_5_board_type', 'gbpl'),
(15797, 721, '_management_5_board_type', 'field_5f554dca6181e'),
(15798, 721, 'management_5_title', 'Founder and Chairman - Board of Directors, GBPL'),
(15799, 721, '_management_5_title', 'field_5efe20add782a'),
(15800, 721, 'management_5_image', ''),
(15801, 721, '_management_5_image', 'field_5f5516e46507c'),
(15802, 721, 'management_5_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(15803, 721, '_management_5_bio', 'field_5efe20b4d782b'),
(15804, 721, 'management_6_name', 'Dr. Manur Jayasheela'),
(15805, 721, '_management_6_name', 'field_5efe20a3d7829'),
(15806, 721, 'management_6_board_type', 'gbpl'),
(15807, 721, '_management_6_board_type', 'field_5f554dca6181e'),
(15808, 721, 'management_6_title', 'Member, Board of Directors GBPL'),
(15809, 721, '_management_6_title', 'field_5efe20add782a'),
(15810, 721, 'management_6_image', ''),
(15811, 721, '_management_6_image', 'field_5f5516e46507c'),
(15812, 721, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(15813, 721, '_management_6_bio', 'field_5efe20b4d782b'),
(15814, 722, 'custom_page_logo', ''),
(15815, 722, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15816, 722, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(15817, 722, '_sections', 'field_5e1273c3f12ad'),
(15818, 722, 'sections_0_admin_title', 'Header Banner'),
(15819, 722, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15820, 722, 'sections_0_disable_mode', '0'),
(15821, 722, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15822, 722, 'sections_0_template_block_part', '/templates/header-banner'),
(15823, 722, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15824, 722, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(15825, 722, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(15826, 722, 'sections_1_disable_mode', '0'),
(15827, 722, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(15828, 722, 'sections_1_template_block_part', '/templates/directors'),
(15829, 722, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(15830, 722, 'management_0_name', 'Suchad Chiaranussati'),
(15831, 722, '_management_0_name', 'field_5efe20a3d7829'),
(15832, 722, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(15833, 722, '_management_0_title', 'field_5efe20add782a'),
(15834, 722, 'management_0_image', ''),
(15835, 722, '_management_0_image', 'field_5f5516e46507c'),
(15836, 722, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(15837, 722, '_management_0_bio', 'field_5efe20b4d782b'),
(15838, 722, 'management_1_name', 'Dean Cash'),
(15839, 722, '_management_1_name', 'field_5efe20a3d7829'),
(15840, 722, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(15841, 722, '_management_1_title', 'field_5efe20add782a'),
(15842, 722, 'management_1_image', '690'),
(15843, 722, '_management_1_image', 'field_5f5516e46507c'),
(15844, 722, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\\\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(15845, 722, '_management_1_bio', 'field_5efe20b4d782b'),
(15846, 722, 'management_2_name', 'Vinod Jadhav'),
(15847, 722, '_management_2_name', 'field_5efe20a3d7829'),
(15848, 722, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(15849, 722, '_management_2_title', 'field_5efe20add782a'),
(15850, 722, 'management_2_image', ''),
(15851, 722, '_management_2_image', 'field_5f5516e46507c'),
(15852, 722, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(15853, 722, '_management_2_bio', 'field_5efe20b4d782b'),
(15854, 722, 'management', '7'),
(15855, 722, '_management', 'field_5efe2097d7828'),
(15856, 722, 'management_0_board_type', 'bactoclear'),
(15857, 722, '_management_0_board_type', 'field_5f554dca6181e'),
(15858, 722, 'management_1_board_type', 'bactoclear'),
(15859, 722, '_management_1_board_type', 'field_5f554dca6181e'),
(15860, 722, 'management_2_board_type', 'bactoclear'),
(15861, 722, '_management_2_board_type', 'field_5f554dca6181e'),
(15862, 722, 'management_3_name', 'Jeffrey Leow'),
(15863, 722, '_management_3_name', 'field_5efe20a3d7829'),
(15864, 722, 'management_3_board_type', 'bactoclear'),
(15865, 722, '_management_3_board_type', 'field_5f554dca6181e'),
(15866, 722, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(15867, 722, '_management_3_title', 'field_5efe20add782a'),
(15868, 722, 'management_3_image', ''),
(15869, 722, '_management_3_image', 'field_5f5516e46507c'),
(15870, 722, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(15871, 722, '_management_3_bio', 'field_5efe20b4d782b'),
(15872, 722, 'management_4_name', 'Dr. T. S. Balganesh'),
(15873, 722, '_management_4_name', 'field_5efe20a3d7829'),
(15874, 722, 'management_4_board_type', 'gbpl'),
(15875, 722, '_management_4_board_type', 'field_5f554dca6181e'),
(15876, 722, 'management_4_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(15877, 722, '_management_4_title', 'field_5efe20add782a'),
(15878, 722, 'management_4_image', '501'),
(15879, 722, '_management_4_image', 'field_5f5516e46507c'),
(15880, 722, 'management_4_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(15881, 722, '_management_4_bio', 'field_5efe20b4d782b'),
(15882, 722, 'management_5_name', 'Dr. Janakiraman Ramachandran'),
(15883, 722, '_management_5_name', 'field_5efe20a3d7829'),
(15884, 722, 'management_5_board_type', 'gbpl'),
(15885, 722, '_management_5_board_type', 'field_5f554dca6181e'),
(15886, 722, 'management_5_title', 'Founder and Chairman - Board of Directors, GBPL'),
(15887, 722, '_management_5_title', 'field_5efe20add782a'),
(15888, 722, 'management_5_image', ''),
(15889, 722, '_management_5_image', 'field_5f5516e46507c'),
(15890, 722, 'management_5_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(15891, 722, '_management_5_bio', 'field_5efe20b4d782b'),
(15892, 722, 'management_6_name', 'Dr. Manur Jayasheela'),
(15893, 722, '_management_6_name', 'field_5efe20a3d7829'),
(15894, 722, 'management_6_board_type', 'gbpl'),
(15895, 722, '_management_6_board_type', 'field_5f554dca6181e'),
(15896, 722, 'management_6_title', 'Member, Board of Directors GBPL'),
(15897, 722, '_management_6_title', 'field_5efe20add782a'),
(15898, 722, 'management_6_image', ''),
(15899, 722, '_management_6_image', 'field_5f5516e46507c'),
(15900, 722, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(15901, 722, '_management_6_bio', 'field_5efe20b4d782b'),
(15902, 723, 'custom_page_logo', ''),
(15903, 723, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(15904, 723, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(15905, 723, '_sections', 'field_5e1273c3f12ad'),
(15906, 723, 'sections_0_admin_title', 'Header Banner'),
(15907, 723, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(15908, 723, 'sections_0_disable_mode', '0'),
(15909, 723, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(15910, 723, 'sections_0_template_block_part', '/templates/header-banner'),
(15911, 723, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(15912, 723, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(15913, 723, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(15914, 723, 'sections_1_disable_mode', '0'),
(15915, 723, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(15916, 723, 'sections_1_template_block_part', '/templates/directors'),
(15917, 723, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(15918, 723, 'management_0_name', 'Suchad Chiaranussati'),
(15919, 723, '_management_0_name', 'field_5efe20a3d7829'),
(15920, 723, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(15921, 723, '_management_0_title', 'field_5efe20add782a'),
(15922, 723, 'management_0_image', ''),
(15923, 723, '_management_0_image', 'field_5f5516e46507c'),
(15924, 723, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(15925, 723, '_management_0_bio', 'field_5efe20b4d782b'),
(15926, 723, 'management_1_name', 'Dean Cash'),
(15927, 723, '_management_1_name', 'field_5efe20a3d7829'),
(15928, 723, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(15929, 723, '_management_1_title', 'field_5efe20add782a'),
(15930, 723, 'management_1_image', '690'),
(15931, 723, '_management_1_image', 'field_5f5516e46507c'),
(15932, 723, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(15933, 723, '_management_1_bio', 'field_5efe20b4d782b'),
(15934, 723, 'management_2_name', 'Vinod Jadhav'),
(15935, 723, '_management_2_name', 'field_5efe20a3d7829'),
(15936, 723, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(15937, 723, '_management_2_title', 'field_5efe20add782a'),
(15938, 723, 'management_2_image', ''),
(15939, 723, '_management_2_image', 'field_5f5516e46507c'),
(15940, 723, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>');
INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(15941, 723, '_management_2_bio', 'field_5efe20b4d782b'),
(15942, 723, 'management', '7'),
(15943, 723, '_management', 'field_5efe2097d7828'),
(15944, 723, 'management_0_board_type', 'bactoclear'),
(15945, 723, '_management_0_board_type', 'field_5f554dca6181e'),
(15946, 723, 'management_1_board_type', 'bactoclear'),
(15947, 723, '_management_1_board_type', 'field_5f554dca6181e'),
(15948, 723, 'management_2_board_type', 'bactoclear'),
(15949, 723, '_management_2_board_type', 'field_5f554dca6181e'),
(15950, 723, 'management_3_name', 'Jeffrey Leow'),
(15951, 723, '_management_3_name', 'field_5efe20a3d7829'),
(15952, 723, 'management_3_board_type', 'bactoclear'),
(15953, 723, '_management_3_board_type', 'field_5f554dca6181e'),
(15954, 723, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(15955, 723, '_management_3_title', 'field_5efe20add782a'),
(15956, 723, 'management_3_image', ''),
(15957, 723, '_management_3_image', 'field_5f5516e46507c'),
(15958, 723, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(15959, 723, '_management_3_bio', 'field_5efe20b4d782b'),
(15960, 723, 'management_4_name', 'Dr. T. S. Balganesh'),
(15961, 723, '_management_4_name', 'field_5efe20a3d7829'),
(15962, 723, 'management_4_board_type', 'gbpl'),
(15963, 723, '_management_4_board_type', 'field_5f554dca6181e'),
(15964, 723, 'management_4_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(15965, 723, '_management_4_title', 'field_5efe20add782a'),
(15966, 723, 'management_4_image', '501'),
(15967, 723, '_management_4_image', 'field_5f5516e46507c'),
(15968, 723, 'management_4_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(15969, 723, '_management_4_bio', 'field_5efe20b4d782b'),
(15970, 723, 'management_5_name', 'Dr. Janakiraman Ramachandran'),
(15971, 723, '_management_5_name', 'field_5efe20a3d7829'),
(15972, 723, 'management_5_board_type', 'gbpl'),
(15973, 723, '_management_5_board_type', 'field_5f554dca6181e'),
(15974, 723, 'management_5_title', 'Founder and Chairman - Board of Directors, GBPL'),
(15975, 723, '_management_5_title', 'field_5efe20add782a'),
(15976, 723, 'management_5_image', ''),
(15977, 723, '_management_5_image', 'field_5f5516e46507c'),
(15978, 723, 'management_5_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(15979, 723, '_management_5_bio', 'field_5efe20b4d782b'),
(15980, 723, 'management_6_name', 'Dr. Manur Jayasheela'),
(15981, 723, '_management_6_name', 'field_5efe20a3d7829'),
(15982, 723, 'management_6_board_type', 'gbpl'),
(15983, 723, '_management_6_board_type', 'field_5f554dca6181e'),
(15984, 723, 'management_6_title', 'Member, Board of Directors GBPL'),
(15985, 723, '_management_6_title', 'field_5efe20add782a'),
(15986, 723, 'management_6_image', ''),
(15987, 723, '_management_6_image', 'field_5f5516e46507c'),
(15988, 723, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(15989, 723, '_management_6_bio', 'field_5efe20b4d782b'),
(15990, 724, '_wp_attached_file', '2020/09/Suchad-Chiaranussati.jpg'),
(15991, 724, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:338;s:6:\"height\";i:338;s:4:\"file\";s:32:\"2020/09/Suchad-Chiaranussati.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:32:\"Suchad-Chiaranussati-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:32:\"Suchad-Chiaranussati-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15992, 725, '_wp_attached_file', '2020/09/JL-photo.jpg'),
(15993, 725, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:414;s:6:\"height\";i:414;s:4:\"file\";s:20:\"2020/09/JL-photo.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:20:\"JL-photo-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:20:\"JL-photo-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15994, 726, '_wp_attached_file', '2020/09/JR-photo.jpg'),
(15995, 726, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1000;s:6:\"height\";i:1000;s:4:\"file\";s:20:\"2020/09/JR-photo.jpg\";s:5:\"sizes\";a:3:{s:6:\"medium\";a:4:{s:4:\"file\";s:20:\"JR-photo-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:20:\"JR-photo-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:20:\"JR-photo-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15996, 727, '_wp_attached_file', '2020/09/Vinod-Jadhav-photo.jpg'),
(15997, 727, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:600;s:6:\"height\";i:600;s:4:\"file\";s:30:\"2020/09/Vinod-Jadhav-photo.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:30:\"Vinod-Jadhav-photo-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:30:\"Vinod-Jadhav-photo-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(15998, 728, 'custom_page_logo', ''),
(15999, 728, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16000, 728, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(16001, 728, '_sections', 'field_5e1273c3f12ad'),
(16002, 728, 'sections_0_admin_title', 'Header Banner'),
(16003, 728, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16004, 728, 'sections_0_disable_mode', '0'),
(16005, 728, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16006, 728, 'sections_0_template_block_part', '/templates/header-banner'),
(16007, 728, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16008, 728, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(16009, 728, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(16010, 728, 'sections_1_disable_mode', '0'),
(16011, 728, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(16012, 728, 'sections_1_template_block_part', '/templates/directors'),
(16013, 728, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(16014, 728, 'management_0_name', 'Suchad Chiaranussati'),
(16015, 728, '_management_0_name', 'field_5efe20a3d7829'),
(16016, 728, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(16017, 728, '_management_0_title', 'field_5efe20add782a'),
(16018, 728, 'management_0_image', '724'),
(16019, 728, '_management_0_image', 'field_5f5516e46507c'),
(16020, 728, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(16021, 728, '_management_0_bio', 'field_5efe20b4d782b'),
(16022, 728, 'management_1_name', 'Dean Cash'),
(16023, 728, '_management_1_name', 'field_5efe20a3d7829'),
(16024, 728, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(16025, 728, '_management_1_title', 'field_5efe20add782a'),
(16026, 728, 'management_1_image', '690'),
(16027, 728, '_management_1_image', 'field_5f5516e46507c'),
(16028, 728, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(16029, 728, '_management_1_bio', 'field_5efe20b4d782b'),
(16030, 728, 'management_2_name', 'Vinod Jadhav'),
(16031, 728, '_management_2_name', 'field_5efe20a3d7829'),
(16032, 728, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(16033, 728, '_management_2_title', 'field_5efe20add782a'),
(16034, 728, 'management_2_image', '727'),
(16035, 728, '_management_2_image', 'field_5f5516e46507c'),
(16036, 728, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(16037, 728, '_management_2_bio', 'field_5efe20b4d782b'),
(16038, 728, 'management', '7'),
(16039, 728, '_management', 'field_5efe2097d7828'),
(16040, 728, 'management_0_board_type', 'bactoclear'),
(16041, 728, '_management_0_board_type', 'field_5f554dca6181e'),
(16042, 728, 'management_1_board_type', 'bactoclear'),
(16043, 728, '_management_1_board_type', 'field_5f554dca6181e'),
(16044, 728, 'management_2_board_type', 'bactoclear'),
(16045, 728, '_management_2_board_type', 'field_5f554dca6181e'),
(16046, 728, 'management_3_name', 'Jeffrey Leow'),
(16047, 728, '_management_3_name', 'field_5efe20a3d7829'),
(16048, 728, 'management_3_board_type', 'bactoclear'),
(16049, 728, '_management_3_board_type', 'field_5f554dca6181e'),
(16050, 728, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(16051, 728, '_management_3_title', 'field_5efe20add782a'),
(16052, 728, 'management_3_image', '725'),
(16053, 728, '_management_3_image', 'field_5f5516e46507c'),
(16054, 728, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(16055, 728, '_management_3_bio', 'field_5efe20b4d782b'),
(16056, 728, 'management_4_name', 'Dr. T. S. Balganesh'),
(16057, 728, '_management_4_name', 'field_5efe20a3d7829'),
(16058, 728, 'management_4_board_type', 'gbpl'),
(16059, 728, '_management_4_board_type', 'field_5f554dca6181e'),
(16060, 728, 'management_4_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(16061, 728, '_management_4_title', 'field_5efe20add782a'),
(16062, 728, 'management_4_image', '501'),
(16063, 728, '_management_4_image', 'field_5f5516e46507c'),
(16064, 728, 'management_4_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(16065, 728, '_management_4_bio', 'field_5efe20b4d782b'),
(16066, 728, 'management_5_name', 'Dr. Janakiraman Ramachandran'),
(16067, 728, '_management_5_name', 'field_5efe20a3d7829'),
(16068, 728, 'management_5_board_type', 'gbpl'),
(16069, 728, '_management_5_board_type', 'field_5f554dca6181e'),
(16070, 728, 'management_5_title', 'Founder and Chairman - Board of Directors, GBPL'),
(16071, 728, '_management_5_title', 'field_5efe20add782a'),
(16072, 728, 'management_5_image', '726'),
(16073, 728, '_management_5_image', 'field_5f5516e46507c'),
(16074, 728, 'management_5_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(16075, 728, '_management_5_bio', 'field_5efe20b4d782b'),
(16076, 728, 'management_6_name', 'Dr. Manur Jayasheela'),
(16077, 728, '_management_6_name', 'field_5efe20a3d7829'),
(16078, 728, 'management_6_board_type', 'gbpl'),
(16079, 728, '_management_6_board_type', 'field_5f554dca6181e'),
(16080, 728, 'management_6_title', 'Member, Board of Directors GBPL'),
(16081, 728, '_management_6_title', 'field_5efe20add782a'),
(16082, 728, 'management_6_image', ''),
(16083, 728, '_management_6_image', 'field_5f5516e46507c'),
(16084, 728, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(16085, 728, '_management_6_bio', 'field_5efe20b4d782b'),
(16086, 729, 'custom_page_logo', ''),
(16087, 729, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16088, 729, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(16089, 729, '_sections', 'field_5e1273c3f12ad'),
(16090, 729, 'sections_0_admin_title', 'Header Banner'),
(16091, 729, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16092, 729, 'sections_0_disable_mode', '0'),
(16093, 729, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16094, 729, 'sections_0_template_block_part', '/templates/header-banner'),
(16095, 729, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16096, 729, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(16097, 729, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(16098, 729, 'sections_1_disable_mode', '0'),
(16099, 729, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(16100, 729, 'sections_1_template_block_part', '/templates/directors'),
(16101, 729, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(16102, 729, 'management_0_name', 'Suchad Chiaranussati'),
(16103, 729, '_management_0_name', 'field_5efe20a3d7829'),
(16104, 729, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(16105, 729, '_management_0_title', 'field_5efe20add782a'),
(16106, 729, 'management_0_image', '724'),
(16107, 729, '_management_0_image', 'field_5f5516e46507c'),
(16108, 729, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(16109, 729, '_management_0_bio', 'field_5efe20b4d782b'),
(16110, 729, 'management_1_name', 'Dean Cash'),
(16111, 729, '_management_1_name', 'field_5efe20a3d7829'),
(16112, 729, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(16113, 729, '_management_1_title', 'field_5efe20add782a'),
(16114, 729, 'management_1_image', '690'),
(16115, 729, '_management_1_image', 'field_5f5516e46507c'),
(16116, 729, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(16117, 729, '_management_1_bio', 'field_5efe20b4d782b'),
(16118, 729, 'management_2_name', 'Vinod Jadhav'),
(16119, 729, '_management_2_name', 'field_5efe20a3d7829'),
(16120, 729, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(16121, 729, '_management_2_title', 'field_5efe20add782a'),
(16122, 729, 'management_2_image', '727'),
(16123, 729, '_management_2_image', 'field_5f5516e46507c'),
(16124, 729, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(16125, 729, '_management_2_bio', 'field_5efe20b4d782b'),
(16126, 729, 'management', '7'),
(16127, 729, '_management', 'field_5efe2097d7828'),
(16128, 729, 'management_0_board_type', 'bactoclear'),
(16129, 729, '_management_0_board_type', 'field_5f554dca6181e'),
(16130, 729, 'management_1_board_type', 'bactoclear'),
(16131, 729, '_management_1_board_type', 'field_5f554dca6181e'),
(16132, 729, 'management_2_board_type', 'bactoclear'),
(16133, 729, '_management_2_board_type', 'field_5f554dca6181e'),
(16134, 729, 'management_3_name', 'Jeffrey Leow'),
(16135, 729, '_management_3_name', 'field_5efe20a3d7829'),
(16136, 729, 'management_3_board_type', 'bactoclear'),
(16137, 729, '_management_3_board_type', 'field_5f554dca6181e'),
(16138, 729, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(16139, 729, '_management_3_title', 'field_5efe20add782a'),
(16140, 729, 'management_3_image', '725'),
(16141, 729, '_management_3_image', 'field_5f5516e46507c'),
(16142, 729, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(16143, 729, '_management_3_bio', 'field_5efe20b4d782b'),
(16144, 729, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(16145, 729, '_management_4_name', 'field_5efe20a3d7829'),
(16146, 729, 'management_4_board_type', 'gbpl'),
(16147, 729, '_management_4_board_type', 'field_5f554dca6181e'),
(16148, 729, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(16149, 729, '_management_4_title', 'field_5efe20add782a'),
(16150, 729, 'management_4_image', '726'),
(16151, 729, '_management_4_image', 'field_5f5516e46507c'),
(16152, 729, 'management_4_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(16153, 729, '_management_4_bio', 'field_5efe20b4d782b'),
(16154, 729, 'management_5_name', 'Dr. T. S. Balganesh'),
(16155, 729, '_management_5_name', 'field_5efe20a3d7829'),
(16156, 729, 'management_5_board_type', 'gbpl'),
(16157, 729, '_management_5_board_type', 'field_5f554dca6181e'),
(16158, 729, 'management_5_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(16159, 729, '_management_5_title', 'field_5efe20add782a'),
(16160, 729, 'management_5_image', '501'),
(16161, 729, '_management_5_image', 'field_5f5516e46507c'),
(16162, 729, 'management_5_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(16163, 729, '_management_5_bio', 'field_5efe20b4d782b'),
(16164, 729, 'management_6_name', 'Dr. Manur Jayasheela'),
(16165, 729, '_management_6_name', 'field_5efe20a3d7829'),
(16166, 729, 'management_6_board_type', 'gbpl'),
(16167, 729, '_management_6_board_type', 'field_5f554dca6181e'),
(16168, 729, 'management_6_title', 'Member, Board of Directors GBPL'),
(16169, 729, '_management_6_title', 'field_5efe20add782a'),
(16170, 729, 'management_6_image', ''),
(16171, 729, '_management_6_image', 'field_5f5516e46507c'),
(16172, 729, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(16173, 729, '_management_6_bio', 'field_5efe20b4d782b'),
(16174, 236, '_thumbnail_id', '705'),
(16175, 730, 'custom_page_logo', ''),
(16176, 730, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16177, 730, 'sections', 'a:4:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";i:2;s:10:\"code_block\";i:3;s:10:\"code_block\";}'),
(16178, 730, '_sections', 'field_5e1273c3f12ad'),
(16179, 730, 'sections_0_admin_title', 'Header Banner'),
(16180, 730, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16181, 730, 'sections_0_disable_mode', '0'),
(16182, 730, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16183, 730, 'sections_0_template_block_part', '/templates/header-banner'),
(16184, 730, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16185, 730, 'sections_1_admin_title', ''),
(16186, 730, '_sections_1_admin_title', 'field_5e865038f6507'),
(16187, 730, 'sections_1_disable_mode', '0'),
(16188, 730, '_sections_1_disable_mode', 'field_5e865043f6508'),
(16189, 730, 'sections_1_content', '<div id=\"ectolysin-intro\" class=\"gg-calypso abx-white-text\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center anim-hidden fade-in-up\">\r\n    <h2 class=\"fw-900\">What are Ectolysins?</h2>\r\n    <p style=\"font-size:1.4rem; line-height:2;\">Ectolysins are phage structural proteins, which enable phages to penetrate the bacterial cell. They cleave specific chemical bonds on the bacterial cell wall, leading to bacterial lysis and death. </p>\r\n  </div>\r\n</div>'),
(16190, 730, '_sections_1_content', 'field_5e127410f12ae'),
(16191, 730, 'sections_1_disable_section', '0'),
(16192, 730, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16193, 730, 'sections_1_section_id', ''),
(16194, 730, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16195, 730, 'sections_1_klasses', ''),
(16196, 730, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16197, 730, 'sections_1_styles', ''),
(16198, 730, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16199, 730, 'sections_1_attributes', ''),
(16200, 730, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16201, 730, 'sections_1_background_image', ''),
(16202, 730, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16203, 730, 'sections_1_background_color', ''),
(16204, 730, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16205, 730, 'sections_1_text_color', ''),
(16206, 730, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16207, 730, 'sections_1_block_header', ''),
(16208, 730, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16209, 730, 'sections_1_block_footer', ''),
(16210, 730, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16211, 730, 'sections_2_admin_title', 'Advantages of Ectolysins'),
(16212, 730, '_sections_2_admin_title', 'field_5e865038f6507'),
(16213, 730, 'sections_2_disable_mode', '0'),
(16214, 730, '_sections_2_disable_mode', 'field_5e865043f6508'),
(16215, 730, 'sections_2_content', '<div id=\"ectolysin-advantages\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 py-5\">\r\n    <div class=\"text-center mb-4\">\r\n    	<h2 class=\"fw-900 gg-calypso-text anim-hidden fade-in-up\">Advantages of Ectolysins over Antibiotics</h2>\r\n    	<p class=\"gg-calypso-text anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins have the following advantages over antibiotics</p>\r\n    </div>\r\n    \r\n    <ul class=\"fa-ul\">\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Rapid Action</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are rapid acting and cleave the cell wall immediately on contact, within minutes, as against antibiotics that need longer duration to kill the cells.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Specific</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are very specific to the target bacterial species and hence kill only the target pathogen without affecting the microbiome or the commensal bacterial flora as compared to antibiotics which kill both the pathogens as well as the beneficial bacteria.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Mechanism of Action</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins have novel mode of action- they include enzymatic mechanisms like Muramidase, Glucosaminidase, Amidase or endopeptidase depending upon the cell wall bond targeted by the individual ectolysin.  The availability of a library of enzymatic domains offers the opportunity of protein engineering.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Bacterial Activity Independence</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Bactericidal activity is not dependent on the metabolic stage of the cell – Ectolysins kill both actively growing as well as stationary phase cells irrespective of the metabolic state. But antibiotics act only on metabolically active cells.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Active on Biofilms</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are active both on planktonic bacteria &amp; bacterial biofilms as against antibiotics, which act poorly on bacterial biofilms.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Less Propensity for Resistance</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins cleave essential cell wall chemical bonds, which are highly conserved and omnipresent on the bacterial cell surface; hence the propensity for the development of bacterial resistance is low.</p> \r\n    </ul>\r\n  </div>\r\n</div>\r\n\r\n'),
(16216, 730, '_sections_2_content', 'field_5e127410f12ae'),
(16217, 730, 'sections_2_disable_section', '0'),
(16218, 730, '_sections_2_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16219, 730, 'sections_2_section_id', ''),
(16220, 730, '_sections_2_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16221, 730, 'sections_2_klasses', ''),
(16222, 730, '_sections_2_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16223, 730, 'sections_2_styles', ''),
(16224, 730, '_sections_2_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16225, 730, 'sections_2_attributes', ''),
(16226, 730, '_sections_2_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16227, 730, 'sections_2_background_image', ''),
(16228, 730, '_sections_2_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16229, 730, 'sections_2_background_color', ''),
(16230, 730, '_sections_2_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16231, 730, 'sections_2_text_color', ''),
(16232, 730, '_sections_2_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16233, 730, 'sections_2_block_header', ''),
(16234, 730, '_sections_2_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16235, 730, 'sections_2_block_footer', ''),
(16236, 730, '_sections_2_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16237, 730, 'sections_3_admin_title', 'Ectolysins Against Gram Positive and Negative Bacteria'),
(16238, 730, '_sections_3_admin_title', 'field_5e865038f6507'),
(16239, 730, 'sections_3_disable_mode', '0'),
(16240, 730, '_sections_3_disable_mode', 'field_5e865043f6508'),
(16241, 730, 'sections_3_content', '<div id=\"protein-antibiotic-classes\">\r\n  \r\n  <div class=\" abx-white-text\">\r\n    \r\n    <div style=\"position:relative\">\r\n      \r\n      <div class=\"split-color\" style=\"position: absolute; top: 0; right: 0; bottom: 0; left: 0; width: 100%; height: 100%;\">\r\n        <div class=\"gg-japanese-laurel\" style=\"float:left; height: 100%; width: 50%; display: inline-block;\"></div>\r\n        <div class=\"gg-calypso\" style=\"float:left; height: 100%; width: 50%; display: inline-block; z-index: 0;\"></div>\r\n      </div>\r\n      \r\n      <div class=\"px-3 py-5 text-center\" style=\"position:relative;\">\r\n        <h2>Ectolysins Against Gram-Positive and Gram-Negative Bacteria</h2>\r\n      </div>\r\n      \r\n    </div>\r\n      \r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-md px-3 pt-5\">\r\n      <div class=\"row\">\r\n\r\n        <div class=\"col-12 col-md-6 pb-5 text-center anim-hidden fade-in-left\">\r\n          	<!-- <div class=\"gg-japanese-laurel abx-white-text mb-3\" style=\"width:100px; height:100px; border-radius:50%; margin:0 auto; padding-top:1.2rem;\"><i class=\"fa fa-4x fa-plus\"></i></div> -->\r\n          	<img src=\"/wp-content/uploads/2020/09/gram-positive.jpg\" alt=\"gram-positive\" />\r\n          	<h3 class=\"mb-4 gg-japanese-laurel-text\">Gram-Positive</h3>\r\n            <a href=\"/ectolysins-against-gram-positive-bacteria\"><button class=\"gangagen-button\">Learn More</button></a>\r\n        </div>\r\n\r\n        <div class=\"col-12 col-md-6 pb-5 text-center anim-hidden fade-in-right\">\r\n          	<!-- <div class=\"gg-calypso abx-white-text mb-3\" style=\"width:100px; height:100px; border-radius:50%; margin:0 auto; padding-top:1.2rem;\"><i class=\"fa fa-4x fa-minus\"></i></div> -->\r\n          	<img src=\"/wp-content/uploads/2020/09/gram-negative.jpg\" alt=\"gram-negative\" />\r\n          	<h3 class=\"mb-4 gg-calypso-text\">Gram Negative</h3>\r\n            <a href=\"/ectolysins-against-gram-negative-bacteria\"><button class=\"gangagen-button-calypso\">Learn More</button></a>\r\n        </div>\r\n\r\n      </div>\r\n    </div>\r\n  </div>\r\n    \r\n</div>'),
(16242, 730, '_sections_3_content', 'field_5e127410f12ae'),
(16243, 730, 'sections_3_disable_section', '0'),
(16244, 730, '_sections_3_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16245, 730, 'sections_3_section_id', ''),
(16246, 730, '_sections_3_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16247, 730, 'sections_3_klasses', ''),
(16248, 730, '_sections_3_klasses', 'field_5e127428f12af_field_5e1271a591855');
INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(16249, 730, 'sections_3_styles', ''),
(16250, 730, '_sections_3_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16251, 730, 'sections_3_attributes', ''),
(16252, 730, '_sections_3_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16253, 730, 'sections_3_background_image', ''),
(16254, 730, '_sections_3_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16255, 730, 'sections_3_background_color', ''),
(16256, 730, '_sections_3_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16257, 730, 'sections_3_text_color', ''),
(16258, 730, '_sections_3_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16259, 730, 'sections_3_block_header', ''),
(16260, 730, '_sections_3_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16261, 730, 'sections_3_block_footer', ''),
(16262, 730, '_sections_3_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16263, 731, 'custom_page_logo', ''),
(16264, 731, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16265, 731, 'sections', 'a:3:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";i:2;s:10:\"code_block\";}'),
(16266, 731, '_sections', 'field_5e1273c3f12ad'),
(16267, 731, 'sections_0_admin_title', 'Header Banner'),
(16268, 731, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16269, 731, 'sections_0_disable_mode', '0'),
(16270, 731, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16271, 731, 'sections_0_template_block_part', '/templates/header-banner'),
(16272, 731, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16273, 731, 'sections_1_admin_title', 'Bacteriocins Intro'),
(16274, 731, '_sections_1_admin_title', 'field_5e865038f6507'),
(16275, 731, 'sections_1_disable_mode', '0'),
(16276, 731, '_sections_1_disable_mode', 'field_5e865043f6508'),
(16277, 731, 'sections_1_content', '<div id=\"protein-antibiotic-technology\" class=\"gg-calypso\">\r\n	<div class=\"centerize ctz-lg px-3 py-5 text-center anim-hidden fade-in-up\">\r\n        <h2 class=\"abx-white-text fw-900\">What are Bacteriocins?</h2>\r\n		<p class=\"abx-white-text\" style=\"font-size:1.4rem; line-height:2;\">Bacteriocins are a diverse family of protein molecules produced by many Gram positive and Gram negative bacteria with antibacterial activity. Bacteria produce these bacteriocins to inhibit or eliminate other closely related bacteria to eliminate competition. Bacteriocins present a unique family of naturally occurring antibacterial proteins with a potential to be developed into antibiotics.</p>\r\n	</div>\r\n</div>\r\n\r\n  <div class=\"px-0 py-0\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12 col-md-6 abx-white py-5 text-center\">\r\n        <div class=\"centerize ctz-sm\">\r\n        	<h2 class=\"gg-calypso-text fw-900 anim-hidden fade-in-left\">How Does It Work?</h2>\r\n        	<p class=\"gg-calypso-text anim-hidden fade-in-left\" style=\"font-size:1.4rem; line-height:2;\">The CLBs entry into the bacterial cell is mediated through its interaction with cell-surface receptors, and thus conferring both specificity and selectivity. The Bacteriocin producing bacterium is protected from its own action by an immunity protein co-expressed with it.</p>\r\n        </div>\r\n      </div>\r\n      <div class=\"col-12 col-md-6 gg-light py-5 text-center\">\r\n        <div class=\"centerize ctz-sm\">\r\n        	<h2 class=\"gg-japanese-laurel-text fw-900 anim-hidden fade-in-right\">Mechanism of Action</h2>\r\n        	<p class=\"gg-japanese-laurel-text anim-hidden fade-in-right\" style=\"font-size:1.4rem; line-height:2;\">The mechanism of killing is through multiple modes such as cell wall damage, cell membrane damage, interfering in metabolic pathways, and DNase or RNase activities.</p>\r\n        </div>\r\n      </div>\r\n    </div>\r\n  </div>\r\n      	\r\n      \r\n\r\n'),
(16278, 731, '_sections_1_content', 'field_5e127410f12ae'),
(16279, 731, 'sections_1_disable_section', '0'),
(16280, 731, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16281, 731, 'sections_1_section_id', ''),
(16282, 731, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16283, 731, 'sections_1_klasses', ''),
(16284, 731, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16285, 731, 'sections_1_styles', ''),
(16286, 731, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16287, 731, 'sections_1_attributes', ''),
(16288, 731, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16289, 731, 'sections_1_background_image', ''),
(16290, 731, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16291, 731, 'sections_1_background_color', ''),
(16292, 731, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16293, 731, 'sections_1_text_color', ''),
(16294, 731, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16295, 731, 'sections_1_block_header', ''),
(16296, 731, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16297, 731, 'sections_1_block_footer', ''),
(16298, 731, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16299, 731, 'sections_2_admin_title', 'Gram Negative Bacteriocins'),
(16300, 731, '_sections_2_admin_title', 'field_5e865038f6507'),
(16301, 731, 'sections_2_disable_mode', '0'),
(16302, 731, '_sections_2_disable_mode', 'field_5e865043f6508'),
(16303, 731, 'sections_2_content', '<div id=\"gram-negative-bacteriocins\">\r\n  \r\n  <div class=\"gg-japanese-laurel abx-white-text text-center\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 anim-hidden fade-in-up\">\r\n      <h2 class=\"fw-900\">Gram Negative Bacteriocins</h2>\r\n      <p style=\"line-height:2; font-size:1.4rem;\">Bacteriocins from Gram negative bacteria are broadly classified into 3 types based on their size as:</p>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n\r\n      <div class=\"row\">\r\n        \r\n        <div class=\"col-12 col-md-4 text-center anim hidden fade-in-left\">\r\n          <img class=\"mb-3\" src=\"/wp-content/uploads/2020/09/2a.-Peptide-Bacteriocins.jpg.jpg\" alt=\"peptide-bacteriocins\" />\r\n          <h3 class=\"gg-japanese-laurel-text mb-3\">Peptide Bacteriocins</h3>\r\n          <p>Peptide Bacteriocins like microcins of less than 10 kDa size</p>\r\n        </div>\r\n        \r\n        <div class=\"col-12 col-md-4 text-center anim-hidden fade-in-up\">\r\n          <img class=\"mb-3\" src=\"/wp-content/uploads/2020/09/2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990.jpg\" alt=\"colicin-like-bacteriocins\" />\r\n          <h3 class=\"gg-japanese-laurel-text mb-3\">Colicin-Like Bacteriocins (CLB)</h3>\r\n          <p>Colicin-Like Bacteriocins (CLB) of 25 – 80 kDa size</p>\r\n        </div>\r\n        \r\n        <div class=\"col-12 col-md-4 text-center anim-hidden fade-in-right\">\r\n          <img class=\"mb-3\" src=\"https://via.placeholder.com/150x150?text=Image+Goes+Here\" alt=\"tailocins\" />\r\n          <h3 class=\"gg-japanese-laurel-text mb-3\">Tailocins</h3>\r\n          <p>Tailocins which are high molecular size bacteriocins that resemble the tail structures of bacteriophages.</p>\r\n        </div>\r\n        \r\n      </div>\r\n      \r\n    </div>\r\n  </div>\r\n  \r\n  <div id=\"bacteriocin-advantages-header\" class=\"gg-calypso text-center\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n    	<h2 class=\"fw-900 abx-white-text anim-hidden fade-in-up\">Advantages of Bacteriocins</h2>\r\n    	<p class=\"abx-white-text anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">Bacteriocins offer several advantages over antibiotics making them attractive starting points for developing anti-bacterial agents:</p>\r\n    </div>\r\n  </div>\r\n  \r\n  <div id=\"bacteriocin-advantages\" class=\"gg-light\">\r\n   <div class=\"centerize ctz-md px-3 py-5\">\r\n    \r\n    <ul class=\"fa-ul\">\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Specific</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Their specificity offers a targeted approach and kills only the target pathogen, without damaging the commensal human microbiota or microbiome.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Resistance Development</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">The Bacteriocins have a unique mode of action and hence there is no primed resistance in the bacterial community.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Selective</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Bacteriocins enter the bacterial cell through specific receptors which are absent on eukaryotic cells and hence are very selective agents.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Modular Architecture</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">The colicin like bacteriocins (CLB) have modular domain structure that can be engineered to generate new bacteriocins with enhanced functionalities like activity/stability.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Low Toxicity</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">For generations the commensal bacteria in human body has been employing the bacteriocins to ward off invasions by pathogenic bacteria, hence natural bacteriocins can be expected to be safe to Humans.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Synergy</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">The potency of Bacteriocin can further be enhanced by combining them with standard of care antibiotics.</p>\r\n      </li>\r\n      \r\n    </ul>\r\n  \r\n</div>'),
(16304, 731, '_sections_2_content', 'field_5e127410f12ae'),
(16305, 731, 'sections_2_disable_section', '0'),
(16306, 731, '_sections_2_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16307, 731, 'sections_2_section_id', ''),
(16308, 731, '_sections_2_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16309, 731, 'sections_2_klasses', ''),
(16310, 731, '_sections_2_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16311, 731, 'sections_2_styles', ''),
(16312, 731, '_sections_2_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16313, 731, 'sections_2_attributes', ''),
(16314, 731, '_sections_2_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16315, 731, 'sections_2_background_image', ''),
(16316, 731, '_sections_2_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16317, 731, 'sections_2_background_color', ''),
(16318, 731, '_sections_2_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16319, 731, 'sections_2_text_color', ''),
(16320, 731, '_sections_2_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16321, 731, 'sections_2_block_header', ''),
(16322, 731, '_sections_2_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16323, 731, 'sections_2_block_footer', ''),
(16324, 731, '_sections_2_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16325, 704, '_wp_attachment_backup_sizes', 'a:12:{s:9:\"full-orig\";a:3:{s:5:\"width\";i:1900;s:6:\"height\";i:1831;s:4:\"file\";s:38:\"2b.-Colicins-Like-Bacteriocins.jpg.jpg\";}s:14:\"thumbnail-orig\";a:4:{s:4:\"file\";s:46:\"2b.-Colicins-Like-Bacteriocins.jpg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:11:\"medium-orig\";a:4:{s:4:\"file\";s:46:\"2b.-Colicins-Like-Bacteriocins.jpg-300x289.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:289;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:17:\"medium_large-orig\";a:4:{s:4:\"file\";s:46:\"2b.-Colicins-Like-Bacteriocins.jpg-768x740.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:740;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:10:\"large-orig\";a:4:{s:4:\"file\";s:47:\"2b.-Colicins-Like-Bacteriocins.jpg-1024x987.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:987;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:14:\"1536x1536-orig\";a:4:{s:4:\"file\";s:48:\"2b.-Colicins-Like-Bacteriocins.jpg-1536x1480.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1480;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:18:\"full-1600372580990\";a:3:{s:5:\"width\";i:1831;s:6:\"height\";i:1900;s:4:\"file\";s:53:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372551718.jpg\";}s:23:\"thumbnail-1600372580990\";a:4:{s:4:\"file\";s:61:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372551718-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:20:\"medium-1600372580990\";a:4:{s:4:\"file\";s:61:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372551718-289x300.jpg\";s:5:\"width\";i:289;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:26:\"medium_large-1600372580990\";a:4:{s:4:\"file\";s:61:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372551718-768x797.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:797;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:19:\"large-1600372580990\";a:4:{s:4:\"file\";s:62:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372551718-987x1024.jpg\";s:5:\"width\";i:987;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:23:\"1536x1536-1600372580990\";a:4:{s:4:\"file\";s:63:\"2b.-Colicins-Like-Bacteriocins.jpg-e1600372551718-1480x1536.jpg\";s:5:\"width\";i:1480;s:6:\"height\";i:1536;s:9:\"mime-type\";s:10:\"image/jpeg\";}}'),
(16326, 732, 'custom_page_logo', ''),
(16327, 732, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16328, 732, 'sections', 'a:3:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";i:2;s:10:\"code_block\";}'),
(16329, 732, '_sections', 'field_5e1273c3f12ad'),
(16330, 732, 'sections_0_admin_title', 'Header Banner'),
(16331, 732, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16332, 732, 'sections_0_disable_mode', '0'),
(16333, 732, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16334, 732, 'sections_0_template_block_part', '/templates/header-banner'),
(16335, 732, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16336, 732, 'sections_1_admin_title', 'Bacteriocins Intro'),
(16337, 732, '_sections_1_admin_title', 'field_5e865038f6507'),
(16338, 732, 'sections_1_disable_mode', '0'),
(16339, 732, '_sections_1_disable_mode', 'field_5e865043f6508'),
(16340, 732, 'sections_1_content', '<div id=\"protein-antibiotic-technology\" class=\"gg-calypso\">\r\n	<div class=\"centerize ctz-lg px-3 py-5 text-center anim-hidden fade-in-up\">\r\n        <h2 class=\"abx-white-text fw-900\">What are Bacteriocins?</h2>\r\n		<p class=\"abx-white-text\" style=\"font-size:1.4rem; line-height:2;\">Bacteriocins are a diverse family of protein molecules produced by many Gram positive and Gram negative bacteria with antibacterial activity. Bacteria produce these bacteriocins to inhibit or eliminate other closely related bacteria to eliminate competition. Bacteriocins present a unique family of naturally occurring antibacterial proteins with a potential to be developed into antibiotics.</p>\r\n	</div>\r\n</div>\r\n\r\n  <div class=\"px-0 py-0\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12 col-md-6 abx-white py-5 text-center\">\r\n        <div class=\"centerize ctz-sm\">\r\n        	<h2 class=\"gg-calypso-text fw-900 anim-hidden fade-in-left\">How Does It Work?</h2>\r\n        	<p class=\"gg-calypso-text anim-hidden fade-in-left\" style=\"font-size:1.4rem; line-height:2;\">The CLBs entry into the bacterial cell is mediated through its interaction with cell-surface receptors, and thus conferring both specificity and selectivity. The Bacteriocin producing bacterium is protected from its own action by an immunity protein co-expressed with it.</p>\r\n        </div>\r\n      </div>\r\n      <div class=\"col-12 col-md-6 gg-light py-5 text-center\">\r\n        <div class=\"centerize ctz-sm\">\r\n        	<h2 class=\"gg-japanese-laurel-text fw-900 anim-hidden fade-in-right\">Mechanism of Action</h2>\r\n        	<p class=\"gg-japanese-laurel-text anim-hidden fade-in-right\" style=\"font-size:1.4rem; line-height:2;\">The mechanism of killing is through multiple modes such as cell wall damage, cell membrane damage, interfering in metabolic pathways, and DNase or RNase activities.</p>\r\n        </div>\r\n      </div>\r\n    </div>\r\n  </div>\r\n      	\r\n      \r\n\r\n'),
(16341, 732, '_sections_1_content', 'field_5e127410f12ae'),
(16342, 732, 'sections_1_disable_section', '0'),
(16343, 732, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16344, 732, 'sections_1_section_id', ''),
(16345, 732, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16346, 732, 'sections_1_klasses', ''),
(16347, 732, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16348, 732, 'sections_1_styles', ''),
(16349, 732, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16350, 732, 'sections_1_attributes', ''),
(16351, 732, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16352, 732, 'sections_1_background_image', ''),
(16353, 732, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16354, 732, 'sections_1_background_color', ''),
(16355, 732, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16356, 732, 'sections_1_text_color', ''),
(16357, 732, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16358, 732, 'sections_1_block_header', ''),
(16359, 732, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16360, 732, 'sections_1_block_footer', ''),
(16361, 732, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16362, 732, 'sections_2_admin_title', 'Gram Negative Bacteriocins'),
(16363, 732, '_sections_2_admin_title', 'field_5e865038f6507'),
(16364, 732, 'sections_2_disable_mode', '0'),
(16365, 732, '_sections_2_disable_mode', 'field_5e865043f6508'),
(16366, 732, 'sections_2_content', '<div id=\"gram-negative-bacteriocins\">\r\n  \r\n  <div class=\"gg-japanese-laurel abx-white-text text-center\">\r\n    <div class=\"centerize ctz-lg px-3 py-5 anim-hidden fade-in-up\">\r\n      <h2 class=\"fw-900\">Gram Negative Bacteriocins</h2>\r\n      <p style=\"line-height:2; font-size:1.4rem;\">Bacteriocins from Gram negative bacteria are broadly classified into 3 types based on their size as:</p>\r\n    </div>\r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n\r\n      <div class=\"row\">\r\n        \r\n        <div class=\"col-12 col-md-4 text-center anim hidden fade-in-left\">\r\n          <img style=\"height:190px;\" class=\"mb-3\" src=\"/wp-content/uploads/2020/09/2a.-Peptide-Bacteriocins.jpg.jpg\" alt=\"peptide-bacteriocins\" />\r\n          <h3 class=\"gg-japanese-laurel-text mb-3\">Peptide Bacteriocins</h3>\r\n          <p>Peptide Bacteriocins like microcins of less than 10 kDa size</p>\r\n        </div>\r\n        \r\n        <div class=\"col-12 col-md-4 text-center anim-hidden fade-in-up\">\r\n          <img style=\"height:190px;\" class=\"mb-3\" src=\"/wp-content/uploads/2020/09/2b.-Colicins-Like-Bacteriocins.jpg-e1600372580990.jpg\" alt=\"colicin-like-bacteriocins\" />\r\n          <h3 class=\"gg-japanese-laurel-text mb-3\">Colicin-Like Bacteriocins (CLB)</h3>\r\n          <p>Colicin-Like Bacteriocins (CLB) of 25 – 80 kDa size</p>\r\n        </div>\r\n        \r\n        <div class=\"col-12 col-md-4 text-center anim-hidden fade-in-right\">\r\n          <img style=\"height:190px;\" class=\"mb-3\" src=\"https://via.placeholder.com/150x150?text=Image+Goes+Here\" alt=\"tailocins\" />\r\n          <h3 class=\"gg-japanese-laurel-text mb-3\">Tailocins</h3>\r\n          <p>Tailocins which are high molecular size bacteriocins that resemble the tail structures of bacteriophages.</p>\r\n        </div>\r\n        \r\n      </div>\r\n      \r\n    </div>\r\n  </div>\r\n  \r\n  <div id=\"bacteriocin-advantages-header\" class=\"gg-calypso text-center\">\r\n    <div class=\"centerize ctz-lg px-3 py-5\">\r\n    	<h2 class=\"fw-900 abx-white-text anim-hidden fade-in-up\">Advantages of Bacteriocins</h2>\r\n    	<p class=\"abx-white-text anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">Bacteriocins offer several advantages over antibiotics making them attractive starting points for developing anti-bacterial agents:</p>\r\n    </div>\r\n  </div>\r\n  \r\n  <div id=\"bacteriocin-advantages\" class=\"gg-light\">\r\n   <div class=\"centerize ctz-md px-3 py-5\">\r\n    \r\n    <ul class=\"fa-ul\">\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Specific</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Their specificity offers a targeted approach and kills only the target pathogen, without damaging the commensal human microbiota or microbiome.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Resistance Development</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">The Bacteriocins have a unique mode of action and hence there is no primed resistance in the bacterial community.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Selective</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Bacteriocins enter the bacterial cell through specific receptors which are absent on eukaryotic cells and hence are very selective agents.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Modular Architecture</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">The colicin like bacteriocins (CLB) have modular domain structure that can be engineered to generate new bacteriocins with enhanced functionalities like activity/stability.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Low Toxicity</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">For generations the commensal bacteria in human body has been employing the bacteriocins to ward off invasions by pathogenic bacteria, hence natural bacteriocins can be expected to be safe to Humans.</p>\r\n      </li>\r\n      \r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Synergy</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">The potency of Bacteriocin can further be enhanced by combining them with standard of care antibiotics.</p>\r\n      </li>\r\n      \r\n    </ul>\r\n  \r\n</div>'),
(16367, 732, '_sections_2_content', 'field_5e127410f12ae'),
(16368, 732, 'sections_2_disable_section', '0'),
(16369, 732, '_sections_2_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16370, 732, 'sections_2_section_id', ''),
(16371, 732, '_sections_2_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16372, 732, 'sections_2_klasses', ''),
(16373, 732, '_sections_2_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16374, 732, 'sections_2_styles', ''),
(16375, 732, '_sections_2_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16376, 732, 'sections_2_attributes', ''),
(16377, 732, '_sections_2_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16378, 732, 'sections_2_background_image', ''),
(16379, 732, '_sections_2_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16380, 732, 'sections_2_background_color', ''),
(16381, 732, '_sections_2_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16382, 732, 'sections_2_text_color', ''),
(16383, 732, '_sections_2_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16384, 732, 'sections_2_block_header', ''),
(16385, 732, '_sections_2_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16386, 732, 'sections_2_block_footer', ''),
(16387, 732, '_sections_2_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16388, 733, 'custom_page_logo', ''),
(16389, 733, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16390, 733, 'sections_0_admin_title', 'Header Banner'),
(16391, 733, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16392, 733, 'sections_0_disable_mode', '0'),
(16393, 733, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16394, 733, 'sections_0_template_block_part', '/templates/header-banner'),
(16395, 733, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16396, 733, 'sections_1_admin_title', 'Information'),
(16397, 733, '_sections_1_admin_title', 'field_5e865038f6507'),
(16398, 733, 'sections_1_disable_mode', '0'),
(16399, 733, '_sections_1_disable_mode', 'field_5e865043f6508'),
(16400, 733, 'sections_1_content', '<div id=\"p128\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 anim-hidden fade-in\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12\">\r\n        <h2 class=\"gg-japanese-laurel-text fw-900 text-center\">How Does Ectolysin P128 Work?</h2>\r\n        <p class=\"gg-japanese-laurel-text\" style=\"font-size:1.4rem; line-height:2;\">Ectolysin P128, Gangagen’s lead ectolysin is a recombinant, chimeric protein that comprises of two functionally distinct domains. The catalytic domain is a muralytic enzyme and the binding domain specifically interacts with the pentaglycine bridge connecting the D-Ala-D-Ala moieties of adjacent peptidoglycan strands. Functionally, P128 is an endopeptidase and its enzymatic action on the staphylococcal peptidoglycan results in the cleavage of the specifc peptide linkages. This leads to the degradation of the cell wall, followed by osmotic lysis and rapid death of the bacterium. P128 targets both coagulase positive and coagulase negative Staphylococci.</p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n</div>\r\n    \r\n<div id=\"mechanism-of-action\" class=\"abx-white\">\r\n  <div class=\"centerize ctz-lg px-3 pt-5\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12 col-md-6 anim-hidden fade-in-left\">\r\n        <img src=\"https://via.placeholder.com/400x300/?text=P128+Mechanism+of+Action+Chart+2\" alt=\"p128\" />\r\n      </div>\r\n      <div class=\"col-12 col-md-6 anim-hidden fade-in-right\">\r\n        <h2 class=\"gg-japanese-laurel-text fw-900\">Mechanism of Action</h2>\r\n        <p class=\"gg-calypso-text\" style=\"font-size:1.4rem; line-height:2;\">P128 has a novel mechanism of action and has been proven to be very effective both in vitro &amp; in vivo against multidrug resistant pathogens like Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Staphylococcus aureus (VRSA) and Daptomycin Resistant Staphylococcus aureus (DRSA).</p> \r\n      </div>\r\n    </div>\r\n  </div>\r\n</div>\r\n    \r\n<div id=\"p128-manufacturing\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 pt-5\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12 anim-hidden fade-in-up text-center\">\r\n        <h2 class=\"gg-japanese-laurel-text fw-900\">Scalable Manufacturing Innovation</h2>\r\n        <p class=\"gg-calypso-text\" style=\"font-size:1.4rem; line-height:2;\">Gangagen has successfully developed the manufacturing process for large scale production of P128 to meet the regulatory standards for clinical studies. P128 formulated as a gel for topical use has been tested in a first-in-human clinical trial, a Phase I/IIA study directed towards treatment of nasal carriage of S. aureus.</p>\r\n      </div>\r\n      <!-- <div class=\"col-12 col-md-6 order-1 order-md-2 anim-hidden fade-in-right\">\r\n        <img src=\"https://via.placeholder.com/400x300/?text=P128+Mechanism+of+Action+Chart\" alt=\"p128\" />\r\n      </div> -->\r\n    </div>\r\n  </div>\r\n</div>\r\n\r\n<div id=\"p128-chart\" class=\"abx-white\">\r\n  <div class=\"centerize ctz-lg px-3 py-5\">\r\n    <img class=\"anim-hidden fade-in-up\" src=\"/wp-content/uploads/2020/09/4.-P128-Mechanism-of-Action.jpg\" alt=\"p128-chart\" />\r\n  </div>\r\n</div>\r\n\r\n<div id=\"p128-quote\" style=\"padding:10% 2rem; background:linear-gradient(rgba(0,0,0,0.4),rgba(0,0,0,0.4)), url(\'/wp-content/uploads/2020/09/gangagen-007.jpg\'); background-attachment:fixed; background-size:cover; background-repeat:no-repeat;\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n    <p class=\"abx-white-text fw-700 anim-hidden zoom-in\" style=\"font-size:1.4rem; line-height:2;\"><span class=\"quot\" style=\"display:block;\"><i class=\"fa fa-3x fa-quote-left\"></i></span><em>In 15 European countries more than 10% of blood-stream Staphylococcus aureus infections are caused by methicillin-resistant strains (MRSA), with several of these countries seeing resistance rates closer to 50%.</em><span class=\"quot\" style=\"display:block;\"><i class=\"fa fa-4x fa-quote-right\"></i></span></p>\r\n  </div>\r\n</div>\r\n    \r\n<div id=\"p128-innovation\" class=\"gg-calypso abx-white-text\">\r\n  <div class=\"centerize ctz-md px-3 py-5 text-center\">\r\n     <h2 class=\"fw-900 anim-hidden fade-in-down\">Intravenous Treatment</h2>\r\n  	 <p class=\"anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">Gangagen is also advancing Ectolysin P128 for intravenous treatment of bacteremia caused by Staphylococcus Species.</p>    \r\n  </div>\r\n</div>'),
(16401, 733, '_sections_1_content', 'field_5e127410f12ae'),
(16402, 733, 'sections_1_disable_section', '0'),
(16403, 733, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16404, 733, 'sections_1_section_id', ''),
(16405, 733, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16406, 733, 'sections_1_klasses', ''),
(16407, 733, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16408, 733, 'sections_1_styles', ''),
(16409, 733, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16410, 733, 'sections_1_attributes', ''),
(16411, 733, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16412, 733, 'sections_1_background_image', ''),
(16413, 733, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16414, 733, 'sections_1_background_color', ''),
(16415, 733, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16416, 733, 'sections_1_text_color', ''),
(16417, 733, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16418, 733, 'sections_1_block_header', ''),
(16419, 733, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16420, 733, 'sections_1_block_footer', ''),
(16421, 733, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16422, 733, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(16423, 733, '_sections', 'field_5e1273c3f12ad'),
(16424, 734, 'custom_page_logo', ''),
(16425, 734, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16426, 734, 'sections_0_admin_title', 'Header Banner'),
(16427, 734, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16428, 734, 'sections_0_disable_mode', '0'),
(16429, 734, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16430, 734, 'sections_0_template_block_part', '/templates/header-banner'),
(16431, 734, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16432, 734, 'sections_1_admin_title', 'Information'),
(16433, 734, '_sections_1_admin_title', 'field_5e865038f6507'),
(16434, 734, 'sections_1_disable_mode', '0'),
(16435, 734, '_sections_1_disable_mode', 'field_5e865043f6508'),
(16436, 734, 'sections_1_content', '<div id=\"p128\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 anim-hidden fade-in\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12\">\r\n        <h2 class=\"gg-japanese-laurel-text fw-900 text-center\">How Does Ectolysin P128 Work?</h2>\r\n        <p class=\"gg-japanese-laurel-text\" style=\"font-size:1.4rem; line-height:2;\">Ectolysin P128, Gangagen’s lead ectolysin is a recombinant, chimeric protein that comprises of two functionally distinct domains. The catalytic domain is a muralytic enzyme and the binding domain specifically interacts with the pentaglycine bridge connecting the D-Ala-D-Ala moieties of adjacent peptidoglycan strands. Functionally, P128 is an endopeptidase and its enzymatic action on the staphylococcal peptidoglycan results in the cleavage of the specifc peptide linkages. This leads to the degradation of the cell wall, followed by osmotic lysis and rapid death of the bacterium. P128 targets both coagulase positive and coagulase negative Staphylococci.</p>\r\n      </div>\r\n    </div>\r\n  </div>\r\n</div>\r\n    \r\n<div id=\"mechanism-of-action\" class=\"abx-white\">\r\n  <div class=\"centerize ctz-lg px-3 pt-5\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12 col-md-6 anim-hidden fade-in-left\">\r\n        <img src=\"/wp-content/uploads/2020/09/4.-P128-Mechanism-of-Action.jpg\" alt=\"p128\" />\r\n      </div>\r\n      <div class=\"col-12 col-md-6 anim-hidden fade-in-right\">\r\n        <h2 class=\"gg-japanese-laurel-text fw-900\">Mechanism of Action</h2>\r\n        <p class=\"gg-calypso-text\" style=\"font-size:1.4rem; line-height:2;\">P128 has a novel mechanism of action and has been proven to be very effective both in vitro &amp; in vivo against multidrug resistant pathogens like Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Staphylococcus aureus (VRSA) and Daptomycin Resistant Staphylococcus aureus (DRSA).</p> \r\n      </div>\r\n    </div>\r\n  </div>\r\n</div>\r\n    \r\n<div id=\"p128-manufacturing\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 pt-5\">\r\n    <div class=\"row\">\r\n      <div class=\"col-12 anim-hidden fade-in-up text-center\">\r\n        <h2 class=\"gg-japanese-laurel-text fw-900\">Scalable Manufacturing Innovation</h2>\r\n        <p class=\"gg-calypso-text\" style=\"font-size:1.4rem; line-height:2;\">Gangagen has successfully developed the manufacturing process for large scale production of P128 to meet the regulatory standards for clinical studies. P128 formulated as a gel for topical use has been tested in a first-in-human clinical trial, a Phase I/IIA study directed towards treatment of nasal carriage of S. aureus.</p>\r\n      </div>\r\n      <!-- <div class=\"col-12 col-md-6 order-1 order-md-2 anim-hidden fade-in-right\">\r\n        <img src=\"https://via.placeholder.com/400x300/?text=P128+Mechanism+of+Action+Chart\" alt=\"p128\" />\r\n      </div> -->\r\n    </div>\r\n  </div>\r\n</div>\r\n\r\n<div id=\"p128-chart\" class=\"abx-white\">\r\n  <div class=\"px-3 py-5\">\r\n    <img class=\"anim-hidden fade-in-up\" src=\"/wp-content/uploads/2020/09/6.-P128-banner_final-scaled.jpg\" alt=\"p128-chart\" />\r\n  </div>\r\n</div>\r\n\r\n<div id=\"p128-quote\" style=\"padding:10% 2rem; background:linear-gradient(rgba(0,0,0,0.4),rgba(0,0,0,0.4)), url(\'/wp-content/uploads/2020/09/gangagen-007.jpg\'); background-attachment:fixed; background-size:cover; background-repeat:no-repeat;\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center\">\r\n    <p class=\"abx-white-text fw-700 anim-hidden zoom-in\" style=\"font-size:1.4rem; line-height:2;\"><span class=\"quot\" style=\"display:block;\"><i class=\"fa fa-3x fa-quote-left\"></i></span><em>In 15 European countries more than 10% of blood-stream Staphylococcus aureus infections are caused by methicillin-resistant strains (MRSA), with several of these countries seeing resistance rates closer to 50%.</em><span class=\"quot\" style=\"display:block;\"><i class=\"fa fa-4x fa-quote-right\"></i></span></p>\r\n  </div>\r\n</div>\r\n    \r\n<div id=\"p128-innovation\" class=\"gg-calypso abx-white-text\">\r\n  <div class=\"centerize ctz-md px-3 py-5 text-center\">\r\n     <h2 class=\"fw-900 anim-hidden fade-in-down\">Intravenous Treatment</h2>\r\n  	 <p class=\"anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">Gangagen is also advancing Ectolysin P128 for intravenous treatment of bacteremia caused by Staphylococcus Species.</p>    \r\n  </div>\r\n</div>'),
(16437, 734, '_sections_1_content', 'field_5e127410f12ae'),
(16438, 734, 'sections_1_disable_section', '0'),
(16439, 734, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16440, 734, 'sections_1_section_id', ''),
(16441, 734, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16442, 734, 'sections_1_klasses', ''),
(16443, 734, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16444, 734, 'sections_1_styles', ''),
(16445, 734, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16446, 734, 'sections_1_attributes', ''),
(16447, 734, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16448, 734, 'sections_1_background_image', ''),
(16449, 734, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16450, 734, 'sections_1_background_color', ''),
(16451, 734, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16452, 734, 'sections_1_text_color', ''),
(16453, 734, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16454, 734, 'sections_1_block_header', ''),
(16455, 734, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16456, 734, 'sections_1_block_footer', ''),
(16457, 734, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16458, 734, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";}'),
(16459, 734, '_sections', 'field_5e1273c3f12ad'),
(16460, 735, '_wp_attached_file', '2020/09/gangagen-puppy.jpg'),
(16461, 735, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1499;s:6:\"height\";i:787;s:4:\"file\";s:26:\"2020/09/gangagen-puppy.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:26:\"gangagen-puppy-300x158.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:158;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:27:\"gangagen-puppy-1024x538.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:538;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:26:\"gangagen-puppy-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:26:\"gangagen-puppy-768x403.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:403;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16462, 736, '_wp_attached_file', '2020/09/gram-positive.jpg'),
(16463, 736, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:374;s:6:\"height\";i:370;s:4:\"file\";s:25:\"2020/09/gram-positive.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:25:\"gram-positive-300x297.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:297;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:25:\"gram-positive-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16464, 737, '_wp_attached_file', '2020/09/gram-negative.jpg'),
(16465, 737, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:374;s:6:\"height\";i:372;s:4:\"file\";s:25:\"2020/09/gram-negative.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:25:\"gram-negative-300x298.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:298;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:25:\"gram-negative-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16466, 738, 'custom_page_logo', ''),
(16467, 738, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16468, 738, 'sections', 'a:4:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";i:2;s:10:\"code_block\";i:3;s:10:\"code_block\";}'),
(16469, 738, '_sections', 'field_5e1273c3f12ad'),
(16470, 738, 'sections_0_admin_title', 'Header Banner'),
(16471, 738, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16472, 738, 'sections_0_disable_mode', '0'),
(16473, 738, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16474, 738, 'sections_0_template_block_part', '/templates/header-banner'),
(16475, 738, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16476, 738, 'sections_1_admin_title', ''),
(16477, 738, '_sections_1_admin_title', 'field_5e865038f6507'),
(16478, 738, 'sections_1_disable_mode', '0'),
(16479, 738, '_sections_1_disable_mode', 'field_5e865043f6508'),
(16480, 738, 'sections_1_content', '<div id=\"ectolysin-intro\" class=\"gg-calypso abx-white-text\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center anim-hidden fade-in-up\">\r\n    <h2 class=\"fw-900\">What are Ectolysins?</h2>\r\n    <p style=\"font-size:1.4rem; line-height:2;\">Ectolysins are phage structural proteins, which enable phages to penetrate the bacterial cell. They cleave specific chemical bonds on the bacterial cell wall, leading to bacterial lysis and death. </p>\r\n  </div>\r\n</div>'),
(16481, 738, '_sections_1_content', 'field_5e127410f12ae'),
(16482, 738, 'sections_1_disable_section', '0'),
(16483, 738, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16484, 738, 'sections_1_section_id', ''),
(16485, 738, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16486, 738, 'sections_1_klasses', ''),
(16487, 738, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16488, 738, 'sections_1_styles', ''),
(16489, 738, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16490, 738, 'sections_1_attributes', ''),
(16491, 738, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16492, 738, 'sections_1_background_image', ''),
(16493, 738, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16494, 738, 'sections_1_background_color', ''),
(16495, 738, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16496, 738, 'sections_1_text_color', ''),
(16497, 738, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16498, 738, 'sections_1_block_header', ''),
(16499, 738, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16500, 738, 'sections_1_block_footer', ''),
(16501, 738, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16502, 738, 'sections_2_admin_title', 'Advantages of Ectolysins'),
(16503, 738, '_sections_2_admin_title', 'field_5e865038f6507'),
(16504, 738, 'sections_2_disable_mode', '0'),
(16505, 738, '_sections_2_disable_mode', 'field_5e865043f6508'),
(16506, 738, 'sections_2_content', '<div id=\"ectolysin-advantages\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 py-5\">\r\n    <div class=\"text-center mb-4\">\r\n    	<h2 class=\"fw-900 gg-calypso-text anim-hidden fade-in-up\">Advantages of Ectolysins over Antibiotics</h2>\r\n    	<p class=\"gg-calypso-text anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins have the following advantages over antibiotics</p>\r\n    </div>\r\n    \r\n    <ul class=\"fa-ul\">\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Rapid Action</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are rapid acting and cleave the cell wall immediately on contact, within minutes, as against antibiotics that need longer duration to kill the cells.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Specific</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are very specific to the target bacterial species and hence kill only the target pathogen without affecting the microbiome or the commensal bacterial flora as compared to antibiotics which kill both the pathogens as well as the beneficial bacteria.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Mechanism of Action</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins have novel mode of action- they include enzymatic mechanisms like Muramidase, Glucosaminidase, Amidase or endopeptidase depending upon the cell wall bond targeted by the individual ectolysin.  The availability of a library of enzymatic domains offers the opportunity of protein engineering.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Bacterial Activity Independence</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Bactericidal activity is not dependent on the metabolic stage of the cell – Ectolysins kill both actively growing as well as stationary phase cells irrespective of the metabolic state. But antibiotics act only on metabolically active cells.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Active on Biofilms</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are active both on planktonic bacteria &amp; bacterial biofilms as against antibiotics, which act poorly on bacterial biofilms.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Less Propensity for Resistance</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins cleave essential cell wall chemical bonds, which are highly conserved and omnipresent on the bacterial cell surface; hence the propensity for the development of bacterial resistance is low.</p> \r\n    </ul>\r\n  </div>\r\n</div>\r\n\r\n'),
(16507, 738, '_sections_2_content', 'field_5e127410f12ae'),
(16508, 738, 'sections_2_disable_section', '0'),
(16509, 738, '_sections_2_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16510, 738, 'sections_2_section_id', ''),
(16511, 738, '_sections_2_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16512, 738, 'sections_2_klasses', ''),
(16513, 738, '_sections_2_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16514, 738, 'sections_2_styles', ''),
(16515, 738, '_sections_2_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16516, 738, 'sections_2_attributes', ''),
(16517, 738, '_sections_2_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16518, 738, 'sections_2_background_image', ''),
(16519, 738, '_sections_2_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16520, 738, 'sections_2_background_color', ''),
(16521, 738, '_sections_2_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16522, 738, 'sections_2_text_color', ''),
(16523, 738, '_sections_2_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16524, 738, 'sections_2_block_header', ''),
(16525, 738, '_sections_2_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16526, 738, 'sections_2_block_footer', ''),
(16527, 738, '_sections_2_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16528, 738, 'sections_3_admin_title', 'Ectolysins Against Gram Positive and Negative Bacteria'),
(16529, 738, '_sections_3_admin_title', 'field_5e865038f6507'),
(16530, 738, 'sections_3_disable_mode', '0'),
(16531, 738, '_sections_3_disable_mode', 'field_5e865043f6508');
INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(16532, 738, 'sections_3_content', '<div id=\"protein-antibiotic-classes\">\r\n  \r\n  <div class=\" abx-white-text\">\r\n    \r\n    <div style=\"position:relative\">\r\n      \r\n      <div class=\"split-color\" style=\"position: absolute; top: 0; right: 0; bottom: 0; left: 0; width: 100%; height: 100%;\">\r\n        <div class=\"gg-japanese-laurel\" style=\"float:left; height: 100%; width: 50%; display: inline-block;\"></div>\r\n        <div class=\"gg-calypso\" style=\"float:left; height: 100%; width: 50%; display: inline-block; z-index: 0;\"></div>\r\n      </div>\r\n      \r\n      <div class=\"px-3 py-5 text-center\" style=\"position:relative;\">\r\n        <h2>Ectolysins Against Gram-Positive and Gram-Negative Bacteria</h2>\r\n      </div>\r\n      \r\n    </div>\r\n      \r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-md px-3 pt-5\">\r\n      <div class=\"row\">\r\n\r\n        <div class=\"col-12 col-md-6 pb-5 text-center anim-hidden fade-in-left\">\r\n          	<!-- <div class=\"gg-japanese-laurel abx-white-text mb-3\" style=\"width:100px; height:100px; border-radius:50%; margin:0 auto; padding-top:1.2rem;\"><i class=\"fa fa-4x fa-plus\"></i></div> -->\r\n          	<img src=\"/wp-content/uploads/2020/09/gram-positive.jpg\" alt=\"gram-positive\" style=\"width:200px; border:solid 3px var(--gg-calypso)\" />\r\n          	<h3 class=\"mb-4 gg-japanese-laurel-text\">Gram-Positive</h3>\r\n            <a href=\"/ectolysins-against-gram-positive-bacteria\"><button class=\"gangagen-button\">Learn More</button></a>\r\n        </div>\r\n\r\n        <div class=\"col-12 col-md-6 pb-5 text-center anim-hidden fade-in-right\">\r\n          	<!-- <div class=\"gg-calypso abx-white-text mb-3\" style=\"width:100px; height:100px; border-radius:50%; margin:0 auto; padding-top:1.2rem;\"><i class=\"fa fa-4x fa-minus\"></i></div> -->\r\n          	<img src=\"/wp-content/uploads/2020/09/gram-negative.jpg\" alt=\"gram-negative\" style=\"width:200px; border:solid 3px var(--gg-calypso)\" />\r\n          	<h3 class=\"mb-4 gg-calypso-text\">Gram Negative</h3>\r\n            <a href=\"/ectolysins-against-gram-negative-bacteria\"><button class=\"gangagen-button-calypso\">Learn More</button></a>\r\n        </div>\r\n\r\n      </div>\r\n    </div>\r\n  </div>\r\n    \r\n</div>'),
(16533, 738, '_sections_3_content', 'field_5e127410f12ae'),
(16534, 738, 'sections_3_disable_section', '0'),
(16535, 738, '_sections_3_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16536, 738, 'sections_3_section_id', ''),
(16537, 738, '_sections_3_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16538, 738, 'sections_3_klasses', ''),
(16539, 738, '_sections_3_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16540, 738, 'sections_3_styles', ''),
(16541, 738, '_sections_3_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16542, 738, 'sections_3_attributes', ''),
(16543, 738, '_sections_3_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16544, 738, 'sections_3_background_image', ''),
(16545, 738, '_sections_3_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16546, 738, 'sections_3_background_color', ''),
(16547, 738, '_sections_3_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16548, 738, 'sections_3_text_color', ''),
(16549, 738, '_sections_3_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16550, 738, 'sections_3_block_header', ''),
(16551, 738, '_sections_3_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16552, 738, 'sections_3_block_footer', ''),
(16553, 738, '_sections_3_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16554, 739, 'custom_page_logo', ''),
(16555, 739, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16556, 739, 'sections', 'a:4:{i:0;s:14:\"template_block\";i:1;s:10:\"code_block\";i:2;s:10:\"code_block\";i:3;s:10:\"code_block\";}'),
(16557, 739, '_sections', 'field_5e1273c3f12ad'),
(16558, 739, 'sections_0_admin_title', 'Header Banner'),
(16559, 739, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16560, 739, 'sections_0_disable_mode', '0'),
(16561, 739, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16562, 739, 'sections_0_template_block_part', '/templates/header-banner'),
(16563, 739, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16564, 739, 'sections_1_admin_title', ''),
(16565, 739, '_sections_1_admin_title', 'field_5e865038f6507'),
(16566, 739, 'sections_1_disable_mode', '0'),
(16567, 739, '_sections_1_disable_mode', 'field_5e865043f6508'),
(16568, 739, 'sections_1_content', '<div id=\"ectolysin-intro\" class=\"gg-calypso abx-white-text\">\r\n  <div class=\"centerize ctz-lg px-3 py-5 text-center anim-hidden fade-in-up\">\r\n    <h2 class=\"fw-900\">What are Ectolysins?</h2>\r\n    <p style=\"font-size:1.4rem; line-height:2;\">Ectolysins are phage structural proteins, which enable phages to penetrate the bacterial cell. They cleave specific chemical bonds on the bacterial cell wall, leading to bacterial lysis and death. </p>\r\n  </div>\r\n</div>'),
(16569, 739, '_sections_1_content', 'field_5e127410f12ae'),
(16570, 739, 'sections_1_disable_section', '0'),
(16571, 739, '_sections_1_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16572, 739, 'sections_1_section_id', ''),
(16573, 739, '_sections_1_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16574, 739, 'sections_1_klasses', ''),
(16575, 739, '_sections_1_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16576, 739, 'sections_1_styles', ''),
(16577, 739, '_sections_1_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16578, 739, 'sections_1_attributes', ''),
(16579, 739, '_sections_1_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16580, 739, 'sections_1_background_image', ''),
(16581, 739, '_sections_1_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16582, 739, 'sections_1_background_color', ''),
(16583, 739, '_sections_1_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16584, 739, 'sections_1_text_color', ''),
(16585, 739, '_sections_1_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16586, 739, 'sections_1_block_header', ''),
(16587, 739, '_sections_1_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16588, 739, 'sections_1_block_footer', ''),
(16589, 739, '_sections_1_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16590, 739, 'sections_2_admin_title', 'Advantages of Ectolysins'),
(16591, 739, '_sections_2_admin_title', 'field_5e865038f6507'),
(16592, 739, 'sections_2_disable_mode', '0'),
(16593, 739, '_sections_2_disable_mode', 'field_5e865043f6508'),
(16594, 739, 'sections_2_content', '<div id=\"ectolysin-advantages\" class=\"gg-light\">\r\n  <div class=\"centerize ctz-lg px-3 py-5\">\r\n    <div class=\"text-center mb-4\">\r\n    	<h2 class=\"fw-900 gg-calypso-text anim-hidden fade-in-up\">Advantages of Ectolysins over Antibiotics</h2>\r\n    	<p class=\"gg-calypso-text anim-hidden fade-in-up\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins have the following advantages over antibiotics</p>\r\n    </div>\r\n    \r\n    <ul class=\"fa-ul\">\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Rapid Action</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are rapid acting and cleave the cell wall immediately on contact, within minutes, as against antibiotics that need longer duration to kill the cells.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Specific</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are very specific to the target bacterial species and hence kill only the target pathogen without affecting the microbiome or the commensal bacterial flora as compared to antibiotics which kill both the pathogens as well as the beneficial bacteria.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Mechanism of Action</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins have novel mode of action- they include enzymatic mechanisms like Muramidase, Glucosaminidase, Amidase or endopeptidase depending upon the cell wall bond targeted by the individual ectolysin.  The availability of a library of enzymatic domains offers the opportunity of protein engineering.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Bacterial Activity Independence</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Bactericidal activity is not dependent on the metabolic stage of the cell – Ectolysins kill both actively growing as well as stationary phase cells irrespective of the metabolic state. But antibiotics act only on metabolically active cells.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Active on Biofilms</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins are active both on planktonic bacteria &amp; bacterial biofilms as against antibiotics, which act poorly on bacterial biofilms.</p>\r\n      <li class=\"anim-hidden fade-in-left mb-4\"><span class=\"fa-li\"><i class=\"fa fa-check gg-check\"></i></span> \r\n        <h3 class=\"fw-900 gg-calypso-text ml-3\">Less Propensity for Resistance</h3> \r\n        <p class=\"ml-3\" style=\"font-size:1.4rem; line-height:2;\">Ectolysins cleave essential cell wall chemical bonds, which are highly conserved and omnipresent on the bacterial cell surface; hence the propensity for the development of bacterial resistance is low.</p> \r\n    </ul>\r\n  </div>\r\n</div>\r\n\r\n'),
(16595, 739, '_sections_2_content', 'field_5e127410f12ae'),
(16596, 739, 'sections_2_disable_section', '0'),
(16597, 739, '_sections_2_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16598, 739, 'sections_2_section_id', ''),
(16599, 739, '_sections_2_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16600, 739, 'sections_2_klasses', ''),
(16601, 739, '_sections_2_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16602, 739, 'sections_2_styles', ''),
(16603, 739, '_sections_2_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16604, 739, 'sections_2_attributes', ''),
(16605, 739, '_sections_2_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16606, 739, 'sections_2_background_image', ''),
(16607, 739, '_sections_2_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16608, 739, 'sections_2_background_color', ''),
(16609, 739, '_sections_2_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16610, 739, 'sections_2_text_color', ''),
(16611, 739, '_sections_2_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16612, 739, 'sections_2_block_header', ''),
(16613, 739, '_sections_2_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16614, 739, 'sections_2_block_footer', ''),
(16615, 739, '_sections_2_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16616, 739, 'sections_3_admin_title', 'Ectolysins Against Gram Positive and Negative Bacteria'),
(16617, 739, '_sections_3_admin_title', 'field_5e865038f6507'),
(16618, 739, 'sections_3_disable_mode', '0'),
(16619, 739, '_sections_3_disable_mode', 'field_5e865043f6508'),
(16620, 739, 'sections_3_content', '<div id=\"protein-antibiotic-classes\">\r\n  \r\n  <div class=\" abx-white-text\">\r\n    \r\n    <div style=\"position:relative\">\r\n      \r\n      <div class=\"split-color\" style=\"position: absolute; top: 0; right: 0; bottom: 0; left: 0; width: 100%; height: 100%;\">\r\n        <div class=\"gg-japanese-laurel\" style=\"float:left; height: 100%; width: 50%; display: inline-block;\"></div>\r\n        <div class=\"gg-calypso\" style=\"float:left; height: 100%; width: 50%; display: inline-block; z-index: 0;\"></div>\r\n      </div>\r\n      \r\n      <div class=\"px-3 py-5 text-center\" style=\"position:relative;\">\r\n        <h2>Ectolysins Against Gram-Positive and Gram-Negative Bacteria</h2>\r\n      </div>\r\n      \r\n    </div>\r\n      \r\n  </div>\r\n  \r\n  <div class=\"abx-white\">\r\n    <div class=\"centerize ctz-md px-3 pt-5\">\r\n      <div class=\"row\">\r\n\r\n        <div class=\"col-12 col-md-6 pb-5 text-center anim-hidden fade-in-left\">\r\n          	<!-- <div class=\"gg-japanese-laurel abx-white-text mb-3\" style=\"width:100px; height:100px; border-radius:50%; margin:0 auto; padding-top:1.2rem;\"><i class=\"fa fa-4x fa-plus\"></i></div> -->\r\n          	<img src=\"/wp-content/uploads/2020/09/gram-positive.jpg\" alt=\"gram-positive\" style=\"width:200px; border:solid 3px var(--gg-japanese-laurel)\" />\r\n          	<h3 class=\"mb-4 gg-japanese-laurel-text\">Gram-Positive</h3>\r\n            <a href=\"/ectolysins-against-gram-positive-bacteria\"><button class=\"gangagen-button\">Learn More</button></a>\r\n        </div>\r\n\r\n        <div class=\"col-12 col-md-6 pb-5 text-center anim-hidden fade-in-right\">\r\n          	<!-- <div class=\"gg-calypso abx-white-text mb-3\" style=\"width:100px; height:100px; border-radius:50%; margin:0 auto; padding-top:1.2rem;\"><i class=\"fa fa-4x fa-minus\"></i></div> -->\r\n          	<img src=\"/wp-content/uploads/2020/09/gram-negative.jpg\" alt=\"gram-negative\" style=\"width:200px; border:solid 3px var(--gg-calypso)\" />\r\n          	<h3 class=\"mb-4 gg-calypso-text\">Gram Negative</h3>\r\n            <a href=\"/ectolysins-against-gram-negative-bacteria\"><button class=\"gangagen-button-calypso\">Learn More</button></a>\r\n        </div>\r\n\r\n      </div>\r\n    </div>\r\n  </div>\r\n    \r\n</div>'),
(16621, 739, '_sections_3_content', 'field_5e127410f12ae'),
(16622, 739, 'sections_3_disable_section', '0'),
(16623, 739, '_sections_3_disable_section', 'field_5e127428f12af_field_5e1273509185b'),
(16624, 739, 'sections_3_section_id', ''),
(16625, 739, '_sections_3_section_id', 'field_5e127428f12af_field_5e12719f91854'),
(16626, 739, 'sections_3_klasses', ''),
(16627, 739, '_sections_3_klasses', 'field_5e127428f12af_field_5e1271a591855'),
(16628, 739, 'sections_3_styles', ''),
(16629, 739, '_sections_3_styles', 'field_5e127428f12af_field_5e1271ab91856'),
(16630, 739, 'sections_3_attributes', ''),
(16631, 739, '_sections_3_attributes', 'field_5e127428f12af_field_5e1271b591857'),
(16632, 739, 'sections_3_background_image', ''),
(16633, 739, '_sections_3_background_image', 'field_5e127428f12af_field_5e12727391858'),
(16634, 739, 'sections_3_background_color', ''),
(16635, 739, '_sections_3_background_color', 'field_5e127428f12af_field_5e12729491859'),
(16636, 739, 'sections_3_text_color', ''),
(16637, 739, '_sections_3_text_color', 'field_5e127428f12af_field_5e1272ad9185a'),
(16638, 739, 'sections_3_block_header', ''),
(16639, 739, '_sections_3_block_header', 'field_5e15000de3a71_field_5e14fd8ea4022'),
(16640, 739, 'sections_3_block_footer', ''),
(16641, 739, '_sections_3_block_footer', 'field_5e15000de3a71_field_5e14fe5ba4023'),
(16642, 740, '_wp_attached_file', '2020/09/gg-business.jpg'),
(16643, 740, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1200;s:6:\"height\";i:799;s:4:\"file\";s:23:\"2020/09/gg-business.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:23:\"gg-business-300x200.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:200;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:24:\"gg-business-1024x682.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:682;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:23:\"gg-business-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:23:\"gg-business-768x511.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:511;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16644, 741, '_wp_attached_file', '2020/09/gg-cell-bank.jpg'),
(16645, 741, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1200;s:6:\"height\";i:900;s:4:\"file\";s:24:\"2020/09/gg-cell-bank.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:24:\"gg-cell-bank-300x225.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:225;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:25:\"gg-cell-bank-1024x768.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:24:\"gg-cell-bank-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:24:\"gg-cell-bank-768x576.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:576;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16646, 742, '_wp_attached_file', '2020/09/gg-collaboration.jpg'),
(16647, 742, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1920;s:6:\"height\";i:1282;s:4:\"file\";s:28:\"2020/09/gg-collaboration.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:28:\"gg-collaboration-300x200.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:200;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:29:\"gg-collaboration-1024x684.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:684;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:28:\"gg-collaboration-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:28:\"gg-collaboration-768x513.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:513;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:30:\"gg-collaboration-1536x1026.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:1026;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16648, 743, '_wp_attached_file', '2020/09/gg-pipeline.jpg'),
(16649, 743, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1920;s:6:\"height\";i:1080;s:4:\"file\";s:23:\"2020/09/gg-pipeline.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:23:\"gg-pipeline-300x169.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:169;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:24:\"gg-pipeline-1024x576.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:576;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:23:\"gg-pipeline-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:23:\"gg-pipeline-768x432.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:432;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:24:\"gg-pipeline-1536x864.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:864;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16650, 298, '_thumbnail_id', '740'),
(16651, 284, '_thumbnail_id', '741'),
(16652, 282, '_thumbnail_id', '742'),
(16653, 744, '_wp_attached_file', '2020/09/gg-pipeline-1.jpg'),
(16654, 744, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1920;s:6:\"height\";i:1080;s:4:\"file\";s:25:\"2020/09/gg-pipeline-1.jpg\";s:5:\"sizes\";a:5:{s:6:\"medium\";a:4:{s:4:\"file\";s:25:\"gg-pipeline-1-300x169.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:169;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:26:\"gg-pipeline-1-1024x576.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:576;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:25:\"gg-pipeline-1-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:25:\"gg-pipeline-1-768x432.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:432;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"1536x1536\";a:4:{s:4:\"file\";s:26:\"gg-pipeline-1-1536x864.jpg\";s:5:\"width\";i:1536;s:6:\"height\";i:864;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16655, 278, '_thumbnail_id', '744'),
(16656, 745, '_wp_attached_file', '2020/09/gg-suchad-profile.jpg'),
(16657, 745, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1288;s:6:\"height\";i:1288;s:4:\"file\";s:29:\"2020/09/gg-suchad-profile.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:29:\"gg-suchad-profile-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:31:\"gg-suchad-profile-1024x1024.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:29:\"gg-suchad-profile-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:29:\"gg-suchad-profile-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16658, 746, 'custom_page_logo', ''),
(16659, 746, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16660, 746, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(16661, 746, '_sections', 'field_5e1273c3f12ad'),
(16662, 746, 'sections_0_admin_title', 'Header Banner'),
(16663, 746, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16664, 746, 'sections_0_disable_mode', '0'),
(16665, 746, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16666, 746, 'sections_0_template_block_part', '/templates/header-banner'),
(16667, 746, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16668, 746, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(16669, 746, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(16670, 746, 'sections_1_disable_mode', '0'),
(16671, 746, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(16672, 746, 'sections_1_template_block_part', '/templates/directors'),
(16673, 746, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(16674, 746, 'management_0_name', 'Suchad Chiaranussati'),
(16675, 746, '_management_0_name', 'field_5efe20a3d7829'),
(16676, 746, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(16677, 746, '_management_0_title', 'field_5efe20add782a'),
(16678, 746, 'management_0_image', '745'),
(16679, 746, '_management_0_image', 'field_5f5516e46507c'),
(16680, 746, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(16681, 746, '_management_0_bio', 'field_5efe20b4d782b'),
(16682, 746, 'management_1_name', 'Dean Cash'),
(16683, 746, '_management_1_name', 'field_5efe20a3d7829'),
(16684, 746, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(16685, 746, '_management_1_title', 'field_5efe20add782a'),
(16686, 746, 'management_1_image', '690'),
(16687, 746, '_management_1_image', 'field_5f5516e46507c'),
(16688, 746, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(16689, 746, '_management_1_bio', 'field_5efe20b4d782b'),
(16690, 746, 'management_2_name', 'Vinod Jadhav'),
(16691, 746, '_management_2_name', 'field_5efe20a3d7829'),
(16692, 746, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(16693, 746, '_management_2_title', 'field_5efe20add782a'),
(16694, 746, 'management_2_image', '727'),
(16695, 746, '_management_2_image', 'field_5f5516e46507c'),
(16696, 746, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(16697, 746, '_management_2_bio', 'field_5efe20b4d782b'),
(16698, 746, 'management', '7'),
(16699, 746, '_management', 'field_5efe2097d7828'),
(16700, 746, 'management_0_board_type', 'bactoclear'),
(16701, 746, '_management_0_board_type', 'field_5f554dca6181e'),
(16702, 746, 'management_1_board_type', 'bactoclear'),
(16703, 746, '_management_1_board_type', 'field_5f554dca6181e'),
(16704, 746, 'management_2_board_type', 'bactoclear'),
(16705, 746, '_management_2_board_type', 'field_5f554dca6181e'),
(16706, 746, 'management_3_name', 'Jeffrey Leow'),
(16707, 746, '_management_3_name', 'field_5efe20a3d7829'),
(16708, 746, 'management_3_board_type', 'bactoclear'),
(16709, 746, '_management_3_board_type', 'field_5f554dca6181e'),
(16710, 746, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(16711, 746, '_management_3_title', 'field_5efe20add782a'),
(16712, 746, 'management_3_image', '725'),
(16713, 746, '_management_3_image', 'field_5f5516e46507c'),
(16714, 746, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(16715, 746, '_management_3_bio', 'field_5efe20b4d782b'),
(16716, 746, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(16717, 746, '_management_4_name', 'field_5efe20a3d7829'),
(16718, 746, 'management_4_board_type', 'gbpl'),
(16719, 746, '_management_4_board_type', 'field_5f554dca6181e'),
(16720, 746, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(16721, 746, '_management_4_title', 'field_5efe20add782a'),
(16722, 746, 'management_4_image', '726'),
(16723, 746, '_management_4_image', 'field_5f5516e46507c'),
(16724, 746, 'management_4_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(16725, 746, '_management_4_bio', 'field_5efe20b4d782b'),
(16726, 746, 'management_5_name', 'Dr. T. S. Balganesh'),
(16727, 746, '_management_5_name', 'field_5efe20a3d7829'),
(16728, 746, 'management_5_board_type', 'gbpl'),
(16729, 746, '_management_5_board_type', 'field_5f554dca6181e'),
(16730, 746, 'management_5_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(16731, 746, '_management_5_title', 'field_5efe20add782a'),
(16732, 746, 'management_5_image', '501'),
(16733, 746, '_management_5_image', 'field_5f5516e46507c'),
(16734, 746, 'management_5_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(16735, 746, '_management_5_bio', 'field_5efe20b4d782b'),
(16736, 746, 'management_6_name', 'Dr. Manur Jayasheela'),
(16737, 746, '_management_6_name', 'field_5efe20a3d7829'),
(16738, 746, 'management_6_board_type', 'gbpl'),
(16739, 746, '_management_6_board_type', 'field_5f554dca6181e'),
(16740, 746, 'management_6_title', 'Member, Board of Directors GBPL'),
(16741, 746, '_management_6_title', 'field_5efe20add782a'),
(16742, 746, 'management_6_image', ''),
(16743, 746, '_management_6_image', 'field_5f5516e46507c'),
(16744, 746, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(16745, 746, '_management_6_bio', 'field_5efe20b4d782b'),
(16746, 747, '_wp_attached_file', '2020/09/gg-suchad-profile-wihte.jpg'),
(16747, 747, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1288;s:6:\"height\";i:1288;s:4:\"file\";s:35:\"2020/09/gg-suchad-profile-wihte.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:35:\"gg-suchad-profile-wihte-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:37:\"gg-suchad-profile-wihte-1024x1024.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:35:\"gg-suchad-profile-wihte-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:35:\"gg-suchad-profile-wihte-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16748, 748, 'custom_page_logo', ''),
(16749, 748, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16750, 748, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(16751, 748, '_sections', 'field_5e1273c3f12ad'),
(16752, 748, 'sections_0_admin_title', 'Header Banner'),
(16753, 748, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16754, 748, 'sections_0_disable_mode', '0'),
(16755, 748, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16756, 748, 'sections_0_template_block_part', '/templates/header-banner'),
(16757, 748, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16758, 748, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(16759, 748, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(16760, 748, 'sections_1_disable_mode', '0'),
(16761, 748, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(16762, 748, 'sections_1_template_block_part', '/templates/directors'),
(16763, 748, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(16764, 748, 'management_0_name', 'Suchad Chiaranussati'),
(16765, 748, '_management_0_name', 'field_5efe20a3d7829'),
(16766, 748, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(16767, 748, '_management_0_title', 'field_5efe20add782a'),
(16768, 748, 'management_0_image', '747'),
(16769, 748, '_management_0_image', 'field_5f5516e46507c'),
(16770, 748, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(16771, 748, '_management_0_bio', 'field_5efe20b4d782b'),
(16772, 748, 'management_1_name', 'Dean Cash'),
(16773, 748, '_management_1_name', 'field_5efe20a3d7829'),
(16774, 748, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(16775, 748, '_management_1_title', 'field_5efe20add782a'),
(16776, 748, 'management_1_image', '690'),
(16777, 748, '_management_1_image', 'field_5f5516e46507c'),
(16778, 748, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(16779, 748, '_management_1_bio', 'field_5efe20b4d782b'),
(16780, 748, 'management_2_name', 'Vinod Jadhav'),
(16781, 748, '_management_2_name', 'field_5efe20a3d7829'),
(16782, 748, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(16783, 748, '_management_2_title', 'field_5efe20add782a'),
(16784, 748, 'management_2_image', '727'),
(16785, 748, '_management_2_image', 'field_5f5516e46507c'),
(16786, 748, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(16787, 748, '_management_2_bio', 'field_5efe20b4d782b'),
(16788, 748, 'management', '7'),
(16789, 748, '_management', 'field_5efe2097d7828'),
(16790, 748, 'management_0_board_type', 'bactoclear'),
(16791, 748, '_management_0_board_type', 'field_5f554dca6181e'),
(16792, 748, 'management_1_board_type', 'bactoclear'),
(16793, 748, '_management_1_board_type', 'field_5f554dca6181e'),
(16794, 748, 'management_2_board_type', 'bactoclear'),
(16795, 748, '_management_2_board_type', 'field_5f554dca6181e'),
(16796, 748, 'management_3_name', 'Jeffrey Leow'),
(16797, 748, '_management_3_name', 'field_5efe20a3d7829'),
(16798, 748, 'management_3_board_type', 'bactoclear'),
(16799, 748, '_management_3_board_type', 'field_5f554dca6181e'),
(16800, 748, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(16801, 748, '_management_3_title', 'field_5efe20add782a'),
(16802, 748, 'management_3_image', '725'),
(16803, 748, '_management_3_image', 'field_5f5516e46507c'),
(16804, 748, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(16805, 748, '_management_3_bio', 'field_5efe20b4d782b'),
(16806, 748, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(16807, 748, '_management_4_name', 'field_5efe20a3d7829'),
(16808, 748, 'management_4_board_type', 'gbpl'),
(16809, 748, '_management_4_board_type', 'field_5f554dca6181e'),
(16810, 748, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(16811, 748, '_management_4_title', 'field_5efe20add782a'),
(16812, 748, 'management_4_image', '726'),
(16813, 748, '_management_4_image', 'field_5f5516e46507c'),
(16814, 748, 'management_4_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(16815, 748, '_management_4_bio', 'field_5efe20b4d782b'),
(16816, 748, 'management_5_name', 'Dr. T. S. Balganesh'),
(16817, 748, '_management_5_name', 'field_5efe20a3d7829'),
(16818, 748, 'management_5_board_type', 'gbpl'),
(16819, 748, '_management_5_board_type', 'field_5f554dca6181e'),
(16820, 748, 'management_5_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(16821, 748, '_management_5_title', 'field_5efe20add782a'),
(16822, 748, 'management_5_image', '501'),
(16823, 748, '_management_5_image', 'field_5f5516e46507c');
INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(16824, 748, 'management_5_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(16825, 748, '_management_5_bio', 'field_5efe20b4d782b'),
(16826, 748, 'management_6_name', 'Dr. Manur Jayasheela'),
(16827, 748, '_management_6_name', 'field_5efe20a3d7829'),
(16828, 748, 'management_6_board_type', 'gbpl'),
(16829, 748, '_management_6_board_type', 'field_5f554dca6181e'),
(16830, 748, 'management_6_title', 'Member, Board of Directors GBPL'),
(16831, 748, '_management_6_title', 'field_5efe20add782a'),
(16832, 748, 'management_6_image', ''),
(16833, 748, '_management_6_image', 'field_5f5516e46507c'),
(16834, 748, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(16835, 748, '_management_6_bio', 'field_5efe20b4d782b'),
(16836, 749, '_wp_attached_file', '2020/09/vinod-jadhav-white-bg.jpg'),
(16837, 749, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:600;s:6:\"height\";i:600;s:4:\"file\";s:33:\"2020/09/vinod-jadhav-white-bg.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:33:\"vinod-jadhav-white-bg-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:33:\"vinod-jadhav-white-bg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16838, 750, 'custom_page_logo', ''),
(16839, 750, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16840, 750, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(16841, 750, '_sections', 'field_5e1273c3f12ad'),
(16842, 750, 'sections_0_admin_title', 'Header Banner'),
(16843, 750, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16844, 750, 'sections_0_disable_mode', '0'),
(16845, 750, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16846, 750, 'sections_0_template_block_part', '/templates/header-banner'),
(16847, 750, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16848, 750, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(16849, 750, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(16850, 750, 'sections_1_disable_mode', '0'),
(16851, 750, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(16852, 750, 'sections_1_template_block_part', '/templates/directors'),
(16853, 750, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(16854, 750, 'management_0_name', 'Suchad Chiaranussati'),
(16855, 750, '_management_0_name', 'field_5efe20a3d7829'),
(16856, 750, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(16857, 750, '_management_0_title', 'field_5efe20add782a'),
(16858, 750, 'management_0_image', '747'),
(16859, 750, '_management_0_image', 'field_5f5516e46507c'),
(16860, 750, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(16861, 750, '_management_0_bio', 'field_5efe20b4d782b'),
(16862, 750, 'management_1_name', 'Dean Cash'),
(16863, 750, '_management_1_name', 'field_5efe20a3d7829'),
(16864, 750, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(16865, 750, '_management_1_title', 'field_5efe20add782a'),
(16866, 750, 'management_1_image', '690'),
(16867, 750, '_management_1_image', 'field_5f5516e46507c'),
(16868, 750, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(16869, 750, '_management_1_bio', 'field_5efe20b4d782b'),
(16870, 750, 'management_2_name', 'Vinod Jadhav'),
(16871, 750, '_management_2_name', 'field_5efe20a3d7829'),
(16872, 750, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(16873, 750, '_management_2_title', 'field_5efe20add782a'),
(16874, 750, 'management_2_image', '749'),
(16875, 750, '_management_2_image', 'field_5f5516e46507c'),
(16876, 750, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(16877, 750, '_management_2_bio', 'field_5efe20b4d782b'),
(16878, 750, 'management', '7'),
(16879, 750, '_management', 'field_5efe2097d7828'),
(16880, 750, 'management_0_board_type', 'bactoclear'),
(16881, 750, '_management_0_board_type', 'field_5f554dca6181e'),
(16882, 750, 'management_1_board_type', 'bactoclear'),
(16883, 750, '_management_1_board_type', 'field_5f554dca6181e'),
(16884, 750, 'management_2_board_type', 'bactoclear'),
(16885, 750, '_management_2_board_type', 'field_5f554dca6181e'),
(16886, 750, 'management_3_name', 'Jeffrey Leow'),
(16887, 750, '_management_3_name', 'field_5efe20a3d7829'),
(16888, 750, 'management_3_board_type', 'bactoclear'),
(16889, 750, '_management_3_board_type', 'field_5f554dca6181e'),
(16890, 750, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(16891, 750, '_management_3_title', 'field_5efe20add782a'),
(16892, 750, 'management_3_image', '725'),
(16893, 750, '_management_3_image', 'field_5f5516e46507c'),
(16894, 750, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(16895, 750, '_management_3_bio', 'field_5efe20b4d782b'),
(16896, 750, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(16897, 750, '_management_4_name', 'field_5efe20a3d7829'),
(16898, 750, 'management_4_board_type', 'gbpl'),
(16899, 750, '_management_4_board_type', 'field_5f554dca6181e'),
(16900, 750, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(16901, 750, '_management_4_title', 'field_5efe20add782a'),
(16902, 750, 'management_4_image', '726'),
(16903, 750, '_management_4_image', 'field_5f5516e46507c'),
(16904, 750, 'management_4_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(16905, 750, '_management_4_bio', 'field_5efe20b4d782b'),
(16906, 750, 'management_5_name', 'Dr. T. S. Balganesh'),
(16907, 750, '_management_5_name', 'field_5efe20a3d7829'),
(16908, 750, 'management_5_board_type', 'gbpl'),
(16909, 750, '_management_5_board_type', 'field_5f554dca6181e'),
(16910, 750, 'management_5_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(16911, 750, '_management_5_title', 'field_5efe20add782a'),
(16912, 750, 'management_5_image', '501'),
(16913, 750, '_management_5_image', 'field_5f5516e46507c'),
(16914, 750, 'management_5_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(16915, 750, '_management_5_bio', 'field_5efe20b4d782b'),
(16916, 750, 'management_6_name', 'Dr. Manur Jayasheela'),
(16917, 750, '_management_6_name', 'field_5efe20a3d7829'),
(16918, 750, 'management_6_board_type', 'gbpl'),
(16919, 750, '_management_6_board_type', 'field_5f554dca6181e'),
(16920, 750, 'management_6_title', 'Member, Board of Directors GBPL'),
(16921, 750, '_management_6_title', 'field_5efe20add782a'),
(16922, 750, 'management_6_image', ''),
(16923, 750, '_management_6_image', 'field_5f5516e46507c'),
(16924, 750, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(16925, 750, '_management_6_bio', 'field_5efe20b4d782b'),
(16926, 751, '_wp_attached_file', '2020/09/jr-photo-white-bg.jpg'),
(16927, 751, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1000;s:6:\"height\";i:1000;s:4:\"file\";s:29:\"2020/09/jr-photo-white-bg.jpg\";s:5:\"sizes\";a:3:{s:6:\"medium\";a:4:{s:4:\"file\";s:29:\"jr-photo-white-bg-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:29:\"jr-photo-white-bg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:29:\"jr-photo-white-bg-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(16928, 752, 'custom_page_logo', ''),
(16929, 752, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(16930, 752, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(16931, 752, '_sections', 'field_5e1273c3f12ad'),
(16932, 752, 'sections_0_admin_title', 'Header Banner'),
(16933, 752, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(16934, 752, 'sections_0_disable_mode', '0'),
(16935, 752, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(16936, 752, 'sections_0_template_block_part', '/templates/header-banner'),
(16937, 752, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(16938, 752, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(16939, 752, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(16940, 752, 'sections_1_disable_mode', '0'),
(16941, 752, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(16942, 752, 'sections_1_template_block_part', '/templates/directors'),
(16943, 752, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(16944, 752, 'management_0_name', 'Suchad Chiaranussati'),
(16945, 752, '_management_0_name', 'field_5efe20a3d7829'),
(16946, 752, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(16947, 752, '_management_0_title', 'field_5efe20add782a'),
(16948, 752, 'management_0_image', '747'),
(16949, 752, '_management_0_image', 'field_5f5516e46507c'),
(16950, 752, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(16951, 752, '_management_0_bio', 'field_5efe20b4d782b'),
(16952, 752, 'management_1_name', 'Dean Cash'),
(16953, 752, '_management_1_name', 'field_5efe20a3d7829'),
(16954, 752, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(16955, 752, '_management_1_title', 'field_5efe20add782a'),
(16956, 752, 'management_1_image', '690'),
(16957, 752, '_management_1_image', 'field_5f5516e46507c'),
(16958, 752, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(16959, 752, '_management_1_bio', 'field_5efe20b4d782b'),
(16960, 752, 'management_2_name', 'Vinod Jadhav'),
(16961, 752, '_management_2_name', 'field_5efe20a3d7829'),
(16962, 752, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(16963, 752, '_management_2_title', 'field_5efe20add782a'),
(16964, 752, 'management_2_image', '749'),
(16965, 752, '_management_2_image', 'field_5f5516e46507c'),
(16966, 752, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(16967, 752, '_management_2_bio', 'field_5efe20b4d782b'),
(16968, 752, 'management', '7'),
(16969, 752, '_management', 'field_5efe2097d7828'),
(16970, 752, 'management_0_board_type', 'bactoclear'),
(16971, 752, '_management_0_board_type', 'field_5f554dca6181e'),
(16972, 752, 'management_1_board_type', 'bactoclear'),
(16973, 752, '_management_1_board_type', 'field_5f554dca6181e'),
(16974, 752, 'management_2_board_type', 'bactoclear'),
(16975, 752, '_management_2_board_type', 'field_5f554dca6181e'),
(16976, 752, 'management_3_name', 'Jeffrey Leow'),
(16977, 752, '_management_3_name', 'field_5efe20a3d7829'),
(16978, 752, 'management_3_board_type', 'bactoclear'),
(16979, 752, '_management_3_board_type', 'field_5f554dca6181e'),
(16980, 752, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(16981, 752, '_management_3_title', 'field_5efe20add782a'),
(16982, 752, 'management_3_image', '725'),
(16983, 752, '_management_3_image', 'field_5f5516e46507c'),
(16984, 752, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(16985, 752, '_management_3_bio', 'field_5efe20b4d782b'),
(16986, 752, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(16987, 752, '_management_4_name', 'field_5efe20a3d7829'),
(16988, 752, 'management_4_board_type', 'gbpl'),
(16989, 752, '_management_4_board_type', 'field_5f554dca6181e'),
(16990, 752, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(16991, 752, '_management_4_title', 'field_5efe20add782a'),
(16992, 752, 'management_4_image', '751'),
(16993, 752, '_management_4_image', 'field_5f5516e46507c'),
(16994, 752, 'management_4_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(16995, 752, '_management_4_bio', 'field_5efe20b4d782b'),
(16996, 752, 'management_5_name', 'Dr. T. S. Balganesh'),
(16997, 752, '_management_5_name', 'field_5efe20a3d7829'),
(16998, 752, 'management_5_board_type', 'gbpl'),
(16999, 752, '_management_5_board_type', 'field_5f554dca6181e'),
(17000, 752, 'management_5_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(17001, 752, '_management_5_title', 'field_5efe20add782a'),
(17002, 752, 'management_5_image', '501'),
(17003, 752, '_management_5_image', 'field_5f5516e46507c'),
(17004, 752, 'management_5_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(17005, 752, '_management_5_bio', 'field_5efe20b4d782b'),
(17006, 752, 'management_6_name', 'Dr. Manur Jayasheela'),
(17007, 752, '_management_6_name', 'field_5efe20a3d7829'),
(17008, 752, 'management_6_board_type', 'gbpl'),
(17009, 752, '_management_6_board_type', 'field_5f554dca6181e'),
(17010, 752, 'management_6_title', 'Member, Board of Directors GBPL'),
(17011, 752, '_management_6_title', 'field_5efe20add782a'),
(17012, 752, 'management_6_image', ''),
(17013, 752, '_management_6_image', 'field_5f5516e46507c'),
(17014, 752, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(17015, 752, '_management_6_bio', 'field_5efe20b4d782b'),
(17016, 753, '_wp_attached_file', '2020/09/ts-balganesh.jpg'),
(17017, 753, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1200;s:6:\"height\";i:1200;s:4:\"file\";s:24:\"2020/09/ts-balganesh.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:24:\"ts-balganesh-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:26:\"ts-balganesh-1024x1024.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:24:\"ts-balganesh-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:24:\"ts-balganesh-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(17018, 754, 'custom_page_logo', ''),
(17019, 754, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(17020, 754, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(17021, 754, '_sections', 'field_5e1273c3f12ad'),
(17022, 754, 'sections_0_admin_title', 'Header Banner'),
(17023, 754, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(17024, 754, 'sections_0_disable_mode', '0'),
(17025, 754, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(17026, 754, 'sections_0_template_block_part', '/templates/header-banner'),
(17027, 754, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(17028, 754, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(17029, 754, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(17030, 754, 'sections_1_disable_mode', '0'),
(17031, 754, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(17032, 754, 'sections_1_template_block_part', '/templates/directors'),
(17033, 754, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(17034, 754, 'management_0_name', 'Suchad Chiaranussati'),
(17035, 754, '_management_0_name', 'field_5efe20a3d7829'),
(17036, 754, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(17037, 754, '_management_0_title', 'field_5efe20add782a'),
(17038, 754, 'management_0_image', '747'),
(17039, 754, '_management_0_image', 'field_5f5516e46507c'),
(17040, 754, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(17041, 754, '_management_0_bio', 'field_5efe20b4d782b'),
(17042, 754, 'management_1_name', 'Dean Cash'),
(17043, 754, '_management_1_name', 'field_5efe20a3d7829'),
(17044, 754, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(17045, 754, '_management_1_title', 'field_5efe20add782a'),
(17046, 754, 'management_1_image', '690'),
(17047, 754, '_management_1_image', 'field_5f5516e46507c'),
(17048, 754, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(17049, 754, '_management_1_bio', 'field_5efe20b4d782b'),
(17050, 754, 'management_2_name', 'Vinod Jadhav'),
(17051, 754, '_management_2_name', 'field_5efe20a3d7829'),
(17052, 754, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(17053, 754, '_management_2_title', 'field_5efe20add782a'),
(17054, 754, 'management_2_image', '749'),
(17055, 754, '_management_2_image', 'field_5f5516e46507c'),
(17056, 754, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(17057, 754, '_management_2_bio', 'field_5efe20b4d782b'),
(17058, 754, 'management', '7'),
(17059, 754, '_management', 'field_5efe2097d7828'),
(17060, 754, 'management_0_board_type', 'bactoclear'),
(17061, 754, '_management_0_board_type', 'field_5f554dca6181e'),
(17062, 754, 'management_1_board_type', 'bactoclear'),
(17063, 754, '_management_1_board_type', 'field_5f554dca6181e'),
(17064, 754, 'management_2_board_type', 'bactoclear'),
(17065, 754, '_management_2_board_type', 'field_5f554dca6181e'),
(17066, 754, 'management_3_name', 'Jeffrey Leow'),
(17067, 754, '_management_3_name', 'field_5efe20a3d7829'),
(17068, 754, 'management_3_board_type', 'bactoclear'),
(17069, 754, '_management_3_board_type', 'field_5f554dca6181e'),
(17070, 754, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(17071, 754, '_management_3_title', 'field_5efe20add782a'),
(17072, 754, 'management_3_image', '725'),
(17073, 754, '_management_3_image', 'field_5f5516e46507c'),
(17074, 754, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(17075, 754, '_management_3_bio', 'field_5efe20b4d782b'),
(17076, 754, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(17077, 754, '_management_4_name', 'field_5efe20a3d7829'),
(17078, 754, 'management_4_board_type', 'gbpl'),
(17079, 754, '_management_4_board_type', 'field_5f554dca6181e'),
(17080, 754, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(17081, 754, '_management_4_title', 'field_5efe20add782a'),
(17082, 754, 'management_4_image', '751'),
(17083, 754, '_management_4_image', 'field_5f5516e46507c'),
(17084, 754, 'management_4_bio', '<p>Dr. J. Ramachandran founded Gangagen Biotechnologies in the year 2000 and established a research laboratory with the aim to find novel solutions to address the increasing menace of antibiotic resistance.</p>\r\n\r\n<p>Dr. Ramachandran brings to the company over 40 years of rich and distinguished executive experience in the biotechnology and pharmaceutical industry. Dr. Ramachandran was Head, R & D of AstraZeneca, Bangalore. He served as President of Astra Biochemicals Private Ltd and of the merged entity AstraZeneca India. During his tenure with Astra and AstraZeneca, he established state-of-the art R & D programs for discovering and developing novel therapies for the treatment of tuberculosis and antibiotic resistant infection.</p>\r\n \r\n<p>In 1988, as Vice President of research at Neurex Corporation in Menlo Park, California, he spearheaded the development of highly selective neuronal calcium channel antagonists derived from the venoms of marine, fish-eating cone snails.. Clinical trials including two pivotal phase III trials were completed successfully and SNX-111 received approvable status under the name Ziconotide in June 2000.</p>\r\n\r\n<p>Dr. Ramachandran started his career in the biotech industry at Genentech, Inc. where he pioneered the molecular cloning and expression of several important cell surface receptors (including the human insulin receptor). Prior to this, he was on the faculty of the University of California as a member of the Hormone Research Laboratory and the Department of Biochemistry and Biophysics where he became Associate Professor (1972) and Professor (1978).. Dr. Ramachandran received his Ph.D.in Biochemistry from the University of California at Berkeley, holds an MS degree in Chemistry from De Paul University in Chicago and Bachelor of Science (Chemistry) with Honours  from the University of Madras.</p>'),
(17085, 754, '_management_4_bio', 'field_5efe20b4d782b'),
(17086, 754, 'management_5_name', 'Dr. T. S. Balganesh'),
(17087, 754, '_management_5_name', 'field_5efe20a3d7829'),
(17088, 754, 'management_5_board_type', 'gbpl'),
(17089, 754, '_management_5_board_type', 'field_5f554dca6181e'),
(17090, 754, 'management_5_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(17091, 754, '_management_5_title', 'field_5efe20add782a'),
(17092, 754, 'management_5_image', '753'),
(17093, 754, '_management_5_image', 'field_5f5516e46507c'),
(17094, 754, 'management_5_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(17095, 754, '_management_5_bio', 'field_5efe20b4d782b'),
(17096, 754, 'management_6_name', 'Dr. Manur Jayasheela'),
(17097, 754, '_management_6_name', 'field_5efe20a3d7829'),
(17098, 754, 'management_6_board_type', 'gbpl'),
(17099, 754, '_management_6_board_type', 'field_5f554dca6181e'),
(17100, 754, 'management_6_title', 'Member, Board of Directors GBPL'),
(17101, 754, '_management_6_title', 'field_5efe20add782a'),
(17102, 754, 'management_6_image', ''),
(17103, 754, '_management_6_image', 'field_5f5516e46507c'),
(17104, 754, 'management_6_bio', '<p>The highlights of his distinguished career include director, BCG Vaccine Laboratory, Chennai, Assistant Director, Central Research Institute, Kasauli, Ministry of Health and Family Welfare, Government of India.</p>\r\n \r\n<p>Dr. Manur taught Microbiology at the All India Institute of Hygiene and Public Health in Calcutta from 1975 to 1983. He then moved to the Central Research Institute in Kasauli, Himachal Pradesh to be Assistant Director. From 1983 to 1991 he was responsible for the National Salmonella and Escherichia Centre (NSEC) and the National Type Culture Collection Centre (NTCC). During this period he gained extensive experience in phage typing of bacteria. In 1991, Dr. Manur was appointed Deputy Director of the Central Leprosy Teaching and Research Institute in Chingalputtu, Tamil Nadu. He came to Bangalore in 1998 as Consultant Microbiologist for the National Institute of Tuberculosis, Bangalore, India.</p>\r\n \r\n<p>Dr. Manur is an MD in Microbiology from the Postgraduate Institute of Medical Education & Research, Chandigarh, India.</p>'),
(17105, 754, '_management_6_bio', 'field_5efe20b4d782b'),
(17106, 755, 'custom_page_logo', ''),
(17107, 755, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(17108, 755, 'sections_0_admin_title', 'Header Banner'),
(17109, 755, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(17110, 755, 'sections_0_disable_mode', '0'),
(17111, 755, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(17112, 755, 'sections_0_template_block_part', '/templates/header-banner'),
(17113, 755, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(17114, 755, 'sections_1_admin_title', 'Management'),
(17115, 755, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(17116, 755, 'sections_1_disable_mode', '0'),
(17117, 755, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(17118, 755, 'sections_1_template_block_part', '/templates/management'),
(17119, 755, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(17120, 755, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(17121, 755, '_sections', 'field_5e1273c3f12ad'),
(17122, 755, 'management', '5'),
(17123, 755, '_management', 'field_5efe2097d7828'),
(17124, 755, 'management_0_name', 'Dr. T. S. Balganesh'),
(17125, 755, '_management_0_name', 'field_5efe20a3d7829'),
(17126, 755, 'management_0_title', 'President, GBPL and Member, Board of Directors, GBPL');
INSERT INTO `wp_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(17127, 755, '_management_0_title', 'field_5efe20add782a'),
(17128, 755, 'management_0_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(17129, 755, '_management_0_bio', 'field_5efe20b4d782b'),
(17130, 755, 'management_1_name', 'Bharathi Sriram'),
(17131, 755, '_management_1_name', 'field_5efe20a3d7829'),
(17132, 755, 'management_1_title', 'Vice President, Research and Development, GBPL'),
(17133, 755, '_management_1_title', 'field_5efe20add782a'),
(17134, 755, 'management_1_bio', '<p> Ms. Sriram has over 25 years of experience in biopharmaceutical R&D, with hands-on knowledge of driving biologics from early research to human clinical trials. She joined GangaGen in 2001 and has held various leadership roles, helping to establish the R&D infrastructure at GangaGen and has built and led multidisciplinary teams towards development of therapeutic phages and phage-derived antibacterial proteins for human therapy.</p>\r\n\r\n<p> Prior to joining GangaGen, Ms. Sriram gained extensive experience in chemistry, manufacturing and controls and regulatory requirements for Bio-therapeutics at Dr. Reddy’s Laboratories, where she was Head of Process Validation and Quality Control. Earlier in her career, she developed DNA-based diagnostics for cerebral malaria and researched anti-malarial compounds for in vitro and in vivo efficacy at Astra Research Center India (Astra Zeneca).</p>\r\n\r\n<p> After completing her Master’s Degree in Clinical Biochemistry, she pursued a Master of Philosophy in Biotechnology from the University of Poona. She is the author of several scientific publications in peer-reviewed journals. Ms. Sriram is an inventor on several patents related to GangaGen’s phage and phage-derived technology.</p>'),
(17135, 755, '_management_1_bio', 'field_5efe20b4d782b'),
(17136, 755, 'management_2_name', 'Aradhana Vipra'),
(17137, 755, '_management_2_name', 'field_5efe20a3d7829'),
(17138, 755, 'management_2_title', 'Head of Microbology, GBPL'),
(17139, 755, '_management_2_title', 'field_5efe20add782a'),
(17140, 755, 'management_2_bio', '<p> Aradhana Vipra is Head of Microbiology at GangaGen Biotechnologies Private Limited. She joined GangaGen in 2003, and leads the company’s Microbiology team. </p>\r\n\r\n<p> Ms. Vipra has extensive experience in bacteriophage research, including characterization of bacteriophages for various Gram-positive and Gram-negative drug resistant bacteria and product development strategies for phage-based prophylactics. She is well-versed in clinical laboratory guidelines for in-vitro testing of new candidate drugs and acquainted with a range of in-vitro based assays. </p>\r\n\r\n<p> Ms. Vipra holds a Master’s Degree in Microbiology from Department of Microbiology, Nagpur University, India. She has published in peer reviewed journals including Antimicrobial Agents and Chemotherapy, Microbiology, BMC Microbiology, Veterinary Research Communications and phage related research articles in Diseases of Aquatic Microorganisms and Advances in Microbiology. She is an inventor on the patent filed for P128 activity on biofilm. </p>'),
(17141, 755, '_management_2_bio', 'field_5efe20b4d782b'),
(17142, 755, 'management_3_name', 'Sukumar Hariharan'),
(17143, 755, '_management_3_name', 'field_5efe20a3d7829'),
(17144, 755, 'management_3_title', 'Head of Development, GBPL'),
(17145, 755, '_management_3_title', 'field_5efe20add782a'),
(17146, 755, 'management_3_bio', '<p> Mr. Sukumar  Hariharan has over 18 years of experience in the Biotech research. Mr. Sukumar Hariharan and his team have developed the manufacturing process for GangaGen’s lead phage products and bacteriophage-derived recombinant protein ectolysin, P128, the Company’s lead therapeutic candidate. He has extensive experience in the process development of therapeutic bacteriophages, phage derived antibacterial agents in bacterial expression system and in their manufacturing (cGMP) for preclinical and early clinical phases of drug development.</p>\r\n\r\n<p>Prior to joining GangaGen in 2004, Mr. Hariharan was responsible for the fermentation process development of therapeutic proteins in yeast expression systems at Bigtec Private Limited, Bangalore. </p>\r\n\r\n<p>Mr. Hariharan has a Bachelor’s Degree in Chemical Engineering. He received his Master’s of Engineering Degree in Biotechnology from the Anna University, Chennai, India.</p>'),
(17147, 755, '_management_3_bio', 'field_5efe20b4d782b'),
(17148, 755, 'management_4_name', 'Vivek Daniel Paul'),
(17149, 755, '_management_4_name', 'field_5efe20a3d7829'),
(17150, 755, 'management_4_title', 'Head of Molecular Biology, GBPL'),
(17151, 755, '_management_4_title', 'field_5efe20add782a'),
(17152, 755, 'management_4_bio', '<p> Vivek Daniel Paul has over 18 years of research experience in driving the discovery and development of therapeutic bacteriophages and bacteriophage-based protein antibacterial agents called ectolysins. Along with his colleagues, he discovered the ectolysin P128, a potent anti-Staphylococcal agent. </p>\r\n\r\n<p> Mr. Paul joined GangaGen in 2002 and later moved to Syngene International in 2009, where he worked as a scientist delivering biology R & D projects for multinational pharmaceutical companies. Before returning to GangaGen in 2013, he worked as a research scholar in Prof. Alan Davidson’s lab at University of Toronto where he got trained in structural and biophysical aspects of protein-protein interaction and macromolecular assembly in the context of phage morphogenesis.</p>\r\n\r\n<p> Mr. Paul received his Master’s degree in Biochemistry from Bharathiar University, Tamil Nadu. He has several patents in the field of phage ectolysins and has published in peer-reviewed journals.</p>'),
(17153, 755, '_management_4_bio', 'field_5efe20b4d782b'),
(17154, 755, 'management_0_board_type', 'none'),
(17155, 755, '_management_0_board_type', 'field_5f554dca6181e'),
(17156, 755, 'management_0_image', '753'),
(17157, 755, '_management_0_image', 'field_5f5516e46507c'),
(17158, 755, 'management_1_board_type', 'none'),
(17159, 755, '_management_1_board_type', 'field_5f554dca6181e'),
(17160, 755, 'management_1_image', '502'),
(17161, 755, '_management_1_image', 'field_5f5516e46507c'),
(17162, 755, 'management_2_board_type', 'none'),
(17163, 755, '_management_2_board_type', 'field_5f554dca6181e'),
(17164, 755, 'management_2_image', '503'),
(17165, 755, '_management_2_image', 'field_5f5516e46507c'),
(17166, 755, 'management_3_board_type', 'none'),
(17167, 755, '_management_3_board_type', 'field_5f554dca6181e'),
(17168, 755, 'management_3_image', '666'),
(17169, 755, '_management_3_image', 'field_5f5516e46507c'),
(17170, 755, 'management_4_board_type', 'none'),
(17171, 755, '_management_4_board_type', 'field_5f554dca6181e'),
(17172, 755, 'management_4_image', '500'),
(17173, 755, '_management_4_image', 'field_5f5516e46507c'),
(17174, 756, '_wp_attached_file', '2020/09/vivek-daniel-paul-white-bg.jpg'),
(17175, 756, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:673;s:6:\"height\";i:673;s:4:\"file\";s:38:\"2020/09/vivek-daniel-paul-white-bg.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:38:\"vivek-daniel-paul-white-bg-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:38:\"vivek-daniel-paul-white-bg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(17176, 757, 'custom_page_logo', ''),
(17177, 757, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(17178, 757, 'sections_0_admin_title', 'Header Banner'),
(17179, 757, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(17180, 757, 'sections_0_disable_mode', '0'),
(17181, 757, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(17182, 757, 'sections_0_template_block_part', '/templates/header-banner'),
(17183, 757, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(17184, 757, 'sections_1_admin_title', 'Management'),
(17185, 757, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(17186, 757, 'sections_1_disable_mode', '0'),
(17187, 757, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(17188, 757, 'sections_1_template_block_part', '/templates/management'),
(17189, 757, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(17190, 757, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(17191, 757, '_sections', 'field_5e1273c3f12ad'),
(17192, 757, 'management', '5'),
(17193, 757, '_management', 'field_5efe2097d7828'),
(17194, 757, 'management_0_name', 'Dr. T. S. Balganesh'),
(17195, 757, '_management_0_name', 'field_5efe20a3d7829'),
(17196, 757, 'management_0_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(17197, 757, '_management_0_title', 'field_5efe20add782a'),
(17198, 757, 'management_0_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(17199, 757, '_management_0_bio', 'field_5efe20b4d782b'),
(17200, 757, 'management_1_name', 'Bharathi Sriram'),
(17201, 757, '_management_1_name', 'field_5efe20a3d7829'),
(17202, 757, 'management_1_title', 'Vice President, Research and Development, GBPL'),
(17203, 757, '_management_1_title', 'field_5efe20add782a'),
(17204, 757, 'management_1_bio', '<p> Ms. Sriram has over 25 years of experience in biopharmaceutical R&D, with hands-on knowledge of driving biologics from early research to human clinical trials. She joined GangaGen in 2001 and has held various leadership roles, helping to establish the R&D infrastructure at GangaGen and has built and led multidisciplinary teams towards development of therapeutic phages and phage-derived antibacterial proteins for human therapy.</p>\r\n\r\n<p> Prior to joining GangaGen, Ms. Sriram gained extensive experience in chemistry, manufacturing and controls and regulatory requirements for Bio-therapeutics at Dr. Reddy’s Laboratories, where she was Head of Process Validation and Quality Control. Earlier in her career, she developed DNA-based diagnostics for cerebral malaria and researched anti-malarial compounds for in vitro and in vivo efficacy at Astra Research Center India (Astra Zeneca).</p>\r\n\r\n<p> After completing her Master’s Degree in Clinical Biochemistry, she pursued a Master of Philosophy in Biotechnology from the University of Poona. She is the author of several scientific publications in peer-reviewed journals. Ms. Sriram is an inventor on several patents related to GangaGen’s phage and phage-derived technology.</p>'),
(17205, 757, '_management_1_bio', 'field_5efe20b4d782b'),
(17206, 757, 'management_2_name', 'Aradhana Vipra'),
(17207, 757, '_management_2_name', 'field_5efe20a3d7829'),
(17208, 757, 'management_2_title', 'Head of Microbology, GBPL'),
(17209, 757, '_management_2_title', 'field_5efe20add782a'),
(17210, 757, 'management_2_bio', '<p> Aradhana Vipra is Head of Microbiology at GangaGen Biotechnologies Private Limited. She joined GangaGen in 2003, and leads the company’s Microbiology team. </p>\r\n\r\n<p> Ms. Vipra has extensive experience in bacteriophage research, including characterization of bacteriophages for various Gram-positive and Gram-negative drug resistant bacteria and product development strategies for phage-based prophylactics. She is well-versed in clinical laboratory guidelines for in-vitro testing of new candidate drugs and acquainted with a range of in-vitro based assays. </p>\r\n\r\n<p> Ms. Vipra holds a Master’s Degree in Microbiology from Department of Microbiology, Nagpur University, India. She has published in peer reviewed journals including Antimicrobial Agents and Chemotherapy, Microbiology, BMC Microbiology, Veterinary Research Communications and phage related research articles in Diseases of Aquatic Microorganisms and Advances in Microbiology. She is an inventor on the patent filed for P128 activity on biofilm. </p>'),
(17211, 757, '_management_2_bio', 'field_5efe20b4d782b'),
(17212, 757, 'management_3_name', 'Sukumar Hariharan'),
(17213, 757, '_management_3_name', 'field_5efe20a3d7829'),
(17214, 757, 'management_3_title', 'Head of Development, GBPL'),
(17215, 757, '_management_3_title', 'field_5efe20add782a'),
(17216, 757, 'management_3_bio', '<p> Mr. Sukumar  Hariharan has over 18 years of experience in the Biotech research. Mr. Sukumar Hariharan and his team have developed the manufacturing process for GangaGen’s lead phage products and bacteriophage-derived recombinant protein ectolysin, P128, the Company’s lead therapeutic candidate. He has extensive experience in the process development of therapeutic bacteriophages, phage derived antibacterial agents in bacterial expression system and in their manufacturing (cGMP) for preclinical and early clinical phases of drug development.</p>\r\n\r\n<p>Prior to joining GangaGen in 2004, Mr. Hariharan was responsible for the fermentation process development of therapeutic proteins in yeast expression systems at Bigtec Private Limited, Bangalore. </p>\r\n\r\n<p>Mr. Hariharan has a Bachelor’s Degree in Chemical Engineering. He received his Master’s of Engineering Degree in Biotechnology from the Anna University, Chennai, India.</p>'),
(17217, 757, '_management_3_bio', 'field_5efe20b4d782b'),
(17218, 757, 'management_4_name', 'Vivek Daniel Paul'),
(17219, 757, '_management_4_name', 'field_5efe20a3d7829'),
(17220, 757, 'management_4_title', 'Head of Molecular Biology, GBPL'),
(17221, 757, '_management_4_title', 'field_5efe20add782a'),
(17222, 757, 'management_4_bio', '<p> Vivek Daniel Paul has over 18 years of research experience in driving the discovery and development of therapeutic bacteriophages and bacteriophage-based protein antibacterial agents called ectolysins. Along with his colleagues, he discovered the ectolysin P128, a potent anti-Staphylococcal agent. </p>\r\n\r\n<p> Mr. Paul joined GangaGen in 2002 and later moved to Syngene International in 2009, where he worked as a scientist delivering biology R & D projects for multinational pharmaceutical companies. Before returning to GangaGen in 2013, he worked as a research scholar in Prof. Alan Davidson’s lab at University of Toronto where he got trained in structural and biophysical aspects of protein-protein interaction and macromolecular assembly in the context of phage morphogenesis.</p>\r\n\r\n<p> Mr. Paul received his Master’s degree in Biochemistry from Bharathiar University, Tamil Nadu. He has several patents in the field of phage ectolysins and has published in peer-reviewed journals.</p>'),
(17223, 757, '_management_4_bio', 'field_5efe20b4d782b'),
(17224, 757, 'management_0_board_type', 'none'),
(17225, 757, '_management_0_board_type', 'field_5f554dca6181e'),
(17226, 757, 'management_0_image', '753'),
(17227, 757, '_management_0_image', 'field_5f5516e46507c'),
(17228, 757, 'management_1_board_type', 'none'),
(17229, 757, '_management_1_board_type', 'field_5f554dca6181e'),
(17230, 757, 'management_1_image', '502'),
(17231, 757, '_management_1_image', 'field_5f5516e46507c'),
(17232, 757, 'management_2_board_type', 'none'),
(17233, 757, '_management_2_board_type', 'field_5f554dca6181e'),
(17234, 757, 'management_2_image', '503'),
(17235, 757, '_management_2_image', 'field_5f5516e46507c'),
(17236, 757, 'management_3_board_type', 'none'),
(17237, 757, '_management_3_board_type', 'field_5f554dca6181e'),
(17238, 757, 'management_3_image', '666'),
(17239, 757, '_management_3_image', 'field_5f5516e46507c'),
(17240, 757, 'management_4_board_type', 'none'),
(17241, 757, '_management_4_board_type', 'field_5f554dca6181e'),
(17242, 757, 'management_4_image', '756'),
(17243, 757, '_management_4_image', 'field_5f5516e46507c'),
(17244, 758, '_wp_attached_file', '2020/09/bharathi-sriram-white-bg.jpg'),
(17245, 758, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1200;s:6:\"height\";i:1200;s:4:\"file\";s:36:\"2020/09/bharathi-sriram-white-bg.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:36:\"bharathi-sriram-white-bg-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:38:\"bharathi-sriram-white-bg-1024x1024.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:36:\"bharathi-sriram-white-bg-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:36:\"bharathi-sriram-white-bg-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(17246, 759, 'custom_page_logo', ''),
(17247, 759, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(17248, 759, 'sections_0_admin_title', 'Header Banner'),
(17249, 759, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(17250, 759, 'sections_0_disable_mode', '0'),
(17251, 759, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(17252, 759, 'sections_0_template_block_part', '/templates/header-banner'),
(17253, 759, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(17254, 759, 'sections_1_admin_title', 'Management'),
(17255, 759, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(17256, 759, 'sections_1_disable_mode', '0'),
(17257, 759, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(17258, 759, 'sections_1_template_block_part', '/templates/management'),
(17259, 759, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(17260, 759, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(17261, 759, '_sections', 'field_5e1273c3f12ad'),
(17262, 759, 'management', '5'),
(17263, 759, '_management', 'field_5efe2097d7828'),
(17264, 759, 'management_0_name', 'Dr. T. S. Balganesh'),
(17265, 759, '_management_0_name', 'field_5efe20a3d7829'),
(17266, 759, 'management_0_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(17267, 759, '_management_0_title', 'field_5efe20add782a'),
(17268, 759, 'management_0_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(17269, 759, '_management_0_bio', 'field_5efe20b4d782b'),
(17270, 759, 'management_1_name', 'Bharathi Sriram'),
(17271, 759, '_management_1_name', 'field_5efe20a3d7829'),
(17272, 759, 'management_1_title', 'Vice President, Research and Development, GBPL'),
(17273, 759, '_management_1_title', 'field_5efe20add782a'),
(17274, 759, 'management_1_bio', '<p> Ms. Sriram has over 25 years of experience in biopharmaceutical R&D, with hands-on knowledge of driving biologics from early research to human clinical trials. She joined GangaGen in 2001 and has held various leadership roles, helping to establish the R&D infrastructure at GangaGen and has built and led multidisciplinary teams towards development of therapeutic phages and phage-derived antibacterial proteins for human therapy.</p>\r\n\r\n<p> Prior to joining GangaGen, Ms. Sriram gained extensive experience in chemistry, manufacturing and controls and regulatory requirements for Bio-therapeutics at Dr. Reddy’s Laboratories, where she was Head of Process Validation and Quality Control. Earlier in her career, she developed DNA-based diagnostics for cerebral malaria and researched anti-malarial compounds for in vitro and in vivo efficacy at Astra Research Center India (Astra Zeneca).</p>\r\n\r\n<p> After completing her Master’s Degree in Clinical Biochemistry, she pursued a Master of Philosophy in Biotechnology from the University of Poona. She is the author of several scientific publications in peer-reviewed journals. Ms. Sriram is an inventor on several patents related to GangaGen’s phage and phage-derived technology.</p>'),
(17275, 759, '_management_1_bio', 'field_5efe20b4d782b'),
(17276, 759, 'management_2_name', 'Aradhana Vipra'),
(17277, 759, '_management_2_name', 'field_5efe20a3d7829'),
(17278, 759, 'management_2_title', 'Head of Microbology, GBPL'),
(17279, 759, '_management_2_title', 'field_5efe20add782a'),
(17280, 759, 'management_2_bio', '<p> Aradhana Vipra is Head of Microbiology at GangaGen Biotechnologies Private Limited. She joined GangaGen in 2003, and leads the company’s Microbiology team. </p>\r\n\r\n<p> Ms. Vipra has extensive experience in bacteriophage research, including characterization of bacteriophages for various Gram-positive and Gram-negative drug resistant bacteria and product development strategies for phage-based prophylactics. She is well-versed in clinical laboratory guidelines for in-vitro testing of new candidate drugs and acquainted with a range of in-vitro based assays. </p>\r\n\r\n<p> Ms. Vipra holds a Master’s Degree in Microbiology from Department of Microbiology, Nagpur University, India. She has published in peer reviewed journals including Antimicrobial Agents and Chemotherapy, Microbiology, BMC Microbiology, Veterinary Research Communications and phage related research articles in Diseases of Aquatic Microorganisms and Advances in Microbiology. She is an inventor on the patent filed for P128 activity on biofilm. </p>'),
(17281, 759, '_management_2_bio', 'field_5efe20b4d782b'),
(17282, 759, 'management_3_name', 'Sukumar Hariharan'),
(17283, 759, '_management_3_name', 'field_5efe20a3d7829'),
(17284, 759, 'management_3_title', 'Head of Development, GBPL'),
(17285, 759, '_management_3_title', 'field_5efe20add782a'),
(17286, 759, 'management_3_bio', '<p> Mr. Sukumar  Hariharan has over 18 years of experience in the Biotech research. Mr. Sukumar Hariharan and his team have developed the manufacturing process for GangaGen’s lead phage products and bacteriophage-derived recombinant protein ectolysin, P128, the Company’s lead therapeutic candidate. He has extensive experience in the process development of therapeutic bacteriophages, phage derived antibacterial agents in bacterial expression system and in their manufacturing (cGMP) for preclinical and early clinical phases of drug development.</p>\r\n\r\n<p>Prior to joining GangaGen in 2004, Mr. Hariharan was responsible for the fermentation process development of therapeutic proteins in yeast expression systems at Bigtec Private Limited, Bangalore. </p>\r\n\r\n<p>Mr. Hariharan has a Bachelor’s Degree in Chemical Engineering. He received his Master’s of Engineering Degree in Biotechnology from the Anna University, Chennai, India.</p>'),
(17287, 759, '_management_3_bio', 'field_5efe20b4d782b'),
(17288, 759, 'management_4_name', 'Vivek Daniel Paul'),
(17289, 759, '_management_4_name', 'field_5efe20a3d7829'),
(17290, 759, 'management_4_title', 'Head of Molecular Biology, GBPL'),
(17291, 759, '_management_4_title', 'field_5efe20add782a'),
(17292, 759, 'management_4_bio', '<p> Vivek Daniel Paul has over 18 years of research experience in driving the discovery and development of therapeutic bacteriophages and bacteriophage-based protein antibacterial agents called ectolysins. Along with his colleagues, he discovered the ectolysin P128, a potent anti-Staphylococcal agent. </p>\r\n\r\n<p> Mr. Paul joined GangaGen in 2002 and later moved to Syngene International in 2009, where he worked as a scientist delivering biology R & D projects for multinational pharmaceutical companies. Before returning to GangaGen in 2013, he worked as a research scholar in Prof. Alan Davidson’s lab at University of Toronto where he got trained in structural and biophysical aspects of protein-protein interaction and macromolecular assembly in the context of phage morphogenesis.</p>\r\n\r\n<p> Mr. Paul received his Master’s degree in Biochemistry from Bharathiar University, Tamil Nadu. He has several patents in the field of phage ectolysins and has published in peer-reviewed journals.</p>'),
(17293, 759, '_management_4_bio', 'field_5efe20b4d782b'),
(17294, 759, 'management_0_board_type', 'none'),
(17295, 759, '_management_0_board_type', 'field_5f554dca6181e'),
(17296, 759, 'management_0_image', '753'),
(17297, 759, '_management_0_image', 'field_5f5516e46507c'),
(17298, 759, 'management_1_board_type', 'none'),
(17299, 759, '_management_1_board_type', 'field_5f554dca6181e'),
(17300, 759, 'management_1_image', '758'),
(17301, 759, '_management_1_image', 'field_5f5516e46507c'),
(17302, 759, 'management_2_board_type', 'none'),
(17303, 759, '_management_2_board_type', 'field_5f554dca6181e'),
(17304, 759, 'management_2_image', '503'),
(17305, 759, '_management_2_image', 'field_5f5516e46507c'),
(17306, 759, 'management_3_board_type', 'none'),
(17307, 759, '_management_3_board_type', 'field_5f554dca6181e'),
(17308, 759, 'management_3_image', '666'),
(17309, 759, '_management_3_image', 'field_5f5516e46507c'),
(17310, 759, 'management_4_board_type', 'none'),
(17311, 759, '_management_4_board_type', 'field_5f554dca6181e'),
(17312, 759, 'management_4_image', '756'),
(17313, 759, '_management_4_image', 'field_5f5516e46507c'),
(17314, 760, '_wp_attached_file', '2020/09/aradhana-vipra-1-white-background.jpg'),
(17315, 760, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:1200;s:6:\"height\";i:1200;s:4:\"file\";s:45:\"2020/09/aradhana-vipra-1-white-background.jpg\";s:5:\"sizes\";a:4:{s:6:\"medium\";a:4:{s:4:\"file\";s:45:\"aradhana-vipra-1-white-background-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:5:\"large\";a:4:{s:4:\"file\";s:47:\"aradhana-vipra-1-white-background-1024x1024.jpg\";s:5:\"width\";i:1024;s:6:\"height\";i:1024;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:45:\"aradhana-vipra-1-white-background-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:12:\"medium_large\";a:4:{s:4:\"file\";s:45:\"aradhana-vipra-1-white-background-768x768.jpg\";s:5:\"width\";i:768;s:6:\"height\";i:768;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(17316, 761, 'custom_page_logo', ''),
(17317, 761, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(17318, 761, 'sections_0_admin_title', 'Header Banner'),
(17319, 761, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(17320, 761, 'sections_0_disable_mode', '0'),
(17321, 761, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(17322, 761, 'sections_0_template_block_part', '/templates/header-banner'),
(17323, 761, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(17324, 761, 'sections_1_admin_title', 'Management'),
(17325, 761, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(17326, 761, 'sections_1_disable_mode', '0'),
(17327, 761, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(17328, 761, 'sections_1_template_block_part', '/templates/management'),
(17329, 761, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(17330, 761, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(17331, 761, '_sections', 'field_5e1273c3f12ad'),
(17332, 761, 'management', '5'),
(17333, 761, '_management', 'field_5efe2097d7828'),
(17334, 761, 'management_0_name', 'Dr. T. S. Balganesh'),
(17335, 761, '_management_0_name', 'field_5efe20a3d7829'),
(17336, 761, 'management_0_title', 'President, GBPL and Member, Board of Directors, GBPL'),
(17337, 761, '_management_0_title', 'field_5efe20add782a'),
(17338, 761, 'management_0_bio', '<p>Dr. Balganesh has three decades of experience in antibacterial drug discovery. As the Head of Research at AstraZeneca, Bangalore, he led the unit to deliver AstraZeneca’s first anti-tuberculosis molecule for clinical development. Before taking up his current appointment at GangaGen, in his capacity as Distinguished Scientist, he mentored drug discovery programs in various Indian National Laboratories under the Government of India’s Council for Scientific and Industrial Research (CSIR).</p>\r\n\r\n<p> Dr. Balganesh’s research experience is in the area of infectious diseases. He led the diarrheal diseases and broad-spectrum anti-bacterial project teams at AstraZeneca, Bangalore. He then went on to lead the anti-tuberculosis program. He has more than 30 publications and 10 patents to his name.</p>\r\n\r\n<p> Dr. Balganesh is trained as a Medical Microbiologist at the University of Calcutta. He gained his post-doctoral experience at Brookhaven National Laboratory, New York, and the Max Planck Institute for Molecular Genetics, Berlin. Dr. Balganesh has been awarded an Honorary Doctorate from the University of Uppsala in recognition of his work in tuberculosis and malaria. He is on the review panel of drug discovery programs like the ‘Innovative Medicines Initiative’; a European Union program to seeking novel treatments for Gram-negative bacterial pathogens. He continues to guide research programs in several National Laboratories in India. He is also a mentor and reviewer of programs initiated by the Wellcome Trust and the Gates Foundation in India.</p>'),
(17339, 761, '_management_0_bio', 'field_5efe20b4d782b'),
(17340, 761, 'management_1_name', 'Bharathi Sriram'),
(17341, 761, '_management_1_name', 'field_5efe20a3d7829'),
(17342, 761, 'management_1_title', 'Vice President, Research and Development, GBPL'),
(17343, 761, '_management_1_title', 'field_5efe20add782a'),
(17344, 761, 'management_1_bio', '<p> Ms. Sriram has over 25 years of experience in biopharmaceutical R&D, with hands-on knowledge of driving biologics from early research to human clinical trials. She joined GangaGen in 2001 and has held various leadership roles, helping to establish the R&D infrastructure at GangaGen and has built and led multidisciplinary teams towards development of therapeutic phages and phage-derived antibacterial proteins for human therapy.</p>\r\n\r\n<p> Prior to joining GangaGen, Ms. Sriram gained extensive experience in chemistry, manufacturing and controls and regulatory requirements for Bio-therapeutics at Dr. Reddy’s Laboratories, where she was Head of Process Validation and Quality Control. Earlier in her career, she developed DNA-based diagnostics for cerebral malaria and researched anti-malarial compounds for in vitro and in vivo efficacy at Astra Research Center India (Astra Zeneca).</p>\r\n\r\n<p> After completing her Master’s Degree in Clinical Biochemistry, she pursued a Master of Philosophy in Biotechnology from the University of Poona. She is the author of several scientific publications in peer-reviewed journals. Ms. Sriram is an inventor on several patents related to GangaGen’s phage and phage-derived technology.</p>'),
(17345, 761, '_management_1_bio', 'field_5efe20b4d782b'),
(17346, 761, 'management_2_name', 'Aradhana Vipra'),
(17347, 761, '_management_2_name', 'field_5efe20a3d7829'),
(17348, 761, 'management_2_title', 'Head of Microbology, GBPL'),
(17349, 761, '_management_2_title', 'field_5efe20add782a'),
(17350, 761, 'management_2_bio', '<p> Aradhana Vipra is Head of Microbiology at GangaGen Biotechnologies Private Limited. She joined GangaGen in 2003, and leads the company’s Microbiology team. </p>\r\n\r\n<p> Ms. Vipra has extensive experience in bacteriophage research, including characterization of bacteriophages for various Gram-positive and Gram-negative drug resistant bacteria and product development strategies for phage-based prophylactics. She is well-versed in clinical laboratory guidelines for in-vitro testing of new candidate drugs and acquainted with a range of in-vitro based assays. </p>\r\n\r\n<p> Ms. Vipra holds a Master’s Degree in Microbiology from Department of Microbiology, Nagpur University, India. She has published in peer reviewed journals including Antimicrobial Agents and Chemotherapy, Microbiology, BMC Microbiology, Veterinary Research Communications and phage related research articles in Diseases of Aquatic Microorganisms and Advances in Microbiology. She is an inventor on the patent filed for P128 activity on biofilm. </p>'),
(17351, 761, '_management_2_bio', 'field_5efe20b4d782b'),
(17352, 761, 'management_3_name', 'Sukumar Hariharan'),
(17353, 761, '_management_3_name', 'field_5efe20a3d7829'),
(17354, 761, 'management_3_title', 'Head of Development, GBPL'),
(17355, 761, '_management_3_title', 'field_5efe20add782a'),
(17356, 761, 'management_3_bio', '<p> Mr. Sukumar  Hariharan has over 18 years of experience in the Biotech research. Mr. Sukumar Hariharan and his team have developed the manufacturing process for GangaGen’s lead phage products and bacteriophage-derived recombinant protein ectolysin, P128, the Company’s lead therapeutic candidate. He has extensive experience in the process development of therapeutic bacteriophages, phage derived antibacterial agents in bacterial expression system and in their manufacturing (cGMP) for preclinical and early clinical phases of drug development.</p>\r\n\r\n<p>Prior to joining GangaGen in 2004, Mr. Hariharan was responsible for the fermentation process development of therapeutic proteins in yeast expression systems at Bigtec Private Limited, Bangalore. </p>\r\n\r\n<p>Mr. Hariharan has a Bachelor’s Degree in Chemical Engineering. He received his Master’s of Engineering Degree in Biotechnology from the Anna University, Chennai, India.</p>'),
(17357, 761, '_management_3_bio', 'field_5efe20b4d782b'),
(17358, 761, 'management_4_name', 'Vivek Daniel Paul'),
(17359, 761, '_management_4_name', 'field_5efe20a3d7829'),
(17360, 761, 'management_4_title', 'Head of Molecular Biology, GBPL'),
(17361, 761, '_management_4_title', 'field_5efe20add782a'),
(17362, 761, 'management_4_bio', '<p> Vivek Daniel Paul has over 18 years of research experience in driving the discovery and development of therapeutic bacteriophages and bacteriophage-based protein antibacterial agents called ectolysins. Along with his colleagues, he discovered the ectolysin P128, a potent anti-Staphylococcal agent. </p>\r\n\r\n<p> Mr. Paul joined GangaGen in 2002 and later moved to Syngene International in 2009, where he worked as a scientist delivering biology R & D projects for multinational pharmaceutical companies. Before returning to GangaGen in 2013, he worked as a research scholar in Prof. Alan Davidson’s lab at University of Toronto where he got trained in structural and biophysical aspects of protein-protein interaction and macromolecular assembly in the context of phage morphogenesis.</p>\r\n\r\n<p> Mr. Paul received his Master’s degree in Biochemistry from Bharathiar University, Tamil Nadu. He has several patents in the field of phage ectolysins and has published in peer-reviewed journals.</p>'),
(17363, 761, '_management_4_bio', 'field_5efe20b4d782b'),
(17364, 761, 'management_0_board_type', 'none'),
(17365, 761, '_management_0_board_type', 'field_5f554dca6181e'),
(17366, 761, 'management_0_image', '753'),
(17367, 761, '_management_0_image', 'field_5f5516e46507c'),
(17368, 761, 'management_1_board_type', 'none'),
(17369, 761, '_management_1_board_type', 'field_5f554dca6181e'),
(17370, 761, 'management_1_image', '758'),
(17371, 761, '_management_1_image', 'field_5f5516e46507c'),
(17372, 761, 'management_2_board_type', 'none'),
(17373, 761, '_management_2_board_type', 'field_5f554dca6181e'),
(17374, 761, 'management_2_image', '760'),
(17375, 761, '_management_2_image', 'field_5f5516e46507c'),
(17376, 761, 'management_3_board_type', 'none'),
(17377, 761, '_management_3_board_type', 'field_5f554dca6181e'),
(17378, 761, 'management_3_image', '666'),
(17379, 761, '_management_3_image', 'field_5f5516e46507c'),
(17380, 761, 'management_4_board_type', 'none'),
(17381, 761, '_management_4_board_type', 'field_5f554dca6181e'),
(17382, 761, 'management_4_image', '756'),
(17383, 761, '_management_4_image', 'field_5f5516e46507c'),
(17384, 762, '_wp_attached_file', '2020/09/jeffrey-leow-white-background.jpg'),
(17385, 762, '_wp_attachment_metadata', 'a:5:{s:5:\"width\";i:414;s:6:\"height\";i:414;s:4:\"file\";s:41:\"2020/09/jeffrey-leow-white-background.jpg\";s:5:\"sizes\";a:2:{s:6:\"medium\";a:4:{s:4:\"file\";s:41:\"jeffrey-leow-white-background-300x300.jpg\";s:5:\"width\";i:300;s:6:\"height\";i:300;s:9:\"mime-type\";s:10:\"image/jpeg\";}s:9:\"thumbnail\";a:4:{s:4:\"file\";s:41:\"jeffrey-leow-white-background-150x150.jpg\";s:5:\"width\";i:150;s:6:\"height\";i:150;s:9:\"mime-type\";s:10:\"image/jpeg\";}}s:10:\"image_meta\";a:12:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";s:11:\"orientation\";s:1:\"0\";s:8:\"keywords\";a:0:{}}}'),
(17386, 763, 'custom_page_logo', ''),
(17387, 763, '_custom_page_logo', 'field_5f05e4c7a26f9'),
(17388, 763, 'sections', 'a:2:{i:0;s:14:\"template_block\";i:1;s:14:\"template_block\";}'),
(17389, 763, '_sections', 'field_5e1273c3f12ad'),
(17390, 763, 'sections_0_admin_title', 'Header Banner'),
(17391, 763, '_sections_0_admin_title', 'field_5ec41f949a9a0'),
(17392, 763, 'sections_0_disable_mode', '0'),
(17393, 763, '_sections_0_disable_mode', 'field_5ec41f9a9a9a1'),
(17394, 763, 'sections_0_template_block_part', '/templates/header-banner'),
(17395, 763, '_sections_0_template_block_part', 'field_5ec41fa49a9a2'),
(17396, 763, 'sections_1_admin_title', 'Board of Directors (Bactoclear)'),
(17397, 763, '_sections_1_admin_title', 'field_5ec41f949a9a0'),
(17398, 763, 'sections_1_disable_mode', '0'),
(17399, 763, '_sections_1_disable_mode', 'field_5ec41f9a9a9a1'),
(17400, 763, 'sections_1_template_block_part', '/templates/directors'),
(17401, 763, '_sections_1_template_block_part', 'field_5ec41fa49a9a2'),
(17402, 763, 'management_0_name', 'Suchad Chiaranussati'),
(17403, 763, '_management_0_name', 'field_5efe20a3d7829'),
(17404, 763, 'management_0_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited'),
(17405, 763, '_management_0_title', 'field_5efe20add782a'),
(17406, 763, 'management_0_image', '747'),
(17407, 763, '_management_0_image', 'field_5f5516e46507c'),
(17408, 763, 'management_0_bio', '<p>Mr. Chiaranussati founded Real Estate Capital Asia Partners (RECAP), a series of Opportunistic Pan-Asian real estate private equity funds, in late 2004. RECAP I, II and III have a successful 10-year cumulative track record and $1.7 billion in invested capital. In July 2014, RECAP IV, with a target of $750 million, was launched with a first close in September of the same year. A final close of $850mm was achieved December 5, 2014. </p>\r\n\r\n<p>Mr. Chiaranussati leads RECAP’s team of 23 professionals, and has provided key leadership and direction since its inception. Mr. Chiaranussati serves as Chairman of the Investment Committee and participates in acquisition, value enhancement and realization activities. </p>\r\n\r\n<p>Before forming RECAP, he spent six years with Westbrook Partners and Westbrook Real Estate Partners (WREP). He opened WREP’s Asia office in Singapore in March 1999 and served as a Managing Director responsible for WREP’s Asian investment activities till late 2004. </p>\r\n\r\n<p>Before joining WREP, Mr. Chiaranussati spent seven years at J.P. Morgan, based in Singapore and covering Southeast Asia, where he served as a Vice President in the Proprietary Investment and Investment Banking Groups, focusing on real estate and financial institutions. Prior to that, he worked with Temasek Holdings, an investment holding company of the Government of Singapore and the Central Bank of Thailand. </p>\r\n\r\n<p>Mr. Chiaranussati received an Honors Degree in Economics in 1986 from the London School of Economics and a Masters of Science in Management Science in 1987 from Imperial College in London. </p>'),
(17409, 763, '_management_0_bio', 'field_5efe20b4d782b'),
(17410, 763, 'management_1_name', 'Dean Cash'),
(17411, 763, '_management_1_name', 'field_5efe20a3d7829'),
(17412, 763, 'management_1_title', 'Member, Board of Directors, Bactoclear Holdings Pte. Limited<br/>President & CEO - ATEL Capital Group'),
(17413, 763, '_management_1_title', 'field_5efe20add782a'),
(17414, 763, 'management_1_image', '690'),
(17415, 763, '_management_1_image', 'field_5f5516e46507c'),
(17416, 763, 'management_1_bio', '<p>Dean Cash is Chairman and CEO of ATEL Capital Group, a San Francisco based international financial services company, founded in 1977. He graduated with a bachelor’s degree in Psychology and Math followed by an MBA from Florida State University. Mr. Cash began his career in 1975 as a systems engineer with Electronic Data Systems (EDS). He then worked for General Electric Corporation in the medical systems division installing computerized patient record systems around North America. Mr. Cash later transferred to GEISCO, General Electric’s information systems division, selling computer time sharing to financial institutions in the Bay Area. He joined ATEL in 1981 as Director of Marketing, became Executive Vice President and Chief Operating Officer in 1983, and a Director in 1984. In 2000 he purchased a majority interest in ATEL and became its Chairman and CEO. </p>\r\n\r\n<p>Mr. Cash owns a controlling interest in Hawaiian Building Maintenance, the largest Honolulu based building services company with approximately 700 employees.</p>\r\n\r\n<p> Mr. Cash is active within the non-profit community and serves on the Board of Governors of the San Francisco Symphony as well as the board of The Florida State University Foundation. He and his wife Eliza established the ATEL Foundation, a private philanthropic organization dedicated to providing funding to organizations that seek to better the lives of citizens in their respective communities. </p>\r\n\r\n<p>He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons: Max, 25 years old who is a graduate of USC, and Sam, 22 years old and is currently a senior at USC.</p>\r\n\r\n<p> He has lived in San Francisco since 1977. Married to Eliza in 1985, they have two sons, Max and Sam, who work with their father at ATEL Capital Group, both are graduates of the University of Southern California.</p>'),
(17417, 763, '_management_1_bio', 'field_5efe20b4d782b'),
(17418, 763, 'management_2_name', 'Vinod Jadhav'),
(17419, 763, '_management_2_name', 'field_5efe20a3d7829'),
(17420, 763, 'management_2_title', 'Member, Board of Directors - Bactoclear Holdings Pte. Limited'),
(17421, 763, '_management_2_title', 'field_5efe20add782a'),
(17422, 763, 'management_2_image', '749'),
(17423, 763, '_management_2_image', 'field_5f5516e46507c'),
(17424, 763, 'management_2_bio', '<p>Mr. Vinod Jadhav is Chairman of SAVA Healthcare Limited and Devtech M2M Limited. He founded SAVA Group (www.savaglobal.com) in 2003. It has grown to be a full-fledged pharmaceutical organization with facets like Contract Research and Manufacturing (CRAM), Domestic and International Marketing, Veterinary drug marketing and herbal extract manufacturing with 2 GMP compliant manufacturing units in India and presence in 30+ countries through network of associates and own marketing offices.</p>\r\n\r\n<p>Mr. Vinod Jadhav started his professional career in 1990 after completing Mechanical Engineering from Cusrow Wadia Institute of Technology, Pune. His 30 years of experience includes Sales & Marketing, Supply Chain Management, International Taxation, Regulatory and Corporate Affairs in various capacities.</p>'),
(17425, 763, '_management_2_bio', 'field_5efe20b4d782b'),
(17426, 763, 'management', '7'),
(17427, 763, '_management', 'field_5efe2097d7828'),
(17428, 763, 'management_0_board_type', 'bactoclear'),
(17429, 763, '_management_0_board_type', 'field_5f554dca6181e'),
(17430, 763, 'management_1_board_type', 'bactoclear'),
(17431, 763, '_management_1_board_type', 'field_5f554dca6181e'),
(17432, 763, 'management_2_board_type', 'bactoclear'),
(17433, 763, '_management_2_board_type', 'field_5f554dca6181e'),
(17434, 763, 'management_3_name', 'Jeffrey Leow'),
(17435, 763, '_management_3_name', 'field_5efe20a3d7829'),
(17436, 763, 'management_3_board_type', 'bactoclear'),
(17437, 763, '_management_3_board_type', 'field_5f554dca6181e'),
(17438, 763, 'management_3_title', 'Member, Board of Directors and CFO - Bactoclear Holdings Pte. Ltd'),
(17439, 763, '_management_3_title', 'field_5efe20add782a'),
(17440, 763, 'management_3_image', '762'),
(17441, 763, '_management_3_image', 'field_5f5516e46507c'),
(17442, 763, 'management_3_bio', '<p>Mr. Leow has had 40 years of experience as a corporate lawyer in New York and Singapore, and as an investment banker and financial adviser in Southeast Asia.</p>'),
(17443, 763, '_management_3_bio', 'field_5efe20b4d782b'),
(17444, 763, 'management_4_name', 'Dr. Janakiraman Ramachandran'),
(17445, 763, '_management_4_name', 'field_5efe20a3d7829'),
(17446, 763, 'management_4_board_type', 'gbpl'),
(17447, 763, '_management_4_board_type', 'field_5f554dca6181e'),
(17448, 763, 'management_4_title', 'Founder and Chairman - Board of Directors, GBPL'),
(17449, 763, '_management_4_title', 'field_5efe20add782a'),
(17450, 763, 'management_4_image', '751'),
(17451, 763, '_management_4_image', 'field_5f5516e46507c');
